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Abstract.
Human small cell lung cancer (SCLC) accounts for approximately 25% of all
primary lung cancers. It is known to metastasise early and follow an aggressive
clinical course. Despite initial sensitivity to chemotherapy, patients almost
invariably relapse and become chemoresistant so that the 2 year survival rate is
between 3 - 8%. Widespread metastasis and resistance to chemotherapy are the two
main causes of these dismal survival figures in SCLC. This thesis focuses on the
potential mechanisms involved.
Anchorage-independent proliferation is essential to enable tumour cells in vivo to
survive and metastasise, and under in vitro conditions allows transformed cells to
form colonies in semi-solid media. Phosphoinositide 3-kinase (PI 3-kinase) has been
shown to critically involved in cell anchorage-independent growth and
tumourigenicity. In this thesis it is shown that PI 3-kinase is constitutively activated
in SCLC cell lines (H69, H345 and H510). Inhibition of PI 3-kinase activity using
the selective inhibitors wortmannin and LY294002 markedly inhibited cell
proliferation and stimulated apoptosis in liquid media. This inhibition of
proliferation was shown to occur via both a ribosomal protein s6 kinase (p70s6k)
dependent and independent mechanism. Furthermore, PI 3-kinase inhibition reduced
basal SCLC cell growth in agarose semi-solid media which could not be rescued by
the addition of neuropeptides. This is the first description of a constitutively
activated PI 3-kinase in any human cancer. It is proposed that this constitutive
activity plays an important role in promoting growth, anchorage-independence and
tumourigenicity in SCLC, and may account for the non-adherent phenotype and
highly metastatic nature of this cancer.
Resistance to chemotherapy is a major problem in the treatment of SCLC. Adhesion
to extracellular matrix (ECM) proteins can protect cells from undergoing
detachment-induced apoptosis. SCLC cells in vivo are surrounded by a specialised
micro-environment rich in ECM containing inpart laminin, fibronectin and collagen
m
IV. It is shown that SCLC cells adhere to the ECM proteins in vitro via a pi
integrin-dependent manner, enhancing tumourigenicity and conferring resistance to
standard chemotherapeutic agents. This adhesion to ECM proteins increases SCLC
cell growth and protects cells from the pro-apoptotic effects of the chemotherapy
agents via a pi-integrin-dependent mechanism requiring tyrosine kinase activation.
Thus ECM proteins in vivo may provide a signal resulting in resistance to
chemotherapy, which accounts for the partial responses and the local recurrence of
SCLC often seen in patients after primary chemotherapy.
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The World Health Organisation estimates that there are approximately 6 million new
patients diagnosed with a form of cancer each year. Two thirds of these people will
then go on to die from cancer, making up 10% of the total world mortality rate.
Lung cancer remains the most frequent cause of cancer death, and is therefore a
major public health problem. Lung cancer is primarily caused by cigarette smoking
(85 - 95% of all lung cancer cases). Other causes of lung cancer are the result of
environmental and occupational factors such as asbestos, arsenic, mustard gas,
polycyclic hydrocarbons and ionising radiation.
1.1.1 Classification.
1.1.1.1 Lung Cancer Classification.
Lung tumours are carcinomas originating from the respiratory epithelium and are
classified by The World Health Organisation (WHO, 1982) on the basis of histology.
The two main types of lung cancer are small cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC) (includes squamous, large and adenocarcinoma).
A recent hypothesis by Mabry (1991) suggests that all types of lung cancer originate
in the bronchial epithelium and are related via a common differentiation pathway.
This hypothesis has been further demonstrated by the use of a non-tumourigenic cell
1
line derived from bronchial epithelium cells (BEAS-2B). These cells were
transfected with the Simian virus (SV40) enabling them to grow continuously
(Gruenert et al., 1988, Pfeifer et ah, 1989, Bonfil et ah, 1989). This lung cancer
model then demonstrated that the overexpression or point mutation of various
oncogenes caused the production of different histological tumour types (Mabry et ah,
1991, Suda et ah, 1987). Insertion of the viral Harvey-ras (y-Ha-ras) gene into a
classical SCLC cell which already endogenously expressed amplified the N-myc
gene, caused transition to the large cell cancer phenotype. Alterations in the
morphological, biochemical and growth characteristics were noted (Falco et al.,
1990, Mabry et al., 1988 and 1989). Amplification of the c-myc gene (known to be
overexpressed in variant SCLC types (Little et al., 1983)), in a classical SCLC cell
line caused alterations to the cell growth rates, an increase in cloning efficiency, but
did not effect neuroendocrine enzyme levels (Johnson, 1986). These studies suggest
that amplification of certain oncogenes may cause a shift of SCLC cell line
characteristics from a classical to a variant or large cell phenotype.
Conversion from a classical to large cell phenotype might also be associated with cell
resistance to chemotherapy in some clinical cases. However, other mechanisms are
likely to be involved in this change, as only 10% of SCLC patients present with
small / large cell mixtures. At autopsy, this rate increases moderately to 13 - 28%
despite the majority of the tumours becoming chemoresistant (Sehested et al., 1986).
1.1.1.2 Small Cell Lung Cancer Classification.
SCLC is the most aggressive form of lung cancer. It occurs predominantly in people
in their seventh or eighth decade of life, constituting 25% of all cases of bronchial
carcinomas (Weiss, 1981 and 1984). SCLC is strongly associated in a dose-
dependent manner with smoking and is rare in non-smokers.
Given that over 90% of patients with SCLC have either local advanced or systemic
cancer at initial presentation, treatment by primary resection is rarely an option. This
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is due to the fact that SCLC metastasises early, and has the fastest growth rates of the
four main types of lung cancer.
The main characteristics of SCLC cells are that they appear as a dense cellular
tumour of round monomorphic cells with an extremely high nuclear to cytoplasmic
ratio. SCLC is classified as a neuroendocrine cancer. Neuroendocrine cells are
defined as being able to produce and secrete polypeptide hormones or amines.
Therefore, small dense core granules containing peptides and hormones are often
seen in the cytoplasm of SCLC cells. The nuclear features of SCLC cells include the
inconspicuous nuclei and uniformly dispersed fine chromatin. When processed for
cytological examination, SCLC cells are seen to be approximately 2-3 times the size
of mature lymphocytes (7-11 microns in diameter) and mitosis is particularly
noticeable.
In a study where cells were removed from SCLC patients either during life or at post
mortem, it was clear that heterogeneity existed within the SCLC general
classification. This allows for further subclassification of SCLC into two types
namely classic SCLC and variant SCLC. Classical SCLC cells account for
approximately 70% of small cell tumours (Belper et al., 1987a and b and c, Carney et
al., 1985a, Gazdar et al., 1980 and 1981 and 1985). Variant cell lines have a larger
cell morphology which is less differentiated and more resistant to chemo- and
radiotherapy (see Table 1.1 for major differences between cell types). It is accepted
that variant cell lines derive not as a result of in vitro culture, but reflect an inherent
property of the in vivo tumour from which they originated.
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Table 1.1: Major Differences between Classical and Variant forms of Small Cell
Lung Cancer Cells in Culture.
Feature Classical (SCLC-C) Variant (SCLC-V)
Growth Pattern Tightly packed Loose floating aggregates
floating aggregates or monolayers
Histology of xenografts Small cell carcinoma Small / large cell
carcinoma
Substrate adherence Absent Sometimes present
Doubling time Long Short
Colony-forming efficiency Low Relatively high
Activation of c-myc Absent Often present
Sensitivity to radiation High Low
Enzymes
L-dopa decarboxylase Present Reduced or absent
Neuron-specific enolase Present Reduced
Creatine-kinase brain Present Present
isoenzyme
Dense-core vesicles Present Usually absent
Secretory products
Bombesin-like peptides Present Usually absent
Other peptides Usually present Usually absent
A feature of SCLC cells is their ability to secrete a large number of hormonal
neuropeptides including gastrin releasing peptide, vasopressin, bombesin and
neurotensin (Sorenson et ah, 1981, Sausville et ah, 1985, Goedert et al., 1984,
Cuttitta et ah, 1985, Belper et ah, 1988. Reviewed Moody & Cuttitta, 1993). These
neuropeptides have been shown to induce the mobilisation of intracellular calcium
stores in SCLC cells (Heikkila et ah, 1987, Woll & Rozengurt, 1989, Bunn et ah,
1990 and 1992, Sethi & Rozengurt, 1991). However, the degree of responsiveness of
the different SCLC cell lines to these neuropeptides varies (Bunn et ah, 1992). This
heterogeneity is thought to be due to the presence of different receptor types and
numbers on the different SCLC cell lines.
The ability of these neuropeptides to promote SCLC clonal growth in semi-solid agar
has previously been demonstrated (Sethi & Rozengurt, 1992, Carney et ah, 1987,
Weber et ah, 1985). Sethi and Rozengurt (1992) were further able to correlate the
increases in neuropeptide-stimulated clonal growth with the increases in calcium
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mobilisation. It is therefore hypothesised that the aggressive growth of SCLC in vivo
is driven by multiple autocrine and paracrine interactions involving these hormonal
neuropeptides. The ability to survive without the requirement of exogenous growth
factors (serum-independence) is a characteristic feature of the transformed
phenotype, and is highlighted in SCLC cell lines in vitro. In liquid culture these cells
are routinely grown in minimal media, i.e. in the presence of key growth
factors/hormones only (e.g. insulin, selenium, transferrin and hydrocortisone)
(Carney et al., 1985b, Bepler et al., 1988).
1.1.2 Hereditary Predisposition.
Most genetic alterations in lung tumours have arisen somatically. However, evidence
is beginning to suggest that an inherited component may predispose people to lung
cancer development. Given that only 10 - 15% of smokers (20+ cigarettes per day)
actually develop lung cancer, it is hypothesised that host factors must alter a persons
risk of developing lung cancer. Also the fact that non-smokers and relatives of
smokers may also develop lung cancer (not taking into account passive smoking),
suggests that people can be predisposed to lung cancer development.
A multi-stage model proposes that two or more genetic mutations are required to
fully transform a cell. If one or more of these mutations was inherited, it may allow
transformation to occur at an earlier stage in life. Increasing evidence has suggested
that genetic alterations that lead to an increased risk in lung cancer formation are
inherited in a mendelian manner (Sellers et ah, 1994). However, with increased
smoking and age, the relative contribution of this inheritance pattern decreases. A
number of epidemiological studies have noted the existence of families where first-
degree relatives have a 2-4 fold increased risk in developing lung cancer (Ooi et ah,
1986) as well as an increased risk in developing other non-smoking related cancers
(Lynch et ah, 1986). It has been observed that relatives of retinoblastoma patients
(Rb), who were carriers of a mutated Rb gene, were 15 times more likely to die from
lung cancer than a person from the general population. This is further evidence
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indicating that inherited predisposition can be a factor in the develpoment of lung
cancer (Saunders et al., 1989).
The reason why only 10 - 15% of smokers develop lung cancer may be explained by
their ability to metabolise/inactivate and remove potential carcinogens from the
body. The majority of carcinogenic factors are the metabolites of environmental
carcinogens (Sims et al., 1974). Enzymes known as phase I enzymes, such as aryl
hydrocarbon hydroxylase and epoxide hyrolase, activate potential compounds into
mutagenic and carcinogenic diol-epoxides (Grover et al., 1976, Newbold & Brookes,
1976). Phase II enzymes such as glutathione-S-transferase and UDP-
glucuronosyltransferase then cause the production of non-toxic water soluble
metabolites (Pelkonen & Nebert, 1982). Theoretically, if patients were unable to
metabolise (activate) the ingested carcinogens, they may not be so prone to
developing cancer. Cigarette smoke has been shown to cause the induction of the
phase I enzymes cytochrome-P450-dependent aryl hydrocarbon hydroxylase and
epoxide hydrolase and the phase II enzyme UDP-glucuronyl transferase (Petruzzeli et
al., 1988). In contrast significant decreases in the phase II enzyme glutathione-S-
transferase were noted. These results suggest that cigarette smoking may be able to
alter the balance between the activation and detoxifying enzymes in the body and this
may modulate susceptibility to carcinogenic damage.
1.1.3 Genetic Pathology.
Development of lung cancer is a multistep process involving a number of
histopathological, biological, molecular and epigenetic changes. These involve
either activation of dominant proto-oncogenes or deactivation of recessive tumour
suppresser oncogenes (anti-oncogenes). The progressive loss of genetic stability is
known to cause cell transformation and cancer development.
Lung cancer formation models have been proposed in which a number of different
stages are incorporated. Broadly these can be split into three main stages:
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1) Exposure to an environmental carcinogen. The extent of injury can depend upon
the genotype and metabolic phenotype of the cell, enabling the extent of injury to
become more enhanced. The formation of DNA:benzo(a)pyrene adducts (from
cigarette smoke) have been detected in people predisposed to lung cancer (Bohr et
ah, 1987). This suggests that upsets in the DNA-adduct excision repair mechanism
may be crucial in the onset of lung cancer.
2) Proliferative Stage. In response to exposure, there is production of growth factors.
This may either be due to initiation of new, or the enhancement of existing growth
factors. Paracrine growth of cells then leads to focal cellular proliferation (normally
benign). These tumours often consist of cells with identical morphological and
phenotypical characteristics to the original cell, and are situated in the same tissue
environment (i.e. as they are not anchorage-independent, no invasion or
metastasising occurs, which is often associated with malignancy). This dysregulation
of growth leading to benign hyperplasia has often been seen in animal models
(Chang et al., 1989, Sandgren et ah, 1990). Expression of different oncogenes that
interrupt and cause activation of the growth stimulatory pathways in the absence of
any ligand (due to mutation or overexpression) can also lead to cells bypassing the
requirement of growth factors causing serum-independence.
3) Promotion and Induction. Involves several chromosome abnormalities (somatic or
inherited) in recessive oncogenes, p53, and epigenetic changes such as the activation
of several proto-oncogenes.
Over the last decade the understanding of lung cancer formation has greatly increased
due to identification of some of the genetic abnormalities involved. Studies have
shown the presence of a large number of acquired (somatic) mutations in lung cancer.
These have been shown to take on many different forms ranging from numerical
abnormalities (hypodiploidy, hyperdiploidy, tetradiploidy) to structural changes
(translocations and deletions) (Whang-Peng, 1989). Some of these mutations are
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present in one type of tumour only, and mutations of the 3p, 13q and 17p
chromosomes have been found in the majority of SCLC cells (Yokota et al., 1987).
Cytogenetic analysis of SCLC reveals the presence of non-random deletions in
chromosome 3 in greater than 90% of cases, with the shortest region being 3p 14-23
(Whang-Peng et ah, 1982, Falor et ah, 1985, Buys et al., 1987). These deletions have
been confirmed in both primary tumours and cell lines. Deletion of 3p has also been
seen in NSCLC (with lesser frequency) (Weston et al., 1989), breast carcinomas and
in renal carcinomas suggesting that it may play a more general role in the
pathogenesis of cancer (Kok et al., 1987, Zbar et al., 1987). In Wilms' tumour
(child's kidney tumour), a deletion in the short arm of chromosome 11 causes the
loss of a tumour suppressor gene. Absence of genetic material in the same region has
been noted in lung carcinomas (Yokota et al., 1987) and it seems likely that the same
gene is involved.
1.1.3.1 Recessive Oncogenes.
Recessive oncogenes (tumour suppressor genes) are genes whose recessive
inactivation or loss allows for dysregulation of cell growth. (Both alleles need to be
inactivated).
Retinoblastoma Gene. Retinoblastoma is a childhood tumour in which both alleles
of the Retinoblastoma (Rb) gene (13ql4) are inactivated. The Rb protein is known
to be a negative regulator of cell death. Studies of somatic genetic changes in SCLC
noted that a number of mutations were found to be localised to the 13q chromosome.
Harbour and colleagues (1988) found upon investigation, the absence of Rb gene
mRNA expression in 60% of SCLC cell lines but only 10% ofNSCLC cell lines and
normal lung tissue. Further studies by a number of different groups have indicated
the loss of the 13q allele in virtually all SCLC tumours (Mori, 1989, Yokota et al.,
1987, Hensel, 1990). These results sharply contrast with a loss in only 32-55% of
NSCLC tumours.
8
There have been studies performed concluding that survivors of hereditary Rb might
be predisposed to lung cancer (Leonard et al., 1988). Sanders and colleagues (1989)
also showed that carriers of the Rbl mutation had a 15-fold increased risk in
developing lung cancer (mainly small cell type). Once again these results indicate
that a predisposition to lung cancer can be inheirited.
p53. p53 is the most commonly mutated gene in human cancer (Hollstein et al.,
1991). Loss of one allele at 17pl3 (where p53 is known to reside (Isobe et al.,
1986)) is common in lung tumours with a mutation (often in the DNA binding
domain region) on the remaining allele. The most common mutation is the
transversion of the nucleotides GC to TA (Harris & Hollstein, 1993). Carcinogens
found in cigarette smoke can cause this transversion. Point mutations in p53 mRNA
have been found in all types of primary tumour specimens (Takahashi et al., 1989).
The highest percentage incidence of p53 mutations in lung cancers have been shown
in SCLC patients (70%) followed by squamous (65%), large cell (60%) and
adenocarcinoma (33%) patients (Greenblatt et al., 1994).
Abrogation of the p53 signalling pathway is the most common specific alteration in
human neoplasia suggesting a central role for the protein in the progression of cancer
(Lane, 1993). Wild type p53 is able to bind to DNA as a multiprotein homo-
dimer/trimer. However, mutated p53 is able to bind to wild type p53 inactivating it
in a dominant negative manner. Wild type p53 is a nuclear protein involved in the
Gl/S checkpoint of the cell cycle. Down regulation of this pathway leads to
uncontrolled cell proliferation due to the loss of p53 regulated growth arrest. The
inability of cells to arrest growth prevents DNA repair from occurring and enables
DNA mutations to be passed on. This may ultimately lead to malignant
transformation.
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p53 was first shown to be involved in the apoptotic process of cells (section 1.2) in a
temperature-sensitive mutant cell line (Yonish-Rouach et ah, 1991). Increases in p53
levels can cause transactivation of the pro-apoptotic gene Bax (Miyashita et ah. 1994,
Selvakumaran et ah, 1994) and repress the anti-apoptotic protein Bcl-2 (Shen &
Shenk, 1994). This causes an alteration in the balance of Bax : Bcl-2 protein levels
within the cell ultimately leading to apoptosis (discussed in section 1.2). However,
p53 activation has since been shown not to be required for all apoptotic mechanisms.
Thymocytes from p53 null mice were resistant to apoptosis induced by chemically
induced DNA breaks (whilst wild type were not). Mutated p53 could not however
prevent glucocorticoid mediated apoptosis (Lowe et ah, 1993, Clarke et ah, 1993).
Thus, there is more than one signalling pathway present in cells that leads to cell
death via apoptosis.
1.1.3.2 Dominant Oncogenes.
Dominant acting oncogenes are genes whose altered expression contributes to the
malignant phenotype. (Only one of the alleles needs to be activated)
Myc Family. This family is composed of six members, c-, L-, N-, P-, R- and B-myc
(Cook et ah, 1993). Among them, only three (c-, L- and N-) seem to be of
significance in the formation of SCLC (Johnson et ah, 1988). These three oncogenes
encode nuclear phosphoproteins that are involved in the regulation of the cell cycle
through their DNA binding properties (Nishimura & Sekiya, 1987). They have all
been shown to co-operate with Ha-ras and rafoncogenes in transforming primary rat
fibroblasts (Schwab et ah, 1985). Although the myc family of genes demonstrates a
high level of conservation at their DNA level, they are expressed on different
chromosomes and have been shown to be mutated by different processes.
Similarities in their DNA structure suggest common roles intracellularly for these
proteins. However, differential tissue expression during growth, and their differing
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complementarity to the ras gene suggests that they play unique roles in the
development of cells (Zimmerman et ah, 1986).
Activation of the myc family of oncogenes normally occurs not by mutation, but by
gene amplification or over-expression in SCLC cells. One of the first reports of myc
amplification in SCLC was observed in the variant form of SCLC (van der Hout et
ah, 1989). Myc amplification was seen to correlate with rapid in vitro growth, altered
morphological characteristics, partial loss of neuroendocrine markers and
radioresistance (Carney et ah, 1985, Gazdar et ah, 1985). Transfection of the c-myc
oncogene into classical SCLC cells results in the appearance of variant SCLC cell
features. Amplification of the N-myc and L-myc oncogenes has also been described
in SCLC, but are not associated with the conversion to a more variant form of SCLC.
Amplification of any of the myc genes is associated with the patient having
undergone prior cytotoxic therapy (Brennan et ah, 1991).
Ras Family. The ras family of proto-oncogenes (K-, H- and N-ras) encode a 21 kDa
membrane associated protein which has been suggested to play a key role in cell
signalling (reviewed further in section 1.6.2.3). Mutations in codons 12, 13 and 61
lead to constitutive activation of these proteins. Ras oncogene mutations have been
shown to exist in a variety of tumour types including colorectal tumours (Bos et ah,
1987, Jiang et ah, 1989), adencarcinomas (Rodenhuis et ah, 1987 and 1988) and
neuroblastomas (Ireland, 1989). This family of proteins is considered to play an
important role in the pathogenesis of certain NSCLC tumours types (e.g.
adenocarcinomas). Suzuki and co-workers (1990) noted that 27% of
adenocarcinomas contained mutations in the ras genes, and that 73% of these
mutations were in the Ki-ras gene isoform. No ras mutations were detected in
squamous tumour specimens. Ras mutations have been detected infrequently in
SCLC cells (Kurzrock et ah, 1986, Kiefer et ah, 1987). However, Mitsudomi and co-
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workers (1991) and Suzuki and co-workers (1990) indicated that there were no ras
mutations in SCLC cells.
1.1.4 Chemotherapy.
Classically, chemotherapeutic reagents were thought to work on the principle that
rapidly dividing transformed cells were more sensitive to chemotherapeutic reagents
causing selective cytotoxic damage, DNA lesions and cell death. However, it has
recently been shown that tumours susceptible to chemotherapy can be relatively slow
growing, where as rapidly dividing tumour cells are resistant (Fischer, 1994). Thus a
more likely mode of action is now thought to be by causing cell apoptosis (Hannun,
1997, Kerret al., 1994).
Given that SCLC patients usually present with disseminated disease due to the high
metastatic abilities of SCLC cells, strategies of treatment focus on systemic therapy.
A study published in 1969 (Veteran's Administration Lung Cancer Study Group)
noted that the survival of SCLC patients treated with various single chemotherapy
drugs or with radiotherapy treatment, was prolonged. Patients given single-agent
cyclophosphamide showed a doubling of their median survival. Further studies using
a combined chemotherapy regime, showed an increase in the median survival time
for patients with limited disease from 3-15 months and extensive disease to around 8
months. Whilst many of the new chemotherapy agents are highly active against
SCLC both as single reagents (Macbeth et al., 1996) or in combination, combination
chemotherapy is usually preferred. Current commonly used combination regimens
for the treatment of SCLC are CAV (cyclophosphamide, doxorubicin and
vincristine), CAVE (as CAV plus etoposide), VICE (Ifosfamide, carboplatin,
etoposide and vincristine) or EP (etoposide and cisplatin).
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1.1.4.1 Chemotherapy Agents.
As described previously, a number of different chemotherapeutic drugs are currently
being used to treat SCLC patients. These include: -
Cyclophosphamide. This is an alkylating agent which is administered in an inactive
form. It becomes activated in the liver where it is metabolised to phosphoramide
mustard. This active metabolite can then bind to DNA and RNA and impair the
replication and transcription processes of the cell.
Cisplatin & Carboplatin. Both are platinum analogues thought to cause
cytotoxicity by forming cross-linkages in and between DNA strands.
Doxorubicin. Doxorubicin is a cytotoxic anthracycline which is considered to be the
most effective chemotherapy drug in the treatment of breast cancer. As with other
chemotherapeutic drugs, it is known to concentrate in the cell nucleus where it binds
to DNA disrupting its structure.
Etoposide. Etoposide (also known as VP-16) is a semi-synthetic derivative of
podophyllotoxin (an antimitotic agent). This anticancer drug functions by inhibiting
cells at the pre-mitotic stage of cell division by inhibiting DNA synthesis.
Disruption of entry/progression into early S phase appears to be important in the
cytostatic action of etoposide.
A large number of clinically important chemotherapeutic drugs including enzymes
that intercalate (e.g. doxorubicin, adriamycin and actinomycin D (Tewey et al., 1984,
Pommier & Kohn, 1989, Trask & Muller, 1988)) and do not intercalate (e.g.
etoposide and tenioposide (Chen et ah, 1984)) with DNA, are known to exert their
cytotoxic effects via the enzyme topoisomerase Hoc (Liu et ah, 1989, Capranico &
Zunino, 1992). Topoisomerase Hoc is a cell cycle regulated nuclear enzyme that
regulates the configuration of cellular DNA. This regulation is essential for DNA
replication, recombination, transcription and repair. The cytotoxic effects of
chemotherapeutic reagents cause the topoisomerase enzyme to become firmly
associated with DNA producing a cleavable complex (Gasser et ah, 1986, Endicott &
Ling, 1989). The formation of these cleavable complexes ultimately leads to the
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production of DNA lesions (Liu et ah, 1989), cell cycle delay (Smith et ah, 1994,
Cummings & Smyth, 1993) and cell death.
1.1.5 Relapse.
Despite initial responsiveness to radio and chemotherapy, SCLC almost invariably
relapses and is resistant to further treatment, so that the patient two year survival rate
remains between 3-8% (Elias, 1997). In Britain one such study showed that the 2-
year survival rate of the 3681 patients entered into a clinical trial was 8.5% for those
presenting with limited disease and 2.2% for extensive disease. Additionally, the
patients who survive in excess of two years also become more susceptible to other
types of lung cancer (Minna et ah, 1985).
Results of second-line chemotherapy are poor with response rates of 20 - 25 % and a
median survival from further relapse of 3 - 4 months. On relapse, the disease is
usually classed as incurable and treatment is offered to try to increase the quality and
extend the life span of the patient. The ultimate cause of treatment failure is the
tumours' resistance to chemotherapy (Elias, 1997). This type of resistance seems to
pre-exist in a small percentage of tumour cells which re-grow after relapse. This type
of chemoresistance is therefore known as a clinically acquired multi drug resistance.
Researchers are still unsure why cancers become resistant to further treatment even
when varied combination chemotherapeutic agents are used.
1.1.6 Cancer Drug Resistance.
Although it is unclear as to what the cause of SCLC multidrug resistance is, a
number of proteins have been shown to mediate cellular resistance to different
chemotherapeutic reagents. One gene known to aid in cell drug resistance is the
multi drug resistance gene (MDR-1). Overexpression of the MDR-1 protein causes
resistance to many anticancer agents such as doxorubicin and etoposide by causing a
decrease in the intracellular steady-state chemotherapy drug concentration.
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The role of MDR-1 in lung cancer has previously been investigated. Levels of
expression were shown to be elevated in only a small number of SCLC cell lines and
tumours. The level of elevation was negligible in comparison to other tumour types
such as colon cancer. It was shown that there was no correlation between the
expression of MDR-1 and whether the tumour specimen was from a previously
treated or untreated patient, or even if the patient had responded well to
chemotherapy. Lai and colleagues (1989) showed that there was no correlation
between the mRNA levels of MDR-1 and in vitro chemosensitivity. The MDR-1
gene has therefore been concluded as not being involved in the mechanism by which
SCLC becomes drug resistant. In contrast to the above conclusions, Kreisholt and
co-workers (1998) recently noticed that in a significant number of SCLC tumour
biopsies there was a decrease in topoisomerase Ila levels, an increase in P-
glycoprotein (P-gp) protein levels, and a small increase in multidrug resistance
protein (MRP) levels after treatment with either etoposide or tenioposide. (Both P-
gp and MRP are drug efflux plasma membrane pumps which result in a decrease in
intracellular steady-state chemotherapy drug concentrations (Cole et ah, 1992, Borst
et ah, 1993)). The limitations of this study were that protein expression levels alone
were assessed and not the actual activity status of the proteins involved.
Alterations in the DNA repair enzyme topoisomerase-IIa have been detected in
SCLC cell lines presenting resistance to chemotherapeutic reagents (Giaccone et ah,
1992b). Nearly all doxorubicin and adriamycin resistant SCLC cell lines have been
shown to have decreased topoisomerase Ila gene expression, and a reduction in drug-
induced DNA breaks (De Jong et ah, 1993 and 1990 respectively). Thus, the
decrease in DNA lesions may effect the apoptosis levels induced by these
chemotherapeutic reagents. However, studies by Supino and co-workers (1993)
showed that although there was a small decrease in topoisomerase Ila expression in
doxorubicin resistant cell lines, this was not sufficient to explain the large increase in
drug resistance observed. Supino concluded that alternative unidentified
mechanisms must therefore be involved in SCLC cell multidrug resistance.
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Finally, tumour responsiveness has also been shown to be dependent upon p53
expression and the activation of cell cycle arrest and apoptosis following exposure to
chemotherapeutic reagents (Clarke et ah, 1993, Lowe et ah, 1993). Therefore, cells
that contain p53 deletions/mutations often overcome cell cycle delay and become
resistant to chemotherapy.
1.2 Apoptosis.
Nowadays the term apoptosis is widely used to describe the active process by which
a cell dies exhibiting a distinct set of biochemical and morphological features (Kerr
et ah, 1972). This mechanism of cell death enables the cells to die in a manner that
will neither harm neighbouring cells, or induce an inflammatory response (Martin,
1993, Fischer, 1994).
Although many of the morphological changes that occur to a cell undergoing
apoptosis are well documented, the actual biochemical process and signalling
pathways involved are unclear. Morphological changes that occur when a cell
undergoes apoptosis include the rounding up of cells and cell shrinkage. As the cell
condenses, the nuclear DNA is condensed and ultimately becomes fragmented by
specific DNAase enzymes. In addition, alterations in the cell surface lipid
composition and receptor expression occur during the apoptotic process. These are
important as they enable phagocytic cells such as macrophages to recognise and
phagocytose apoptotic cells before the toxic breakdown products, or contents of the
cells can injure the surrounding tissue causing inflammation (Savill et ah, 1989).
It is clear that a large number of factors influence the commitment of a cell to the
death programme in response to a wide variety of apoptotic stimuli. These include
cell cycle stage, DNA damage, cell genotype, mutations and the addition of various
growth-, survival- and death-promoting factors. Genetic mutations can decrease the
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susceptibility of a cell to undergo apoptosis on addition of the correct stimuli. In
relation to cancer these mutations may confer an increased growth advantage
resulting in tumourigenesis, or decrease the susceptibly of a cell to chemotherapy-
induced apoptosis. This knowledge is of interest as tumour mass is the result of the
balance between cell proliferation and cell death (via either apoptosis or necrosis),
therefore factors affecting the apoptotic rates of tumour cells have a major impact on
tumour growth.
1.2.1 Effectors of the Apoptotic Pathway.
Interleukin-ip Converting Enzyme. Initially, the majority of studies investigating
the key intracellular elements involved in the apoptotic process were performed in
Caenorhabditis elegans (c. elegans). The ced-3 gene was shown by mutational
studies to be required for apoptosis in development (Ellis & Horvitz, 1986). Cloning
of this gene revealed the presence of a mammalian homologue know known as the
Interleukin-ip converting enzyme (ICE) (Yuan et ah, 1993). ICE is now known to
be part of a larger family of cysteine proteases which include prICE,
CPP32/Yama/Apopain, ICH-2, Flice and others (Thornberry & Lazebnik, 1998)
which induce the terminal and irreversible phase of apoptosis characterised by
macromolecular breakdown and cellular fragmentation. This family of cysteine
proteases is now collectively known as the caspase family (reviewed Porter et ah,
1997).
Bcl-2. Another c. elegan gene discovered to be important in apoptosis was ced-9
(Hengartner et ah, 1992). Ced-9 and its mammalian homologue Bcl-2 (B cell
leukaemia oncogene 2) are negative regulators of cell death, i.e. increased activation
(via phosphorylation) prevents apoptosis. This increased activation often contributes
to certain disease types (including cancer) where dysregulation of cell death occurs.
Bcl-2 was originally identified from a translocation breakpoint 14; 18 (Bcl-2 gene
chromosome 18, immunoglobulin promoter chromosome 14) associated with several
human B cell lymphomas resulting in increased Bcl-2 expression (Tsujimoto et ah,
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1985, Bakhshi et al., 1985). Since its discovery, Bcl-2 has been shown to be a
member of a much larger family which includes both anti-apoptotic (including Bcl-
X,) and pro-apoptotic proteins (including Bad and Bax) (Kaufmann, 1997).
Bcl-2 proteins are able to form homodimers within the cell. Another family member
Bax (pro-apoptotic Bcl-2 homology protein) can also form homodimers as well as
heterodimers with Bcl-2. The balance between the number of Bcl-2 and Bax proteins
within a cell has been indicated as the key regulatory step by which different
mechanisms confer cellular resistance to apoptosis. Studies in yeast showed that the
presence of Bax alone (allowing production of homodimers) caused apoptosis. This
could be prevented by the addition of Bcl-2 proteins, but only if they were able to
associate with the Bax proteins. The presence of Bcl-2 alone did not have any effect
on cell apoptosis levels (Hanada et al., 1995).
1.2.2 Chemotherapy-induced Apoptosis.
Recently, in vitro cell apoptosis has been shown to occur in response to many
different chemotherapeutic drugs including etoposide, cis-platinum,
cyclophosphamide and adriamycin (Kaufmann, 1989, Walker et al., 1991,
Hutschtscha et al., 1996). The onset of apoptosis seems to be independent of the
actual cytotoxic insult, as inhibition of microtubules, nucleotide biosynthesis, direct
DNA damage and topoisomerase inhibition (via different agents) all induce cell death
(reviewed Hannun, 1997). As SCLC cells in patients are known to become resistant
to chemotherapy-induced apoptosis after primary treatment, understanding the
underlying mechanisms of chemotherapy-induced apoptosis are key in the ongoing
effort to try and understand why SCLC cells become resistant to chemotherapy
reagents.
The potential roles of the different known apoptotic mechanisms in chemotherapy-
induced apoptosis are unclear. Overexpression of Bcl-2 is able to protect cells from
undergoing apoptosis in response to the addition of a wide variety of
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chemotherapeutic agents including etoposide, dexamethasone, doxorubicin,
actinomysin D (Kamesaki et al., 1993, Fairbairn et al., 1994, Lotem & Sachs, 1994).
Addition of etoposide has been shown to result in the cleavage of the anti-apoptotic
protein Bcl-2 on administration of the drug to U937 and HL60 cells (Fujita &
Tsuruo, 1998). It was shown that Bcl-2 was directly cleaved by the ICE-like family
protease CPP32/caspase-3.
Increases in the level of Bcl-2 present in cells is not thought to effect the actual entry
of the chemotherapeutic drug into the cell, but rather disable its cytotoxic
capabilities. The actual mechanism by which this is achieved is unclear. It is
thought that by preventing the cell from replicating, it enables the cell to have time to
try and repair any DNA breaks or mutations. Additionally Bcl-2 has been seen to
suppress DNA damage by preventing caspase-3 activation (Sentman et al., 1991).
The efficiency of Bcl-2 is also dependent upon levels of Bax expression (discussed
previously).
Finally, p53 levels are thought to play a role in chemotherapy-induced apoptosis
under certain circumstances, as loss of p53 function can lead to a decrease in the
chemo- and radio-sensitivity of cells (Lowe et al., 1993, Clarke et al., 1993, Lotem &
Sachs, 1993). Conversely, the disruption of p53 has been shown to sensitise breast
carcinoma cells from cis-platinum-induced apoptosis (Fan et al., 1995, Eliopoulous
et al., 1995). In MCF-7 breast cancer cells, survival assays indicated that when p53
signalling was disrupted, increased cis-platin sensitivity was due to defects in cell
cycle G1 checkpoint control, nucleotide excision repair or both.
1.3 The Metastatic Processes Involved in Cancer.
Cancer cells have often been shown to disobey the social organ boundaries within the
body and cross into foreign tissues causing the production of metastatic deposits
(reviewed Liotta & Stetler-Stevenson, 1991). A number of important events take
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place enabling a cancer cell to form the secondary ectopic deposits. These events are
often associated with aggressive cancers such as SCLC. The complex cascade of
events includes tumour growth and invasion, angiogenesis (formation of new blood
vessels within the tumour), intravasation into the lymphatic or blood vessels,
adhesion to the vessel wall, extravasation and the ability to grow within a foreign
environment (Clezardin, 1998). A number of the above processes require the
interaction of cell surface receptors known as integrins, with extracellular matrix
(ECM) components.
To enable cells to metastasise, ECM degradation has to take place. A general feature
of all carcinomas is the presence of defects within the basement membrane. This is
in contrast to benign proliferative disorders which are characterised by a continuous
basement membrane. The degradation of ECM proteins is regulated by a family of
zinc-dependent enzymes known as matrix metaloproteinases (MMP's) (reviewed
MacDougall & Matrisian, 1995, Matrisian, 1992). These enzymes are known to be
regulated by a wide variety of factors including growth factors, oncogenes and
hormones. A number of recent studies have suggested that certain MMPs co-localise
with integrins, and whilst the activation of the integrin heterodimer regulates cell
motility, the MMP potentiates matrix degradation. The co-operation between these
two processes has therefore been suggested to facilitate tumour invasion and
metastasis (Brooks et ah, 1996). Studies by Gonzalez-Avila and co-workers (1998)
indicated that MMP-2 and MMP-9 (type IV collagenases) were expressed by all lung
neoplasms, and that SCLC cell extracts showed the highest enzymatic activity. The
presence of these activated MMPs in SCLC cells is thought to help explain why these
cells are highly metastatic.
1.4 The Extracellular Matrix.
The extracellular matrix (ECM) is an insoluble meshwork of proteins (Kefalides et
ah, 1979) whose adhesive interactions with surrounding cells have been shown to be
important in the regulation of a large number of cellular processes including
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proliferation, migration, survival and differentiation. Many of these processes are
important to the ability of a transformed cell to survive and metastasise.
The ECM can be described as a 3D lattice meshwork of collagen and elastin which is
able to act as a filter allowing the movement of certain molecules through the matrix
aiding in cell / tissue homeostasis. It is able to exert both mechanical and chemical
influences on a cell causing changes in cell shape and biochemistry via the plasma
membrane (Bissell et al., 1982). The cells in turn are able to regulate ECM
production and degradation. Loss of tissue / cell homeostasis, due to a change in
ECM - cell receptor association and in ECM composition, is consistently observed in
cancer.
In comparison to normal cells, the behaviour of their cancerous counterparts is often
altered on adhesion to ECM proteins. A culture of non-malignant primary mammary
epithelial cells in a 3-dimensional reconstituted basement membrane matrix stopped
proliferating and underwent morphogenesis. In contrast, malignant immortalised
mammary epithelial cells continued to proliferate and formed colonies (Peterson et
al., 1992). In addition, Roskelley and co-workers (1995) noted that association of
cells to ECM proteins was able to cause alterations in cell shape and an increase
intracellular tyrosine phosphorylation (via integrin binding). This led to changes in
gene expression in breast epithelial cells. These studies serve to illustrate that
adhesion of cells to ECM proteins is able to cause alterations in the behaviour of
cells.
1.4.1 Extracellular Matrix Proteins.
1.4.1.1 Collagen IV.
Collagen IV is only one of a much larger family of proteoglycans (Kuhn. 1995) and
forms the backbone of the basement membrane. Collagen IV and V are the only
types to be found in the basement membrane, and are localised in the basement
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membrane of the alveolar walls of capillaries and bronchioles of the lung (Madri &
Furthmayr, 1980). Collagen IV is seen to co-localise with laminin with in the
basement membrane and provide a scaffold on to which other components of the
basement membrane are incorporated.
Both collagen IV and V have been shown to be resistant to the classic MMP
collagenases which are known to degrade the interstitium collagens I, II and III. This
observation is important in the maintenance of the basement membrane cell barrier.
Conversely, metastatic tumour cells have been shown to produce a specific MMP
that is able to degrade collagen IV alone (Liotta et ah, 1979). The production of this
MMP possibly enables cancerous cells to degrade the basement membrane allowing
metastasis to occur. Metastatic cells have also been shown to have a higher affinity
for collagen IV in comparison to other types of collagen (Nicolson et ah, 1981,
Terranova et ah, 1982).
1.4.1.2 Laminin.
The laminins are a major family of biologically active glycoproteins (Timpl et ah,
1979) comprising of a, p and y chains. Laminin is the most abundant glycoprotein in
the basement membrane where it is bound to collagen IV. There are a number of
receptor binding sites scattered throughout the ligand including sites for integrins
a3pi, a6pi, aipi and a 67 kDa receptor (Powell & Kleinman, 1997).
Laminin plays a key role in the interactions of tumour cells to the surrounding
basement membrane resulting in the regulation of cell adhesion, proliferation,
migration and morphology (Terranova et ah, 1980, Grover et al., 1983, McCarthy et
ah, 1983). Adhesion to laminin has been shown to stimulate the production of
collagenase IV which goes on degrade collagen IV. Proteins that inhibit collagenase
IV activity and prevent ceils from adhering to laminin inhibit malignant cell
invasion. This implies that adhesion to laminin and collagen IV degradation, are
essential for the formation of tumour metastasis (Reich et ah, 1988). Animal tumour
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models have shown that on selection and injection of tumour cells that adhere
preferentially to laminin, a 10 fold increase in the metastatic ability of the cells was
observed (Terranova et ah, 1982).
1.4.1.3 Fibronectin.
Fibronectins consist of a large family of heterodimer and polymeric glycoproteins
found in the plasma and connective tissue of healthy lungs. Fibronectin is known to
be synthesised by connective tissue cells (Hynes, 1986, Yamada, 1989).
Fibronectins are now recognised as a family of proteins which modulate key cellular
responses via integrin and non-integrin interactions including adhesion, proliferation
and differentiation (depending upon cell type).
In humans, the fibronectin family of proteins are all encoded by a single gene which
undergoes alternative splicing at the pre-mRNA stage to form 20+ isoforms
(Schwarzbauer, 1991) ultimately producing a dimer approximately 250 kDa in size.
Two forms of fibronectin are found within the body: pFn - a soluble form found in
plasma and often secreted by hepatocytes; cFn - cellular fibronectin secreted mainly
by epithelial cells, macrophages and fibroblasts. Both forms are found in the ECM.
Fibronectin is a flexible molecule which contains binding sites for a number of
different receptors including a5pi (classical fibronectin receptor), a3pl and a4pi.
The interaction of fibronectin with integrin receptors has been found to be essential
for the assembly of a fibronectin matrix which is required for vertebrate
development, wound healing and tumourigenesis (Wu et ah, 1995). Fibronectin
secretion has also been shown to cause collagen IV degradation and the invasion of
certain tumour cell types. Shibata and co-workers (1997) showed that fibronectin
caused the production of the matrix metaloproteinase MMP-9 (via an a5pi integrin-
dependent mechanism) leading to the degradation of collagen IV and an increase in
ovarian cancer cell invasiveness.
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1.4.1.4 Tenascin.
The vertebrate tenascins are a family comprised of 4 members (C-, R-, X- and Y-
tenascin (Chiquet-Ehrismann et al., 1994). Tenascin-C was first observed by a
number of groups in the early 1980's and the majority of tenascin research has
focused on this family member. Structurally tenascin-C is a disulphide-linked
hexamer that can be expressed in a number of different isoforms. As with other
ECM proteins, tenascins are degraded by members of the MMP family (Siri et al.,
1995).
The expression of tenascin-C is very complex and has been shown to dramatically
change in pathological conditions including wound healing and cancer (Mackie,
1994). It has been suggested that many processes may influence alterations in
tenascin-C expression including cell type and ligand stimulation. These include
regulation by transforming growth factor-p (Pearson et al., 1988), fibroblast growth
factor (Tucker et al., 1993), interleukin-1 and angiotensin II (Sharifi et al., 1992)
(reviews Chiquet-Ehrismann et al., 1995, Rettig et al., 1994). Additionally,
glucocorticoids (e.g. dexamethasone) have been shown to down regulate tenascin-C
(but increase fibronectin expression) (Chiquet-Ehrismann et al., 1995).
Initial studies were inconclusive as to the adhesive properties of tenascin. Chiquet-
Ehrismann (1991) described tenascin as an anti-adhesive protein. However, Lotz and
co-workers (1989) as well as Sriramarao and co-workers (1993) said that adhesion to
tenascin by different cells is weak and cell type specific. Along with other functional
consequences, the binding of tenascin-C by different receptors (including integrins
and heparin sulphate proteoglycans) under different circumstances, and on different
cell types, has been shown to stimulate / inhibit proliferation, cause neurite
outgrowth (in the development of the nervous system) and support morphogenesis in
lung development (Chiquet & Wehrle-Haller, 1994).
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1.5 Integrins.
Integrins are the major family of cell receptors which enable cells to adhere to ECM
proteins. They are activated when bound to immobilised extracellular matrix
proteins, or by integrin receptor aggregation. Upon integrin activation a number of
cellular processes can occur including alterations in gene expression (Streuli et ah,
1995, Lin et al., 1994, Shaw et ah, 1990), increases in intracellular free calcium
(Schwartz, 1993), increases in cellular pH levels (Schwartz et al., 1991) and
phosphoinositide turnover (McNamee et al., 1993). Additionally, integrins play a
key role in a number of cellular processes that impact on the development of tumours
including the regulation of cell proliferation, apoptosis, cellular motility and
invasion, and angiogenesis (Shaw et al., 1997, Bredin et al., 1998, Zhang et al.,
1995).
Integrins have been shown to produce a large number of signals that converge upon
the growth regulatory pathways and often utilise the same signalling molecules.
Many reports (reviewed Schwartz, 1997) suggest that at least three major signalling
pathways can be activated on the convergence of integrin and growth factor receptor
signalling, these include the phospholipase C (PLC) - protein kinase C (PKC)
pathway, the mitogen activated protein kinase (MAP kinase) pathway and the
phosphoinositide 3-kinase (PI 3-kinase) pathway.
1.5.1 Integrin Receptors.
Integrins are a widespread family of cell surface receptors that are comprised of a
mixture of at least 17a (120 - 180 kDa) and 8p (90 - 110 kDa) subunits (review
Kumar, 1998). These in turn can form at least 22 different non-covalently linked
heterodimers.
Alternative splicing of both the a and p subunits can occur (Hynes, 1992). Each
subunit contains a large extracellular domain, a single hydrophobic transmembrane
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spanning region and a short cytoplasmic tail (with the exception of p4 which has a
long cytoplasmic tail). The cytoplasmic tail of the a subunit differs a great deal
between the different subunits, but they all function to provide ligand specificity,
surface expression and regulate cell adhesion and spreading (Sastry & Horwitz,
1993). The p subunits have a more conserved sequence and are required to target the
integrins to the focal contacts enabling signalling pathways to be activated (La
Flamme et al., 1994).
1.5.2 Integrin Ligands.
Non-covalently associated integrin hetero-dimers are normally able to bind to more
than one ligand type (exception a5pi binds fibronectin only). Integrins are also
known to have different affinities for different ligands depending upon cell type
(Kirchhofer et al., 1990, Elices & Hemler, 1989). In addition, although two different
integrin dimers may bind to the same ligand, and even to the same specific target
sequence, different functional consequences may occur. Zhang and co-workers
(1995a) noted that Chinese hamster ovary (CHO) cells normally under went
apoptosis on withdrawal from serum. However, activation of the a5pi integrin
dimer prevented this from occurring. Activation of the avpi integrin (binds to the
same RGD sequence as a5pl), did not prevent apoptosis from taking place.
1.5.3 Integrin Expression on Cancer Cells.
A number of studies have been performed investigating the differences in integrin
expression on the surface of cancer cells. Mette and co-workers (1993) noted that in
comparison to normal lung cells, the expression of integrins on lung cancer cells was
more heterogeneous. Studies by Damjanovich and co-workers (1992) also noted a
more heterogeneous population of integrin ligands on lung cancer cells. They also
noted that the number of integrins expressed on the cell surface decreased. Further
research into the integrin expression of lung cancer cells (Koukoulis et al., 1997)
showed that no lung cancer cells (including SCLC cells) expressed the a5pl integrin
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dimer (although normal bronchial epithelial cells did). It has also been noted that
lung cancer cells which do not express the a5(31 integrin dimer, are able to bind to
fibronectin in an a3pi-dependent manner (Falconi et al., 1994).
It has long been accepted that the pattern of fibronectin and integrin expression in
cancer cell lines is often altered. Malignant cells often express less fibronectin
leading to alterations in adhesiveness, motility and morphology (Yamada, 1983,
Akiyama et al., 1995). However, addition of exogenous fibronectin is sometimes
sufficient to revert the transformed phenotype (Akiyama et al., 1995). Oncogenic
transformation of cells has often been associated with a decrease in a5pl expression
leading to a decrease in fibronectin matrix formation (Plantefaber & Hynes, 1989,
Wu et al., 1995, Fogerty et al., 1990). Work performed in CHO cells indicated that
overexpression of the a5pl receptor inhibited or abolished tumour progression
(Giancotti & Ruoslathi, 1990), whereas reduced expression increased
tumourigenicity in nude mice (Schreiner et al., 1991). Ras-transformed cells have
also been shown to express reduced levels of the a5pi dimer (Plantefaber & Hynes,
1989).
Initial studies by Stallmach (1994) indicated that colon cancer cells no longer
expressed the a5pl integrin dimer. Conversely, Gong and co-workers (1997) noted
that a highly invasive colon cancer cell line expressed an increased level of a5pi in
comparison to the less invasive colon cancer cell lines. This increased expression led
to strong adhesion to fibronectin in vitro. Injection of colon cells expressing high
levels of a5pi into athymic nude mice resulted in increased tumourigenicity.
Further work has shown that key growth-regulating genes are altered in cells that
overexpress the a5pi integrin (Varner et al., 1995). This alteration in integrin
expression led to a decrease in cell proliferation rates which could be reversed on
adhesion to fibronectin. a5pi has also been shown to be important in colon cell
survival as a5pi-transfected cells were partially protected from serum withdrawal-
induced apoptosis via a Bcl-2-dependent mechanism (Zhang et al., 1995b, O'Brien et
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al., 1996). Thus, ot5(31 can act as a regulator of cell growth, tumourigenicity and
apoptosis in colon cancer cells.
In relation to other integrin types, many primary and metastatic tumours have been
shown to express a3pi (Bartolazzi et al., 1994) and cancers of the lung, neck, head,
colon and bladder have been shown to express the a6 integrin subunit (Van Waes &
Carey, 1992, Liebert et al., 1993, Costantini et al., 1990). In breast carcinomas, poor
expression of a2|31 was shown to induce a more invasive and less differentiated
phenotypic cell. Ectopic expression of the integrin heterodimer suppressed this
transformed phenotype (Zutter et al., 1995) preventing invasion and differentiation.
1.5.4 Integrin-mediated Cell Survival.
Loss of epithelial and endothelial integrin-mediated cell adhesion to ECM proteins
has been shown to trigger detatchment-induced apoptosis (Meredith et al., 1993,
Boudreau et al., 1995, Frisch & Francis, 1994. Reviewed Frisch & Ruoslathi, 1997),
which has since been termed 'anoikis' (meaning apoptosis induced by loss of
anchorage). However, fully transformed cells are known to be anchorage-
independent and overcome anoikis. This anchorage-independence has been shown to
play a key role in the ability of tumour cells to metastasise. Overexpression of a
number of different signalling proteins has often been linked to anchorage-
independence in different cell types. Previous work by Frisch and Francis (1994)
showed that transformation of epithelial cells with the oncogenes ras or src enabled
cells which were normally anchorage-dependent to grow in suspension. This
oncogenic transformation appeared to enable the cells to stimulate signals normally
produced upon integrin activation within the cell. Additionally, Khawja and co¬
workers (1997) noted that activation of ras or src could protect epithelial cells from
under going cell detachment-induced apoptosis via activation of the lipid/tyrosine
kinase phosphoinositide 3-kinase (PI 3-kinase) and one of its downstream targets
protein kinase B (PKB) (review of PI 3-kinase and PKB in the regulation of
apoptosis Franke et al., 1997). The activation of cell adhesion regulated pathways by
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oncogenes such as integrin-linked kinase (ILK) and Bcr-Abl (Schwartz, 1997) have
also been shown to promote anchorage-independent growth (Radeva et ah, 1997).
Finally, Guan & Shalloway (1992) reported that the protein focal adhesion kinase
(FAK) could be activated by both cell adhesion (via integrins) or by oncogenic
transformation. FAK expression has since been shown to correlate with the invasive
potential of a number of metastatic tumours (Brunton et ah, 1997, Jenq et ah, 1996,
Withers et ah, 1996, Owens et ah, 1995), and FAK overexpression is known to block
anoikis (Frisch et ah, 1996a). This implies that FAK maybe important in anchorage-
independent growth in certain transformed cells.
Boudreau and co-workers (1995) have shown that breast epithelial cells undergo
anoikis via a pi integrin- and ICE-dependent pathway (caspase review Porter et ah,
1997). Recently caspases were shown to cause FAK cleavage (Wen et ah, 1997)
suggesting the presence of a positive feedback loop. On activation of caspases, FAK
was cleaved preventing activation of the anti-apoptotic pathway involving PI 3-
kinase and PKB. Additionally PKB has been shown to cause phosphorylation
(causing inactivation) of the pro-apoptotic protein Bad (Datta, et ah, 1997)
strengthening the role of PKB it the prevention of apoptosis. (Bad is a pro-apoptotic
protein of the Bcl-2 family.)
An alternative mechanism involves the anti-apoptotic protein Bcl-2. Zhang and co¬
workers (1995a) noted that adhesion of cells to fibronectin via its classical a5(31
receptor caused an increase in Bcl-2 expression, which in turn aided in cell survival.
Frisch and co-workers (1996a) noted that MAP kinase-mediated Jun kinase anoikis
could be inhibited by expression of Bcl-2. Cardonne and co-workers (1997)
investigated the role of the MAP kinase protein MEKK-1 (MAP/ERK kinase kinase
1) in anoikis and noted that loss of anchorage led to MEKK-1 activation (due to
protein cleavage, via caspase activation) ultimately leading to activation of Jun
kinase. However this process could be blocked by increasing the concentration of
Bcl-2 within the cell which led to the inhibition of caspase activation. Loop holes in
this alternative hypothesis were highlighted by Khwaja and Downward (1997) who
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noted that addition of a dominant negative Jun kinase did not prevent anoikis of
epithelial cells on cell detachment.
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1.6 Phosphoinositide 3-kinase Signalling.
For highly metastatic cells such as SCLC cells to survive, they have to be able to
overcome both serum- and anchorage-dependence to enable them to grow, survive
and metastasise throughout the body. The enzyme phosphoinositide 3-kinase (PI 3-
kinase) has been shown to be involved in the regulation of many key untransformed
and transformed cellular processes including anchorage-independence and survival
(Table 1.2).
Table 1.2: Examples of Cellular Functions which Require Phosphoinositide 3-
kinase Activation.
Cellular Function Reference
Proliferation Cantley et ah, 1991, Walker et al., 1998
Carpenter & Cantley, 1996
Transformation Whitman et al., 1985,
Rodriguez-Viciana et al., 1997
Survival Yao & Cooper, 1995, Franke et al., 1997
Khwaja et al., 1997, Kauffman-Zeh et al., 1997
Secretion and trafficking Joly et al., 1994 and 1995
Shepherd et al., 1996
Migration Wennstrom et al., 1994, Kundra et al., 1994
Anchorage-independence King et al., 1997, Shaw et al., 1997,
Meredith et al., 1993, Frisch & Francis, 1994
Morphological Alterations Kotani et al., 1995 and 1996
Invasion and metastasis Shaw et al., 1997, Keely et al., 1997
PI 3-kinase is a dual specificity kinase which can phosphorylate both phospholipids
and proteins (Carpenter et ah, 1993, Dhand et ah, 1994), therefore acting as a direct
biochemical link between proteins containing kinase activity and products of the
phosphoinositide pathway.
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Initially PI 3-kinase was shown to phosphorylate the D3 position of the inositol ring
of phosphotidylinositol (PI) to produce phosphotidylinositol (3) phosphate (PI3P)
(Whitman et ah, 1988). Since then, a whole family of enzymes have been discovered
(some conserved to higher eukaryotes only) which are capable of phosphorylating the
D3 position of the inositol ring including Vps34p and Cpk (Toker & Cantley, 1997).
The first described mammalian PI 3-kinase family member was the p85/p 110
heterodimer (structural and functional analysis reviewed by Dhand et ah, 1994).
Whilst p85/p 110 PI 3-kinase can phosphorylate the lipid substrates PI, PI4P,
PI(4,5)P2 in vitro with equal efficiency, PI(4,5)P2 is thought to be its preferred
substrate in vivo. (Note, Vps34p (yeast protein) is able to phosphorylate PI only,
where as Cpk (c. elegans protein) can phosphorylate PI and PI4P.) Along with other
lipid kinases and phosphatases that are able to phosphorylate and dephosphorylate
other positions on the inositiol ring, a highly complex family of secondary lipid
second messengers is found within the cell (Figure 1.1).
To date 2 p85 isoforms (a and P) (class 1A) and 4 pi 10 subunit isoforms have been
identified (reviewed Vanhaesebroeck et ah, 1997). In addition to the two p85 a and
P isoforms, a third p85-like subunit was recently discovered (pi01) (class 1B). This
isoform has been shown to be activated by G-protein coupled receptors only, and
bind to the pllOy isoform (Stephens et ah, 1997). Of the pi 10 isoforms, a and p
(class 1A) have been shown to be ubiquitously expressed in all eukaryotic cell types.
The y isoform (class 1B), has been shown to be exclusively regulated by the G-protein
coupled family of receptors, and to date has been shown to be expressed in
haemopoietic cell types (Stephens et ah, 1994) and osteosarcoma cell lines only
(Morris et ah, 1995). The more recently discovered 8 isoform has so far been shown
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1.6.1 Activation of Phosphoinositide 3-kinase.
As mentioned previously, PI 3-kinase has been shown to be involved in many
different cellular processes (Table 1.2). In view of this, research has shown that PI 3-
kinase can be activated by multiple different mechanisms including integrin
activation (King et ah, 1997, Chen & Guan, 1994), growth factor receptor activation
(Carter & Downes, 1992, Chen & Guan, 1994a), G-protein coupled receptor
activation (Lopez-Ilasaca et ah, 1997 and 1998, Morris et ah, 1995) and oncogene
expression/receptor mutation (Moscatello et ah, 1998).
1.6.1.1 Receptor Tyrosine Kinase Activation.
Tyrosine kinase receptors are a large family of single membrane spanning receptors
that include growth factors and hormones. Upon activation (due to ligand binding),
the receptors oligomerise due to conformational changes in the extracellular regions
of the receptors (exception insulin receptor which already exists as a dimer). The
adjacent cytoplasmic domains of the receptor subunits interact causing
phosphorylation of certain intracellular proteins and/or autophosphorylation of the
receptor itself (reviewed Ullrich & Schlessinger, 1990).
The intracellular catalytic tyrosine kinase domains of the receptor provide a number
of docking sites for different intracellular proteins including Ras (Kaplan et ah,
1990), phospholipase C (PLCy) (Ronnstrand et ah, 1992), the adaptor protein Grb2
(Arvidsson et al., 1994) and PI 3-kinase (Kazlauskas & Cooper, 1990). The
phosphotyrosine residues (with motif YxxM) form docking sites for the two SH2
domains of the PI 3-kinase regulatory p85 subunit. (SH2 = src homology 2 domains.
These associate with specific phosphorylated tyrosine residues.) This association
causes activation of PI 3-kinase. The receptor tyrosine kinase domain catalyses the
transfer of the y-phosphate of ATP to tyrosine residues on PI 3-kinase, and aids in
positioning the pi 10 PI 3-kinase catalytic subunit close to the plasma membrane
(which contains the in vivo PI 3-kinase lipid substrate PI(4,5)P2).
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1.6.1.2 G-protein Coupled Receptor Activation.
The G-protein coupled family of receptors have a conserved topology within the
plasma membrane and consist of a single protein chain which transverses the cell
membrane seven times (amino terminal situated on the outside of the cell and the
carboxyl terminal inside). Classically, activation of G protein-coupled receptors
leads to the formation of Ga-GTP and GPy subunits. These are able to activate PLC
leading to phosphoinositide hydrolysis, the formation of diacylglycerol and IP3, and
the subsequent release of calcium from intracellular stores.
Looking at the mechanism in more detail it is known that on ligand binding
conformational changes are observed in the receptor enabling it to interact with
distinct classes of GaPy protein heterotrimers (Conklin & Bourne, 1993, Neer,
1995). This triggers exchange of GDP for GTP on the a subunit of the heterotrimer
leading to dissociation of the G protein complex from the receptor and the formation
of GTP-Ga and GPy subunits. These subunits then interact with distinct enzymes
and ion channels eliciting specific physiological responses within the cell. The GTP
associated with the a subunit is then exchanged for GDP causing re-association of
the GaPy heterotrimer at the plasma membrane.
Activation of PI 3-kinase via the G-protein coupled receptor is not fully understood.
The Py subunit of the heterotrimer has been shown to associate with the Class 1B PI
3-kinase (plOl-pllOy) heterodimer causing activation (Stephens et al., 1994,
Stephens et al., 1997). Also the possibility of transactivation of a class 1A PI 3-
kinase residing in close proximity to the activated G-protein coupled receptor has
been postulated by a number of research groups (see Figure 1.3).
1.6.1.3 Adhesion/Integrin Activation.
Integrin-dependent signalling pathways are known to occur in the majority of cell
types. As many of the proteins involved can be stimulated by growth factor receptor
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stimulation also, many integrin-associated proteins have been identified. The actual
mechanisms involved in integrin signalling are still however poorly understood.
Activation of PI 3-kinase via integrin stimulation is thought to occur by a number of
mechanisms including association of the SH2 domains of the p85 subunit with the
protein FAK. FAK is known to bind to, and become phosphorylated on p integrin
subunit stimulation. PI 3-kinase is then known to associate with the phosphorylated
tyrosine residues on FAK (Chen & Guan, 1994, Chen et ah, 1996a). This association
enables PI 3-kinase to be targeted to the cytoplasmic face of the plasma membrane
where its lipid substrates are localised. The pi 10 catalytic subunit binds with very
high affinity to the inter-SH2 region of the p85 subunit and contains intrinsic
catalytic activity. A lipid-binding site is also found to be situated in the inter-SH2
region of the p85 subunit and may confer some specificity as to the enzyme substrate
preference.
Another mechanism of PI 3-kinase activation involves SH2 - SH3 adaptor protein
she. She is known to preside in close proximity to focal adhesion plaques which are
formed on the integrin binding of specific heterodimers (Clarke & Brugge, 1995)
such as a 1 pi, avP3 and a5pi (Wary et ah, 1996, Giancotti, 1997). Association with
the adaptor protein she (associates with a limited number of integrin heterodimers
(via caveolin binding to the a subunit)) can lead to indirect activation of PI 3-kinase
via Grb2 - mSOS and ras (Wary et al., 1996).
1.6.2 Downstream Targets of Phosphoinositide 3-kinase.
Discovery of the pharmacological tools wortmannin (Arcaro & Wymann, 1993,
Yano et al., 1993) and LY294002 (Vlahos et al., 1994) have enabled scientists to
investigate the role of PI 3-kinase in many different cell types and signal transduction
pathways. Wortmannin is a fungal metabolite which has been shown to be a specific
non-competitive inhibitor of PI 3-kinase (Arcaro & Wymann, 1993, Ui et al., 1995)
by associating with the ATP binding site of PI 3-kinase (Powis et al., 1994, Yano et
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al., 1993). It binds irreversibly to the pi 10 catalytic subunit of PI 3-kinase (Arcaro &
Wymann, 1993, Wymann et al., 1996) and has been shown in many cell types to
have an IC50 of around 3 nM (Powis et al., 1994). LY294002 is structurally different
to wortmannin and inhibits PI 3-kinase in an alternative manner. It behaves as a
competitive inhibitor for the ATP binding site of PI 3-kinase (Vlahos et al., 1994)
with an IC50 in the low micromolar range.
Recently, the production of a number of PI 3-kinase dominant negative mutants
(Hara et ah, 1994) and constitutively active pi 10 mutants (Hu et al., 1995) has
enabled further investigations to be undertaken to try and elucidate specific down
stream targets of PI 3-kinase in different cell types (reviewed Duronio et al., 1998).
These targets include ras (Hu et al., 1995), PKB (Franke et ah, 1995, Burgering &
Coffer, 1995), p70s6k (Monfar et ah, 1995), protein kinase C family members (Toker
et ah, 1994), mitogen activating protein kinase signalling pathway members (Lopez-
Ilasaca et ah, 1997), selective Rho/Rac dependent pathway members (Kotani et ah,
1995) and Jun N-terminal kinase (Klippel et ah, 1996).
These studies have shown that PI 3-kinase is important in a wide range of cellular
processes (Table 1.2). The mechanisms by which these varied cellular functions are
regulated are not fully understood. However, as research begins to identify key
downstream targets of PI 3-kinase, the major role of PI 3-kinase becomes more
apparent.
1.6.2.1 Protein Kinase B and PI(3,4,5)P3-Dependent Kinase 1.
The serine/threonine proto-oncogene protein kinase B (PKB) (also known as Akt or
RACPK (related to A and C protein kinase)) was first identified in 1991 (Coffer &
Woodgett, 1991, Jones et al., 1991, Bellacosa et al. 1991). Differing research
strategies were utilised in the identification of PKB: PCR (Coffer & Woodgett,
1991), low-stringency library screening with a cAMP-dependent kinse probe (Jones
et ah, 1991) and sequencing of a human cDNA hybridising with v-akt (Bellacosa et
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al., 1991). To date three separate isoforms have been discovered (a, P and y). PKB
a and p have been shown to be widely expressed within many types of tissue.
Highest levels have been shown to be in the brain, thymus and lung (Coffer &
Woodgett, 1991, Jones et al., 1991). Expression of the y isoform is thought to be
more selective, with the highest levels found to be in the brain and testes. Low
expression levels have also been seen in lung, heart, spleen and skeletal muscle.
Since its discovery, PKB has been show to be the product of the oncogene v-akt and
highly expressed in a number of cancers. Overexpression of the PKBp isoform has
been seen in ovarian (approximately 12%) (Cheng et al., 1992, Bellacosa et al.,
1995), and pancreatic (10%) (Ruggeri et al., 1998, Cheng et al., 1996) cancers.
Overexpression of the a isoform has been reported in a small number of breast
cancers (3%) (Bellacosa et al., 1995).
PKB Activation. Over the last year, the mechanism of PKB activation has begun to
be understood (reviewed Alessi & Cohen, 1998, Downward, 1998, Bellacosa et al.,
1998). Whilst association of PKB to PI 3-kinase lipid product PI(3,4,5)P3 (due to the
presence of a plekstrin homology (PH) domain (Shaw, 1996)) causes activation, it is
not sufficient for full activation. This suggests that the association is required to
induce a conformational change in PKB allowing it to be targeted to the plasma
membrane and activated by additional enzymes.
In unstimulated cells, PKB is situated in the cytosol, and upon stimulation it is
rapidly translocated to the plasma membrane. The mechanism causing the
translocation of PKB to the plasma membrane has been shown to be prevented by
inhibitors of PI 3-kinase activity and by deletion of the PH domain of PKB.
Conversely, addition of a membrane-targeting sequence to PKB enables it to be
activated in unstimulated cells at the membrane (Andjelkovic et al., 1997).
Once located at the plasma membrane, another stage involving the phosphorylation
and activation of PKB occurs. A PI(3,4,5)P3-dependent kinase (PDK1) has been
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shown to phosphorylate Thr308 but not Ser473 of PKBa. A serine kinase that has
yet to be discovered is still required to phosphorylate Ser473 (hereafter known as
PDK2). In vitro PDK1 is strongly activated by PI(3,4,5)P3 (to lesser extent by
PI(3,4)P2), and is known to possess a PH domain (Alessi et ah, 1997a). The
mechanism of activation of PKB whereby association with PI(3,4,5)P3 causes a
conformational change in PKB enabling PDK1 to phosphorylate a specific residue of
PKB (Figure 1.2) is supported by the observation that a PKBa mutant unable to
interact with PI(3,4,5)P3 was not phosphorylated by PDK1 (Stokoe et al., 1997). In
addition, PKBa lacking its PIT domain could be phosphorylated by PDK1 in the
absence of PI(3,4,5)P3 or PI(3,4)P2 (Alessi et al., 1997a) as the conformational
restraints of the PFI domain were removed.
Recent work by Delcommenne and co-workers (1998) has indicated that the integrin
associated protein integrin-linked kinase (ILK) (Hannigan et al., 1996) is able to
phosphorylate PKB at Ser473. The second kinase, known at this time as PDK2 may
therefore possibly be ILK. ILK activation is known to be PI 3-kinase dependent,











Figure 1.2: Diagram of the Potential Mechanism by which Protein
Kinase B is Activated.
Adapted from Alessi & Cohen, 1998.
Abbreviations: PI 3-kinase, phosphoinositide 3-kinase; PH, pleckstrin




Downstream of PKB. PKB is thought to be involved in the regulation of the protein
glycogen synthase kinase-3 (GSK3) by deactivating the protein via phosphorylation
(Sutherland et ah, 1993, van Weeren et ah, 1998). GSK3 is known to control the
synthesis of glycogen via insulin and ultimately regulates the transcription factors
AP-1 and cyclic-AMP-responsive element (CREB) (Cross et ah, 1995). Recently
PKB has also been shown to regulate insulin stimulation of mammalian target of
rapamycin (mTOR) (Scott et ah, 1998). By artificially activating PKB, they showed
that PKB caused an increase in mTOR activity using an in vitro kinase assay. mTOR
is known to lye upstream of p70s6k (discussed further in section 1.6.2.2). Studies by
Burgering and Coffer (1995) also suggested that PKB was responsible from the
activation of p70s6k via mTOR.
PI 3-kinase mediated activation of PKB appears to play an important role in the
prevention of apoptosis in many cell types (reviewed Downward, 1998, Marte &
Downward, 1997, Hemmings, 1997, Eves et ah, 1998, Franke et ah, 1997). PKB has
been shown to be able to phosphorylate the p53 regulated pro-apoptotic Bcl-2 family
member Bad (del Peso et ah, 1997, Datta et al., 1997) both in vivo and in vitro. Once
phosphorylated (inactive), the adaptor protein 14-3-3 is able to bind to Bad
preventing it from being able to heterodimerise with and inhibit the activity of the
anti-apoptotic proteins Bcl-2 and Bcl-x, (Zha et al., 1996, Zundel & Giaccia, 1998,
del Peso et al., 1997). The ability of PKB to aid in cell survival has also been shown
to synergise with the ability of the ras oncogene to promote cell survival via the PI 3-
kinase/PKB and not MAP kinase pathway (Khwaja et al., 1997). Given that over a
quarter of human malignancies have undergone ras mutations (occur very
infrequently in SCLC), it is possible that their ability to survive is triggered via a PI
3-kinase / PKB dependent mechanism. However, all these anti-apoptotic signals
mediated via PI 3-kinase/PKB do seem to be cell type and stimuli specific. Minshall
and colleagues (1996) reported that although activation of PI 3-kinase was able to
protect haemopoietic progenitor cells from undergoing apoptosis, this protection was
dependent upon the external signal supplied to the cell. PI 3-kinase prevented
apoptosis due to IL-3 mediated signals but not IGF-1.
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1.6.2.2 Ribosomal Protein S6 Kinase.
The serine/threonine protein kinase ribosomal protein s6 kinase (p70s6k) (reviewed
Proud, 1996, Chou & Blenis, 1995, Abraham, 1998) has been shown to be associated
with a highly conserved signalling pathway activated in response to many growth
factors and neuropeptides. It exists as two isoforms; the p85 (al) nuclear isoform
and the p70 (all) cytoplasmic isoform. These two proteins are encoded by distinct
transcripts differing in their 5' ends derived from the same gene by alternative
splicing (Reinhard et al., 1994). The enzyme exists in a basally phosphorylated form
in most cell types. On stimulation, it is phosphorylated on a number of novel sites
before it becomes fully activated. A number of these mitogen-induced
phosphorylation sites have now been identified (Ferrari et al., 1992, Cheatham et al.,
1995). It is known that at least 10 serine and threonine residues need to be
phosphorylated to enable p70s6k to become active (Dennis et al., 1996).
p70s6k has been show to be present downstream of PI 3-kinase using a number of
different biochemical methods. These include mutation of the PDGF receptor
Tyr740/751 residues causing the inactivation of PI 3-kinase, use of PI 3-kinase
inhibitors (Chung et al., 1994), and the use of constitutively active PI 3-kinase
mutants causing activation of p70s6k (Weng et al., 1995). Additionally, two
independent groups have recently shown that p70s6k can be activated in a PI 3-kinase-
dependent manner via PDK1 under both in vitro and in vivo situations (Alessi et al.,
1998, Pullen et al., 1998). However, although p70s6k has been shown to be regulated
in a PI 3-kinase-dependent manner, it can also be independently regulated by PKC
(Tudan et al., 1998) (first demonstrated by Chung et al., 1994). Chung and co¬
workers showed that the treatment of HepG2 cells with phorbol esters was able to
cause p70s6k activation. Additionally, using add-back mutants, activation of p70s6k by
PDGF via Pi 3-kinase was shown to be PKC-independent, where as PLCy activation
was dependent upon PKC activation.
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Further elucidation of the role of p70s6k in cell signalling has been possible due to the
discovery of the p70s6k specific pharmacological inhibitor rapamycin (Price et ah,
1992). Rapamycin is an immunosuppressive anti-proliferative macrolide which
becomes activated on binding to a specific 12 kDa protein known as FK506-binding
protein 12 (FKBP12). The rapamycin-FKBP12 complex inhibits the
autophosphorylation of the mammalian target of rapamycin (mTOR), also known as
FRAP (FKBP-rapamycin associated protein) (Brown et ah, 1995) or RAFT1
(rapamycin-FKBP target 1) (Sabatini et ah, 1995).
To date, the association between mTOR and p70s6k is not clear. mTOR has not been
shown to directly phosphorylate p70s6k. Given that the addition of rapamycin does
cause a decrease in p70s6k phosphorylation, an additional component (probably more
than one kinase as p70s6k is phosphorylated at a number of different sites), must lie
between mTOR and p70s6k. As mentioned earlier, one potential kinase (causing
phosphorylation of the Thr252 residue) is PDK1 (Pullen et ah, 1998, Alessi et ah,
1998).
Only recently it was shown that mTOR mediated activation of p70s6k can occur by a
pathway parallel to the PI 3-kinase pathway. The identification of a p70s6k mutant
that was resistant to rapamycin was shown to still be inhibited by wortmannin
(Cheatham et ah, 1995, Weng et ah, 1995). Therefore it seems likely that in certain
circumstances/cell types, mTOR may be regulated by a PI 3-kinase/PKB-dependent
mechanism, where as under different circumstances, mTOR is activated
independently of PI 3-kinase.
The number of potential downstream targets of p70s6k is still not clear. The major
known target is the ribosomal S6 protein (part of the S40 ribosomal subunit) which
becomes phosphorylated on activation of p70s6k (Lavoinne et ah, 1991, Flotow &
Thomas, 1992). In response to mitogenic stimuli p70s6k phosphorylates S6 on
multiple sites causing activation. These changes enable the S40 ribosomal subunit to
translate polysomes (Jefferies & Thomas, 1996). The translation ofmRNAs bearing
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5'-terminal oligopolypyrimidine ends are known to be preferentially enhanced by S6
phosphorylation. Other rapamycin-sensitive signalling molecules include the
initiation factor eIF-4E-binding protein 4E-BP1 (Lin et ah, 1995). This protein has
been shown to be involved in insulin-mediated translational processes. p70s6k has
also been shown to phosphorylate one isoform of the transcription factor, cyclic-
AMP-responsive element (CREM) (de Groot et ah, 1994). This observation
indicates another role for p70s6k in the regulation of mitogen-stimulated
transcriptional activities.
1.6.2.3 Small GTPase Proteins (Ras, Cdc 42 and Rac).
These small GTP binding and hydrolysing proteins act as two-state 'molecular
switches' (Milburn et ah, 1990). A cycle of GTP binding and hydrolysing followed
by the dissociation of the resulting GDP, causes alterations in the conformation of the
proteins. This alteration enables the proteins to interact with specific downstream
targets as part of a signal transduction cascade. The ras GTPase family of proteins
includes a number of proteins with a wide variety of cellular functions (Rubins &
Dickey, 1993), however they are all activated in the same manner.
Ras. Activation of the 'classical' p42/44 MAP kinase signalling cascade can occur via
the activation of ras. Ras signals via the cytoplasmic serine/threonine kinase raf
(Avruch et ah, 1994) which in turn causes phosphorylation of enzymes involved in
the classical MAP kinase cascade (section 1.6.2.5). PI 3-kinase has been shown to
directly interact with the small GTP-binding protein ras (Rodriguez-Viciana et ah,
1994 and 1996 and 1997, Kodaki et ah, 1994) due to the presence of a ras binding
site on the pi 10 catalytic subunit of PI 3-kinase. Activation occurs in a GTP-
dependent manner and has so far been shown to occur with the p85a/pl 10 type of PI
3-kinase only. The positioning of ras and PI 3-kinase in relation to one another along
different signalling cascades is not fully established as different groups have
published data demonstrating the presence of PI 3-kinase both upstream and down
stream of ras (Hu et ah, 1992, Rodriguez-Viciana et ah, 1994 respectively).
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Additionally, due to the fact that in a number of cell types PI 3-kinase activation has
been shown to be required for ras-dependent and -independent MAP kinase
signalling cascade activation (Cross et ah, 1994, Knall et ah, 1996), the exact
positioning may be cell type and stimuli specific.
In relation to cell survival, apoptosis has been shown to be induced in haemopoietic
cells unable to activate the ras signalling pathway (Ihle & Kerr, 1995, Kinoshita et
ah, 1995). Recent studies have highlighted an association of ras with the anti-
apoptotic protein Bcl-2 (Chen & Faller, 1996). As the two proteins are localised to
different areas of the cell (Bcl-2 intracellular membranes), ras (inner leaflet of the
plasma membrane), it is not clear how these two proteins interact. It has been
suggested that other ras family members localise to the intracellular membranes and
associate with Bcl-2, or that activated raf-1 is able to translocate to the intracellular
membranes and interact with Bcl-2 (Krajewski et al., 1993).
Rac and Cdc 42. In vitro PI 3-kinase has been shown to associate with the GTP
bound forms of the Ras-like proteins rac and cdc 42 via the breakpoint cluster-related
(BCR)-homology region of the p85 PI 3-kinase regulatory subunit (Zheng et al.,
1994). Studies by Hawkins and co-workers (1995) indicated that activation of PI 3-
kinase via PDGF caused an increase in GTP-bound rac. Inhibition of membrane
ruffling by wortmannin has been shown to occur via a rac-dependent signalling
mechanism. Given that it is known that cdc 42, rho and rac are regulators of actin
cytoskeletal rearrangements (reviewed Nobes & Hall, 1995), further studies have
strengthened the link between PI 3-kinase and the small GTP-binding protein rac
(reviewed Parker, 1995).
1.6.2.4 Protein Kinase C.
The serine/threonine protein kinases known collectively as the protein kinase C
family (PKC) have been implicated in both short and long-term regulation of cellular
responses including changes in morphology, differentiation, gene expression and
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proliferation. To date three classes of PKC have been discovered which are grouped
according to structural variations and biochemical properties: classical (sometimes
known as conventional) PKC (cPKC) (a, (31, (311 and y) which are calcium- and
diacylglycerol (DAG) or phorbol ester-dependent, novel (nPKC) (8, s, r\ and 0)
which are phorbol ester or DAG-dependent and atypical (aPKC) (£, and X) which do
not require calcium or DAG for activation. In addition the PKCp isoform can be
categorised as either novel (due to its structural characteristics) or atypical (due to its
functional characteristics).
In relation to PI 3-kinase signalling, Nakanishi and co-workers (1993) initially
showed that atypical PKCC was activated by the PI 3-kinase product PI(3,4,5)P3.
Further studies have shown that in vitro 3-phosphorylated lipid products are able to
phosphorylate and activate a number of PKC isoforms also including PKC8, PKCs
and PKCa (Singh et ah, 1993, Toker et ah, 1994, Palmer et ah, 1995). Work
performed by Palmer and co-workers (1995) concluded that in vitro there seemed to
be no PKC isoform specificity, as many PKC isoforms could be activated by the
different 3'phosphorylated products of PI 3-kinase.
In vivo few studies have so far been able to link PKC activation to PI 3-kinase. In
permeabilised platelets, addition of PI(3,4,5)P3 was able to cause phosphorylation of
the major classical PKC substrate plekstrin. This activation was inhibitable in whole
cells by the addition of wortmannin, but bypassed by the addition of PI(3,4,5)P3
(Zhang et ah, 1995a). Further work by other groups has suggested that other PKC
isoforms may also be activated by the lipid products of PI 3-kinase (Akimoto et ah,
1996, Moriya et ah, 1996). Immunoprecipitation studies have shown that certain
PKC isoforms are directly associated with PI 3-kinase in vivo (Moriya et ah, 1996)
and that stimulation of a hemopoietic cell line increased association between the
proteins. Additionally, IL-2 stimulation of mouse T cells was shown to cause
association of a PKC isoform with PI 3-kinase (Ettinger et ah, 1996). In both these
studies an increase in PI 3-kinase serine/threonine activity were observed. Finally,
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recent work by Le Good and co-workers (1998) has shown that specific PKC family
members (e.g. PKC a, 5 and p.) are associated with, and can be activated by PDK1.
PKC proteins have been shown to be potentially involved in the suppression of
apoptosis. PKC has been shown to directly phosphorylate Bcl-2 and that this
phosphorylation has been associated with growth factor-induced suppression of
apoptosis (May et al., 1994). (Other investigations have found that Bcl-2 can be
phosphorylated in a PKC-independent manner by raf-1 (Blagosklonny et al., 1996,
Wang et al., 1994)).
In SCLC cells a number of published investigations have studied the role of PKC
enzymes in growth, apoptosis and resistance to chemotherapy. Using the classical
SCLC cell line (NCI 209) Barr and colleagues (1997) indicated that expression of the
cPKC (311 isoform resulted in a positive selection on transfection of the c-myc
oncogene. This was due to PKC (311 expression slowing down cell proliferation rates
and improving survival statistics. Additionally, Schuller and colleagues (1992) noted
that on addition of the PKC inhibitor dihydropyridine dexniguldipine, certain SCLC
and non-SCLC cell lines were prevented from proliferating. Finally, characterisation
of H69 cisplatin-sensitive and -resistant cell lines indicated that a reduction of cPKC
levels, and an increase in nPKCs may aid in SCLC cell resistance to cisplatin (Basu
et al., 1996).
1.6.2.5 Mitogen Activated Protein Kinase Signalling Pathway.
The most studied cytoplasmic signal transduction pathway which involves the
sequential phosphorylation of a cascade of protein kinases is the mitogen activated
protein kinase cascade (MAP kinase cascade). The proteins are activated by the
phosphorylation of both tyrosine and threonine residues by specific kinases.
Activation of the 'classical' p42 44 MAP kinase signalling cascade (reviewed Marshall,
1995, Davis, 1993) can occur via the activation of ras. Members of the PKC family
have also been shown to activate the protein raf-1 both in vitro and in vivo thereby
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activating the MAP kinase cascade. Ras activation of raf-1 causes phosphorylation
and activation of the MAPK/ERK kinases (MEK 1 & 2 in mammalian cells)
(reviewed Robinson & Cobb, 1997). The MEK kinases then activate the downstream
extracellular-signal regulated kinases (ERK 1 & 2) (also known as p44/p42 MAPK
respectively) ultimately leading to the activation of a wide variety of cellular
responses including cell proliferation and differentiation.
Until recently, growth factor tyrosine kinase receptor mediated activation was the
major mechanism by which the MAP kinase cascade was thought to be activated
(Fantl et al., 1993). Elowever, a number of G-protein coupled receptors have recently
been shown to cause activation of this cascade (Kahan et al., 1992). Many Grprotein
coupled receptors stimulate MAP kinase via GaPy subunits both dependently and
independently of their ability to stimulate PLC (Delia et al., 1997, Hawes et al., 1995
respectively). The involvement of PI 3-kinase in Gj protein receptor stimulation of
the MAP kinase cascade has been demonstrated in COS-7 and CHO cells (Hawes et
al., 1996, Lopez-Ilasaca et al., 1997 respectively). In COS-7 cells (Monkey kidney
cells), Hawes and colleagues (1996) showed that the inhibition ofG-protein mediated
activation of PI 3-kinase by wortmannin, LY294002 or a dominant negative PI 3-
kinase, prevented MAP kinase activation. In these studies PI 3-kinase was shown to
be situated upstream of ras and SOS. (SOS is a guanine nucleotide exchange factor
that converts ras-GDP to ras-GTP ultimately leading to activation of the MAP kinase
signalling pathway). Gq proteins are able to activate the MAP kinase pathway via




















Figure 1.3: Activation of the Classical Mitogen Activated Protein Kinase Cascade.
A) Gq-coupled receptors. B) G i/o-coupled receptors.
Abbreviations: Grb2, growth-factor-receptor-bound protein 2, IP3, inositol 1,4,5-
trisphosphate, MAP kinase, mitogen activated protein kinase, PI 3-kinase,
phosphoinositide 3-kinase, PKC, Protein kinase C, Ras, rat sarcoma virus, PLC,
phospholipase C, Pyk2, proline rich tyrosine kinase 2, SOS, son of sevenless, MEK,
MAP/ERK kinase, DAG, 1,2-diacylglycerol, She, SH2-domain-containing a2-collagen
related protein and sre, rous sarcoma virus.
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Activation of G protein-coupled receptors leads to the formation ofGa-GTP and GPy
subunits. These are able to activate PLC leading to phosphoinositide hydrolysis and
formation of diacylglycerol and IP3. The subsequent release of calcium from
intracellular stores causes phosphorylation of the FAK-related kinase (PYK2) (Dikic
et ah, 1996, Lev et al., 1995). Once phosphorylated, PYK2 associates with Grb2
which in turn brings the small molecular weight GTPase adaptor protein mSOS in to
the signalling complex leading to ras activation and ultimately MAP kinase
activation. PYK2 is also able to activate rac-1 (Deckert et al., 1996, Crespo et al.,
1996 and 1997).
Additionally, Schlaepfer and co-workers (1994) showed that the MAP kinase cascade
could be activated on integrin binding. On the adhesion of NIH 3T3 fibroblasts to
fibronectin, FAK associated with the adaptor molecule Grb2 (a SH2-SH3-SH2
adaptor protein now known to associate with FAK via its NH2-terminal SH2
domain). Grb2 is then known to associate (via its SH3 domain) with mSOS
ultimately leading to MAP kinase activation. This observation was strengthened by
reports that adhesion of Swiss 3T3 fibroblasts to fibronectin caused MAP kinase
activation (Chen et al., 1994). More recently Schlaepfer and Hunter (1997) also
noted that overexpression of FAK led to ras-dependent signalling of the ERK2 MAP
kinase enzyme. Finally, another major pathway by which the MAP kinase cascade is
thought to be activated via integrins involves the adaptor protein she. A dominant
negative she protein was shown to suppress ERK activation in response to integrin
ligation (Wary et al., 1996).
In SCLC cells Seufferlein and Rozengurt (1996a) indicated that activation of the
classical MAP kinase pathway via PKC was important in neuropeptide-mediated cell
growth. SCLC colony formation was also abrogated by the addition of the MEK1
inhibitor PD 098059 or the PKC inhibitor GF 109203X. Additionally, Beekman and
co-workers (1998) showed that inhibition of basal PKC activity (via the prevention
of PLCp activation) inhibited colony formation and receptor stimulated activation of
the MAP kinase proteins ERK 1 & 2. Additionally recent work by Cattaneo and co-
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workers (1997) indicated that indirect nicotine-mediated MAP kinase activation in
SCLC cells was mediated via the release/production of an unknown co-factor. This
co-factor then went on to activate MAP kinase via a pertussis toxin-sensitive (inhibit
G; family of Ga proteins) and tyrosine kinase-sensitive pathway. Finally, Seckl and
Rozengurt (1997) noted that inhibition of neuropeptide-mediated MAP kinase
activity (by [D-Arg1,D-Trpx7'9,Leu"]Substance P), inhibited SCLC tumour growth in
vivo.
1.6.3 Activation of Parallel Signalling Pathways by Phosphoinositide
3-kinase.
It is now being widely accepted that activation of a specific intracellular signalling
molecule may lead to the stimulation of a number of unrelated cellular functions.
The reasoning behind why specific cell signalling pathways are switched on/off by
different cell stimuli is not fully understood. An example of parallel signalling is
described below and relates to work performed by Shaw and co-workers in breast
carcinoma cells (1997).
Shaw and co-workers (1997) noted that an increase in PI 3-kinase activity (due to
a6p4-mediated integrin adhesion), resulted in an increase in migration and invasion.
This cellular function was found be mediated via a PKB- and p70s6k-independent
mechanism (as the inhibition of both enzymes did not effect cell invasion). This
implied the existence of an alternative role for PI 3-kinase other than cell survival or
cell proliferation (via PKB and/or p70s6k). Activation of the small GTPase protein
rac was shown to be required for PI 3-kinase mediated invasion. The resulting
hypothesis that PI 3-kinase regulates the activity of both PKB and rac via different
parallel pathways (each terminating in a different cellular process) was reinforced by
Welch and co-workers (1998). Rac activation (via PDGF stimulation of PI 3-kinase
or by rac mutation) caused the induction of lamellipodia formation, membrane
ruffling and p70s6k activity (previously seen by Chou & Blenis, 1995). Inhibition of
rac activity resulted in loss of lamellipodia formation and membrane ruffling and a
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depletion in p70s6k activity (approximately 60%), indicating that rac had a regulatory
role in p70s6k activity only. Inhibition of p70s6k with rapamycin did not effect the
formation of lamellipodia and membrane ruffles. PDGF stimulation caused
activation of PKB which could not be inhibited by the addition of a kinase dead rac
or rapamycin. Inhibition of PKB inhibited p70s6k activity without effecting rac
activation or membrane ruffling. The conclusions drawn from these observations are
that PKB and rac activation both occur via PI 3-kinase but are situated on parallel
pathways. These two pathways result in differing cell processes (rac cytoskeletal
changes, PKB survival etc.) but are linked downstream as both regulate p70s6k
activity. The role of rac in membrane ruffling and lamellipodia formation is
independent of PKB and p70s6k activity implying the production of two or more
signalling pathways emanating from/downstream of rac, one via p70s6k and another
leading to cytoskeletal rearrangements.
Figure 1.4 summarises a number of the potential signal cascades which are mediated
by PI 3-kinase activation.
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1.7 Plan of Study.
Small cell lung cancer (SCLC) represents approximately 25% of all primary lung
cancers. SCLC patients normally present with disseminated disease and therefore
chemotherapy has become the mainstay of treatment. Given that widespread
metastasis and eventual resistance to chemotherapy are the two main causes of SCLC
patient death, these two areas were to be addressed within this thesis. The overall
aim of the following research was to try to further our understanding of the complex
molecular events which underlie the rapid proliferation times, high metastatic rates
and the cause of chemoresistance in SCLC cells.
I) Anchorage-independent growth is essential to allow tumour cells to survive and
metastasise in vivo. Recent studies have suggested that PI 3-kinase may be critical to
the proli feration, survival and metastatic capabilities of different tumour types (Keely
et ah, 1997, Shaw et ah, 1997). Investigations were undertaken to examine the role
of PI 3-kinase in SCLC cell growth and tumourigenesis.
II) Despite initial sensitivity to chemotherapy, patients almost invariably relapse and
become resistant to chemotherapy so that the two year survival rate is between 3-8
% (Elias, 1997). Recently, investigators have suggested that chemotherapeutic
agents cause cell death via apoptosis (Chen et ah, 1996a, Hannun, 1997). Adhesion
to extracellular matrix (ECM) proteins has been shown to protect many cell types
from under going apoptosis (Meredith et ah, 1993, Frisch & Francis, 1994, Boudreau
et ah, 1995 and 1996). The extracellular matrix and its protein components (section
1.4) have also been shown to regulate tumour cell proliferation, migration, invasion,
survival and differentiation. Therefore, the potential role of ECM proteins in SCLC




2.1 Small Cell Lung Cancer Cell Lines.
Classical small cell lung cancer (SCLC) cell lines NCI-H345, NCI-H69 and NCI-
H510 were purchased from the American Type Tissue Culture Collection (ATCC)
(Rockville, USA). All cell lines were of human origin and routinely screened for
bacterial, fungal and mycoplasma to ensure they were infection free. Screening was
performed by the Department of Microbiology, University of Edinburgh Medical
School, Teviot Place, Edinburgh. Cells were used for experimental purposes at low
passage levels (p5 - 50).
Cells were occasionally screened for the presence of typical SCLC cell surface
markers (Table 2.1). Cytospins were made (as described in section 2.5.3) of SCLC
cells taken directly from culture. Cytospins were air dried and fixed in 3%
formaldehyde before being stored at 4°C until required. Slides were examined by the
Department of Pathology, University of Edinburgh Medical School as part of a
routine screening process.
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Table 2.1: Antibody Markers Routinely used to Screen for Small Cell Lung
Cancer Cell Surface Markers in the Department of Pathology.
H69 H510 H345
Chromogranin +++ ++ +
Factor VIII + - -
Vimentin - - -
CAM 5.2 +++ +++ ++
NSE +++ + +++
+++ strong staining; ++ intermediate staining; + weak staining and - no staining.
NSE - neuron specific enolase. All assessments were performed in conjunction with
positive/negative controls (tissue/ cells known to positively or negatively express the
specific markers in question).
Note: The weak staining observed in H69 SCLC cells of Factor VIII was not
expected. This result maybe due to the fact that a rabbit polyclonal antibody was
utilised which may have cross reacted with another unknown cell surface marker.
2.2 Cell Culture.
2.2.1 Small Cell Lung Cancer Cell Lines.
Stocks were grown in RPMI 1640 medium containing 25 mM HEPES (Sigma, UK.).
They were supplemented with 10% (v/v) foetal calf serum (FCS) (heat-inactivated at
56°C for 1 hr.), 50 U/ml penicillin, 50 pg/ml streptomycin and 5 pg/ml L-glutamine.
Cells were grown in 75 cm3 tissue culture flasks (Costar, UK.) in a humidified
atmosphere of 5% CC>2/95% air at 37°C . Cells were passaged every 5-7 days. For
experimental purposes, cells 3-5 days post-passage were pelleted (225 x g, 4 mins) at
room temperature before being transferred into SITA medium consisting of RPMI
1640 medium with 25 mM HEPES supplemented with 30 nM selenium, 5 pg/ml
insulin, 10 pg/ml transferrin, 0.25% (w/v) bovine serum albumin (BSA), 50 U/ml
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penicillin, 50 pg/ml streptomycin and 5 pg/ml L-glutamine. Cells were cultured for a
further two days prior to use. Alternatively, cells were taken from growth medium,
washed thoroughly with quiescent medium and incubated in fresh quiescent medium
for 24 hours prior to experimentation. Quiescent medium comprised of RPMI 1640
medium containing 25 mM HEPES which was supplemented with 0.25% (w/v) BSA,
50 U/ml penicillin, 50 pg/ml streptomycin and 5 pg/ml L-glutamine. All stocks of
media were stored at +4°C and solutions at -20°C. Once prepared, media were not
stored for more than 7 days. Figure 2.1 shows representative photographs of SCLC
cell lines growing in liquid culture.
Table 2.2: Small Cell Lung Cancer Cell Line Characteristics.
(Information from ATCC, Gazdar et al., 1980 and Carney et al., 1985a & b.).
Cell Line H69 H345 H510
Year Submitted 1980 1981 1982
Patient Sex Male Male Male
Age (yrs) 55 64 56
Prior Treatment Chemo Chemo Radio
Source PE BM A
SCLC Class Classical Classical Classical
DDC u/mg 240 98 214
CK-BB pg/mg 2.2 5.8 2.7
NSE ng/mg 817 4075 491
BLI pmol/mg 1.7 4.7 7.4
Abbreviations: Chemo, Chemotherapy, Radio, Radiotherapy (to a brain lesion only),
PE, pleural effusion, BM, bone marrow; A, adrenal, DDC, L-dopa decarboxylase (>
1.0 u/mg = elevated), CK-BB, creatine kinase brain isoenzyme (> 0.4 pg/mg =
elevated), NSE, neuron specific enolase (> 100 ng/mg = elevated), BLI, bombesin-
like immunoreactivity (>0.1 pmol/mg = elevated).
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Figure 2.1:Examples of Small Cell Lung Cancer Cell Lines H345 (upper), H69
(centre) and H510 (lower) Growing in Liquid Culture.
Cells were grown in RPMI containing 10% (v/v) foetal calf serum (as described in
section 2.2.1). SCLC cells, 3-4 days post-passage were photographed using an
Olympus inverted light microscope (x 40 magnification).
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2.2.2 Swiss 3T3 Mouse Fibroblasts.
Cells were obtained from the European Tissue Culture Collection (Porton Down,
UK.). Stocks were grown in 162 cm' tissue culture flasks (Costar, UK.) in Dulbecco's
modified Eagle's medium (DMEM) (Sigma, UK.) supplemented with 10% (v/v) FCS,
50 U/ml penicillin, 50 pg/ml streptomycin and 5 pg/ml L-glutamine. Cells were
incubated in a humidified atmosphere of 5% COil95% air at 37°C. Cells were
passaged every 4-6 days. Whilst passaging the cells, they were washed in DMEM
containing no serum, then incubated in pre-warmed trypsin/EDTA (approx. 8
ml/flask) (Sigma, UK.) in a humidified atmosphere of 5% CC>2/95% air at 37°C until
the cells began to detach. DMEM containing 10% (v/v) FCS was added (to deactivate
trypsin), the cells scrapped and pelleted (225 x g, 4 minutes). Cells were then re-
seeded in fresh culture media.
For experimental purposes cells were either lysed directly from culture vessels using
phosphoinositide 3-kinase (PI 3-kinase) lysis buffer (see section 2.3.1a) (for western
blot analysis), or when grown to sub-confluence (90 - 95% confluence by light
microscopy) in 24 well plates (Costar, UK.), they were quiesced for 24 hours in
DMEM containing 0.25% (v/v) FCS before use. All stocks of media and trypsin were
stored at +4°C. Once prepared, media was not stored for more than 7 days.
2.2.3 Rat Pheocromocytoma Cell Culture.
Cells (PC 12s) were a kind gift from Dr G Hoyne, Respiratory Medicine Unit,
University of Edinburgh Medical School. Cells were grown in 162 cm3 tissue culture
flasks (Costar, UK.) in RPMI 1640 supplemented with 10% (v/v) horse serum (Sigma,
UK.), 50 U/ml penicillin, 50 pg/ml streptomycin and 5 pg/ml L-glutamine in a
humidified atmosphere of 5% C02/95% air at 37°C. Cells were passaged every 5 — 7
days using essentially the same method as described for Swiss 3T3 cells (section
2.2.2) (different cell culture medium was used). For western blot analysis cells were
lysed directly from culture vessels using PI 3-kinase lysis buffer (see section 2.3.1a).
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All stocks of media were stored at +4°C. Once prepared, media was not stored for
more than 7 days.
2.2.4 Other Cell Lines.
Other members of the laboratory who routinely used specific cells for
experimentation, provided all other cell types described and utilised in this thesis.
Bovine trachea smooth muscle cells (BTSM) - These primary culture cells were
kindly provided by Dr T.R. Walker.
Human alveolar type II epithelial cells / adenocarcinoma cells (A549s) - These cells
were purchased from the ATCC and routinely cultured by Ms T Watchorn.
Both of the above cell types was cultured in DMEM supplemented with 10% (v/v)
FCS, 50 U/ml penicillin, 50 pg/ml streptomycin and 5 pg/ml L-glutamine.
For western blot analysis, the cells were lysed directly from culture vessels using ice
cold PI 3-kinase lysis buffer (section 2.3.1a) before being equilibrated for total protein
content.
2.3 In Vitro Protein Kinase Activity Assays.
2.3.1 Phosphoinositide 3-kinase Activity Assay.
Section a describes the activity assay used to provide the results described throughout
this thesis. Section b describes some of the alterations carried out to achieve this final
assay procedure. Section c describes additional experimentation performed to ensure
the final assay product was correct.
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2.3.1a Assay Procedure.
PI 3-kinase lysis buffer : Stock Solution : 50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5
mM MgCl2, 1 mM EGTA, 10 mM sodium pyrophosphate, 100 mM sodium fluoride,
10% (v/v) glycerol and 1% (v/v) Triton X-100. The stock solution was stored at +4°C
until required.
Added fresh: 0.5 mM dithiothreitol, 1 mM sodium orthovanadate, 50 pM AEBSF, 5
pg/ml leupeptin, 20 pg/ml aprotinin and 10 pg/ml soybean trypsin inhibitor. Protease
inhibitors were stored at -20°C until required.
Sonicated Lipid Substrate: (Prepared on the day.) Phosphatidylinositol (PI) and
phosphatidylserine (PS) (Sigma, UK.) (150 pi : 50 pi) was dried under vacuum at
room temperature. To the resulting dried lipids, 250 mM HEPES (1 ml) was added
and the lipids sonicated on ice using a small probe (soniprep - MSE) (2 x 10 sec).
Final stock concentration was 2 mg/ml. The resulting lipid micelle were stored on ice
until required.
Essentially, SCLC cells were cultured overnight in quiescent medium, pelleted (225 x
g, 4 mins) and washed three times with warmed PBS. Cells (lxl07 /ml) were gently
disaggregated by two passes through a 21 gauge needle. Cells were then transferred in
to 24 well plates (1 ml PBS/ well) and allowed to equilibrate at 37°C for 1 hour.
Varying concentrations of wortmannin, DMSO vehicle (final concentration 0.001%
v/v) (20 minutes) or specific mitogens (see figure legends) (5 or 10 minutes) were
added. After incubation, the cells were immediately transferred into 1.5 ml
eppendorfs on ice (Starstedt Ltd, Germany.), pelleted (300 x g, 1 min, 4°C), the
resulting supernatant removed and the remaining pellet lysed using 400 pi ice-cold PI
3-kinase lysis buffer (20 minutes on ice). Lysates were clarified by centrifugation at
13000 x g for 10 minutes (4 °C) and supernatants transferred to fresh microfuge tubes.
The supernatants were pre-cleared for 1 hour by addition of 50 pi BSA-sepharose
beads (Sigma, UK.) in 50 pi lysis buffer. Lysates were pre-cleared prior to
immunoprecipitation to limit any non-specific adsorption of proteins to the beads used
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later in the immunoprecipitation step. Protein content was measured using a Pierce
BCA protein assay kit (section 2.7) (Rockville, USA). Approximately 1 mg of total
protein was used per assay point. Lysates were snap frozen by being rapidly
immersed in liquid nitrogen and stored at -80°C until required.
The frozen lysates were slowly thawed on ice prior to the addition of the p85-PI 3-
kinase antibody (2.5 pg/assay point). Following a 90 minute incubation at 4°C on an
orbital shaker, 30 pi of a 50:50 slurry containing goat anti-mouse IgG agarose beads
in lysis buffer was added, and the incubations continued for a further 2 hours. The
beads were then pelleted and washed sequentially: once with lysis buffer, once with
100 mM Tris FIC1 (pH 7.6), 500 mM LiCl, and twice with 200 mM HEPES (pH 7.4),
40 mM MgCl2, 600 mM NaCl.
PI 3-kinase assays were performed using phosphatidylinositol (PI) as the substrate in a
final volume of 200 pi containing: (final concentrations) 50 mM HEPES (pH 7.4), 10
mM MgCl2, 150 mM NaCl, [32P]y-ATP (10 pCi, 3000 Ci/mmol), 50 pM ATP and
0.2 mg/ml sonicated phosphatidylinositol/phosphatidylserine (3:1, w/w). The
reactions were carried out for 20 minutes at 37°C, terminated by the addition of
chloroform/methanol/0.1 M HC1 (40/80/1, v/v/v; 750 pi) and a phase-partition
achieved by the addition of chloroform (250 pi) and 0.1 M HC1 (250 pi). After
centrifugation (13,000 x g, 1 min) the upper phase was aspirated and the lower phase
washed twice with synthetic upper phase (750 pi) consisting of
MeOH:HCl(lM):CHCl3 (48 :47 :3 v/v/v).
The resulting chloroform phase was dried under vacuum at room temperature and the
lipid products separated by thin layer chromatography (TLC) using the following
solvent system: methanol/ chloroform/ cone, ammonia/ dH20 (10/ 7/ 1.5/ 2.5, v/ v/ v/
v.) (prepared fresh when required). Phosphorylated lipids were identified by
autoradiography (TLC plates placed for 1 - 2 days at -70°C, XOMAT film (Kodak)).
The radioactive bands that were visualised by autoradiography were excised from the
TLC plate and transferred into liquid scintillation vials. Liquid scintillation fluid was
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added (3 ml) (Flo-Scint IV (Packard B.V.)) and radioactivity incorporation assessed
using a Packard 1900 TR liquid scintillation analyser.
For assays involving LY294002, immunoprecipitates from untreated cells were
prepared as above, washed and incubated with varying concentrations of LY294002
for 20 minutes at 37°C before being assayed for PI 3-kinase activity as above. Figure
2.2 demonstrates a representative TLC autoradiograph showing the concentration-
dependent inhibition of PI 3-kinase activity on the addition of wortmannin and
LY294002. In the results sections, data is expressed as % change in PI 3-kinase
activity in comparison to untreated control cells.
In figure 2.2 differences between the amount of 'free ATP' present in each sample
was observed on the TLC plate treated with wortmannin. This was due to differences
in the efficiency of the phase partition between the aqueous and organic phases. On
addition of the synthetic upper phase (aqueous), free ATP would move into the
aqueous phase until equilibrium was reached. The aqueous phase would be removed
and replaced twice with fresh synthetic upper phase in the attempt to remove any free
ATP not utilised during the assay procedure. If any of the aqueous phase was not
removed (i.e. was stuck to the side of the eppendorf, or not all the interphase was
removed efficiently), free ATP would remain behind. The amount of free ATP
present in each sample at this stage does not effect the assay result in any way. On the
lower autoradiograph, bands are visualised below the PI3P band. These bands were
analysed by HPLC and shown not to be PI3P. They eluted off the SAX 5 column by
HPLC at a low (NH4)2HP04 concentration. It is thought that these bands were
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Figure 2.2: Representative Autoradiographs of TLC Plates indicating the
Presence of the Lipid Molecule Phosphotidylinositol 3 phosphate (PI3P) on
Addition of different Phosphinositide 3-kinase Inhibitors.
Upper: H345 cells were inhibited with increasing concentrations of wortmannin over
20 minutes. Cells were lysed and immunoprecipitated using a p85-PI 3-kinase
antibody. A PI 3-kinase activity assay was performed and the resulting lipid products
separated by TLC and autoradiographed as described in section 2.3.1a.
Lower: H345 cells were lysed and immunoprecipitated for p85-PI 3-kinase before
being inhibited with increasing concentrations of LY294002 (20 minutes) prior to
assaying for PI 3-kinase activity. The resulting lipid products were separated by TLC
and autoradiographed.
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When assaying for PI 3-kinase activity in the presence of the extracellular matrix
protein laminin, 12 well tissue culture plates were coated with laminin (10 pg/ml, 500
pl/well) overnight at 4°C. Plates were washed in sterile PBS and the cells (1 ml/well)
allowed to adhere for 40 minutes. This time frame was chosen as SCLC cells were
known to be able to adhere to ECM proteins in 40 minutes by both adhesion and
immunofluorescence experiments (see chapter 5). Cells were plated at a concentration
of approximately 8 x 106/ml as this number was assessed visually by light microscopy
to produce a single monolayer of cells. After adhesion in the presence or absence of
wortmannin, cells were transferred onto ice before being centrifuged at 670 x g for 4
minutes at 4°C to enable the cells to pellet on to the base of the wells. Once
transferred back onto ice, media was aspirated off and PI 3-kinase lysis buffer added
to each well (500 pi). This method was adopted because trying to aspirate the cells
out of the wells and in to eppendorfs prior to lysis, caused the strongly adherent cells
to remain in the wells. Cells were then lysed on ice, equilibrated for protein and the
assay performed as described previously.
2.3.1b Initial Experiments
Undertaken to achieve final assay procedure described in section 2.3.1a.
Initial experiments were undertaken to investigate the possibility that PI 3-kinase
would be activated by the addition of various neuropeptides and growth factors that
had previously been shown to activate PI 3-kinase in other cell types (described
further in results chapter 3).
The original PI 3-kinase activity assay was developed using adherent PC 12 cells
(Carter & Downes, 1992). Given that SCLC cells grow in suspension, alterations
were made to the incubation procedure of the assay. Experiments were performed by
placing quiesced SCLC cells (approximately 2 x 107/ml, 0.5 ml/well) (24 well tissue
culture plate (CorningCostar, New York.)) in a water bath at 37°C, prior to the
addition of various mitogens. To terminate the reaction, the tissue culture plates were
placed on ice and 0.5 ml of ice cold PI 3-kinase lysis buffer was added to each well.
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The assay procedure was then followed essentially as described by Carter & Downes
(1992). The first sets of experiments were unsuccessful with no bands/ radioactivity
visualised by autoradiography.
Worries about the efficiency of the lysis step were addressed. Dithiothreitol, sodium
orthovanadate, and the required protease inhibitors were all freshly added to the other
components of the PI 3-kinase lysis buffer to attempt to achieve efficient lysing of the
cells.
To try and provide a more effective lysis technique, and to attempt to decrease the
initial plating concentration of the SCLC cells, cells were incubated in 1 ml of
RPMI/well. After 'stimulation' the plates were transferred on to ice where the
samples were transferred into ice-cold eppendorfs prior to being gently pelleted (as
described in the final assay system) at 4°C. The resulting RJPMI supernatant was
removed and 0.5 ml of ice-cold PI 3-kinase lysis buffer was added to each pellet and
assay continued as before. This second assay procedure took slightly longer to
perform but prevented the lysis buffer from being mixed with warmed RPMI. After
these changes, weak bands were visualised on the autoradiographs. Results primarily
indicated that on the addition of 10% (v/v) foetal calf serum or insulin, there was no
significant increase in PI 3-kinase activity (discussed in chapter 3). However, on the
addition of the PI 3-kinase inhibitor wortmannin, PI 3-kinase activity was shown to
fall below control levels. (Control cells - received diluent alone.)
To attempt to make the immunoprecipitation stage of the assay more efficient, a PI 3-
kinase specific monoclonal antibody was used which recognised the SH3 domain of
the p85 regulatory subunit. The primary antibody was a mouse monoclonal antibody.
To precipitate this type of antibody research has shown that an anti-mouse IgG
agarose is the most efficient.
Results still suggested that the addition of mitogens did not cause a large increase in
PI 3-kinase activity. As this was still thought surprising, it was hypothesised that the
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initial protein concentration in each assay point may be inaccurate (i.e. the number of
cells plated/well varied). Therefore more protein was present in the control samples
artifically elevating the basal PI 3-kinase activity levels calculated. As SCLC cells are
free floating in culture, investigators are unable to grow the cells to subconfluence in
petri/culture dishes. Using adherent cell types, investigators are able to assume that
once the petri dishes are subconfluent there will be approximately an equal
concentration of protein in each dish. To overcome this possible problem of uneven
protein concentration distribution between assay points, an additional step was added
to the assay procedure. Following the pre-clearing stage, lysates were assayed for
total protein concentration so that each point could be equilibrated (protein assay
procedure section 2.7). Even when the samples were equilibrated for total protein
concentration, the same assay result was repeatedly obtained. The addition of
mitogens did not cause a large increase in PI 3-kinase activity levels above control
values. (Note - As experience has increased, it is possible to efficiently aliquot
approximately identical cell numbers per well; however protein assays are still
regularly used to assess total protein content.)
So far the experiments undertaken had been carried out with cells that were quiesced
overnight (before being plated in RPMI for the assay), therefore it seemed unlikely
that wortmannin should be able to reduce the PI 3-kinase basal activity levels by such
a high degree. To attempt to lower the basal activity levels, cells were quiesced
overnight at a lower cell concentration, washed in large volumes of PBS and plated in
PBS for the assay. This was to remove any possible trace of exogenous mitogens.
This made no different to the results obtained.
Further changes carried out to try and ensure that the assay procedure was efficient
were :
I) Carter & Downes (1992) previously dipped the TLC plates in a solution of 1%
potassium oxalate, 2 mM EDTA in 50% methanol/50% water, and dried them at
110°C for 1 - 2 hr prior to use. This was to increase the 'cleanness' of the lipid
separations on the TLC plate because they were assaying for the presence of a number
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of different lipid products in each sample. In view of the fact that the assay described
throughout this thesis investigated only the conversion of the lipid substrate PI to
PI3P, this was deemed not necessary. Parallel experiments run on dipped and
undipped TLC plates showed no differences in the results obtained.
II) Initially the substrate lipid mixture (PI/PS) was sonicated in PI 3-kinase assay
buffer. This resulted in the production of large lipid micelle. To produce smaller lipid
micelle, lipids were sonicated in (250 mM HEPES). This resulted in the production of
a more uniform small lipid micelle solution.
III) The initial experimentation technique by Carter & Downes (1992) described how
the primary antibody was incubated with cell lysates for 2 hours, the secondary
antibody was added and the resulting solution incubated overnight. Investigations
studying the efficiency of the immunoprecipitation procedure were performed.
Results indicated that incubation with the secondary antibody for approximately two
hours was as efficient as overnight. This was assessed by western blotting the
immunoprecipitates and probing with the PI 3-kinase antibody. Densitometry analysis
showed no significant variations between the procedures (data not shown).
IV) As the immunoprecipitation stage now consisted of an 90 minute, and a 2-hour
incubation, studies were carried out to see if snap freezing the cell lysates (after
assessment for total protein) in liquid nitrogen affected PI 3-kinase activity. In
parallel assay investigations, this was shown not to be the case.
Once the above alterations were performed, the assay resulted in the production of a
radioactive PI3P lipid product. The result however was still the same (Figure 2.3) -
addition of mitogens did not cause a large increase in PI 3-kinase activity levels over
basal, and the addition of wortmannin significantly lowered the PI 3-kinase activity
level below basal levels.
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BASAL WM INSULIN
Figure 2.3: Effect ofWortmannin and Insulin on H345 Small Cell Lung Cancer
Cell Phosphoinositide 3-kinase Activity.
Cells were pre-incubated with wortmannin (20 minutes) or insulin (5 minutes) prior
to cell lysis. Cell lysates were then assayed for PI 3-kinase activity as described in
section 2.3.1a. The graph is representative of a single experiment carried out 2-4
times out in duplicate, in SCLC cell lines H345, H510 and H69. Basal = control cells
that received diluent only. (WM, wortmannin (100 nM) and insulin (1 ju.M)).
Above: Representative autoradiograph showing the 3'-phosphorylated product
(PI3P) for each condition in duplicate.
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Further experiments were undertaken to study basal PI 3-kinase activity levels in a
panel of cell types. Results (Chapter 3) indicated that the high basal PI 3-kinase
activity levels observed in SCLC cell lines were not artificial. In a number of parallel
experiments SCLC cell lines routinely expressed PI 3-kinase basal activity levels
significantly higher than other cell types. All cell types were quiesced prior to
assaying for activity and each assay point was equilibrated for total protein
concentration. In view of the fact that the PI 3-kinase activity assay procedure was
now accepted as working correctly, further investigations were performed, and are
discussed further in this thesis.
2.3.1c Clarification Studies.
Throughout the studies, checks were carried out to ensure that the band visualised by
autoradiography and subsequently excised from the TLC plate at the end of the assay,
was phosphotidylinositol 3-phosphate (PI3P). To identify the 3'-phosphorylated
lipids by high pressure liquid chromatography (HPLC) they have to be deacylated.
After removal of the fatty acid backbone (deacylation), the molecules
(glycerolphosphoinositol phosphates) become water soluble and highly negatively
charged. These products were then separated by anion-exchange columns with high
salt buffers, using a modified method first described by Clarke and Dawson (1981).
Radioactive bands were excised, 25% methylamine in water:methanol:butanol (4:4:1
v/v/v mixture, 3 ml) was added, and the resulting mixture capped tightly and placed at
53°C for 30 minutes with 30 second vortexing every 10 minutes (Methylamine causes
cleavage of the fatty acid backbone.) The tube was spun for 3 minutes at
approximately 1,000 x g before being centrifugally dried overnight in a speedivac
(R10.10 Jouan) at room temperature. Once dry, water (1 ml) and butanol:40-60 bp
petrol ether:ethyl formate (20:4:1 v/v/v, 1.2 ml) were added and the solution vortexed.
The top layer (containing transacylated lipids) was discarded. The lower phase was
again washed with the butanol:40-60 bp petrol ether:ethyl formate mix (20:4:1 v/v;
1.2 ml). The final lower phase that was obtained contained the cleaved lipid head
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group. This solution was separated using a HPLC strong anion exchange (SAX) 5 (5
micron pore size) column with a (NH4)2HP04 gradient (Figure 2.4) (1 ml fractions
were collected at 1 minute intervals). Authentic tritiated standards were used as
markers. The tritiated markers were generated by Dr T.R. Walker, Rayne laboratory,
University of Edinburgh from metabolically labelled 132IN astrocytes and
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Figure 2.4: Representative HPLC trace of the 3-phosphorylated Lipid products
formed during a Phosphoinositide 3-kinase Activity Assay.
Areas of a TLC plate were excised which corresponded to the radioactive sections of
the plate. The lipid products were separated from the silicon plate before being
deacylated and analysed by HPLC on a (NH4)2HP04 gradient (see section 2.3.1c).
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2.3.2 Ribosomal Protein S6 Kinase Activity Assay.
p70s6k lysis buffer : Stock Solution : 50 mM Tris/HCl (pH 8.0), 120 mM NaCl, 20
mM NaF, 5 mM EGTA, 1 mM EDTA and 10 mM sodium pyrophosphate (stored at
4°C until required).
Freshly added: 10 mM /?-nitrophenyl phosphate, 1 mM benzamidine, 0.1 mM PMSF
and 1% (v/v) Nonidet P40.
Activation of Pansorbin: Pansorbin (crude extract of protein A from Staphylococcus
aureus) was aliquoted into 1.5 ml eppendorfs (1 ml/eppendorf) and centrifuged (2,000
x g) for 10 minutes. The supernatant was removed and the pellet resuspended in PBS
containing 10% (v/v) (3-mercaptoethanol and 3% (v/v) SDS. The solution was
vortexed and boiled for 15 minutes before being centrifuged at 2000 x g for a further
10 minutes. The resulting pellet was resuspended in the original volume (1 ml) in
p70s6k lysis buffer and stored at -20°C until required.
Washing Buffer : 25 mM HEPES (pH 7.4), 20 mM B-glycerophosphate, 20 mM
MgCl2, 3 mM EGTA, 0.2 mM sodium orthovanadate and 2 mM dithiothreitol. The
buffer was made fresh when required.
The p70s6k activity assay performed was modified from a procedure previously
described by Scott and co-workers (1996). SCLC cells cultured overnight in
quiescent medium were washed in prewarmed PBS before being transferred into 1.5
ml eppendorfs (Starstedt Ltd, Germany). The cells were preincubated at 37°C in a
shaking thermomixer for 30 minutes before the addition of various concentrations of
wortmannin, LY294002, DMSO vehicle (final concentration 0.001% v/v) (20
minutes) or specific mitogens (see figure legends) (5 or 10 minutes). After
incubation, the cells were immediately pelleted (~ 300 x g, 1 min, 4°C), the resulting
supernatant removed and the pellet lysed using 400 pi ice-cold lysis buffer for 30
minutes on ice. Lysates were clarified (13000 x g, 10 minutes at 4°C) and equal
quantities of the protein equilibrated supernatants (approximately 0.4 mg/assay point),
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were incubated with 2 jag polyclonal anti-p70s6k antibody at 4°C on a shaking
platform. After 90 minutes the lysates were further incubated with 25 pi of activated
pansorbin.
After 60 minutes incubation in the presence of pansorbin (4°C), the
immunoprecipitates were washed twice in lysis buffer and twice in the same buffer
without detergent. This was followed by two washes in washing buffer prior to the
pellets being incubated in washing buffer containing 100 pM S40 substrate peptide,
10 pM adenosine 3' 5'-cyclic monophosphate-dependent protein kinase inhibitor and
[32p]y_ATP (10 pM; 1 pCi/condition, 3000 Ci/mmol) in a final volume of 30 pi. (The
S40 peptide substrate was comprised of a 9 amino acid sequence (KKRNRTLTK) that
is specifically recognised by the p70s6k and not the related p90rsk protein). The in vitro
kinase assay was performed over 20 minutes at 30°C in a shaking thermomixer. The
reaction was terminated by the addition of 10 pi of 300 mM phosphoric acid before 30
pi of the resulting mixture was spotted onto P81 chromatography paper (3x3 cm
squares) (Whatmann). The papers were washed twice with 0.5% (v/v) phosphoric
acid and then allowed to dry and being transferred into liquid sctintillation vials and 3
ml of liquid scintillation fluid added (Flo-Scint IV (Packard)). Radioactivity
incorporation was assessed using a Packard 1900 TR liquid scintillation analyser. The
phosphorylation of the S40 substrate peptide was quantified by liquid scintillation
counting as an index of enzymatic activity. Results are expressed as % change in
enzyme activity in comparison to untreated cells.
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2.4 Assessment of Small Cell Lung Cancer Cell
Growth.
Two methods were utilised under liquid culture conditions to assess SCLC cell
growth:
[3H]-thymidine incorporation provides an estimate of the relative number of cells that
are undergoing DNA synthesis in comparison to other cells incubated under a variety
of different conditions. The cells are known to incorporate the thymidine during the
s phase of the cell cycle. Therefore you are looking at changes in the relative number
of cells that are undergoing cell division within the time frame of the experiment.
The liquid growth assay is a more indirect method used to assess cell proliferation.
In this type of experiment you are assessing the total number of cells present in your
culture. This method therefore takes into account not only the increase in cell
number due to cell division, but also the decrease in cell number due to cell death via
apoptosis/necrosis. Additionally, a small percentage of the cells counted may be
undergoing apoptosis whilst still being intact.
2.4.1 [3H]-Thymidine Incorporation.
SCLC cells 3-5 days post passage, were cultured in serum-free SITA medium for two
days before being centrifuged at 225 x g for 3 minutes, washed and resuspended in
SITA medium. Cells were then disaggregated into an essentially single cell
suspension by two passes through a 21 gauge needle. Viability was judged by trypan
blue exclusion to be > 95%. Cell number was determined using a Coulter cell counter
(Coulter electronics, UK.) before the cells (5xl04/ml) were aliquoted into round-
bottomed 96 well plates (Gibco BRL, UK.) (200 pl/well). Plates were incubated for
approximately 4 hours in a humidified atmosphere of 5% CCb/ 95% air at 37°C prior
to the addition of inhibitors (see appropriate figure legends). Cells were then
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incubated under the same conditions for 48 or 72 hours prior to the addition of [JH]-
thymidine (20 - 30 Ci/mmol, 0.1 pCi/well). Cells were incubated in the presence of
[1H]-thymidine for a further 24 hours. Finally the cells were harvested onto GF-B
glass fibre filters using a TOMTEC cell harvester before [3H]-thymidine incorporation
was measured using a Wallac (1205) beta plate counter. All results are expressed as %
inhibition of [3FI]-thymidine incorporation with respect to control cells (treated with
diluent only).
When assaying for [3H]-thymidine incorporation in the presence of the ECM protein
collagen IV, a slightly altered procedure was used. Flat bottomed 96 well plates
(Gibco BRL, UK) were coated overnight at 4°C with various concentrations of
collagen IV (50 pl/well). The next day the wells were washed with sterile PBS to
remove excess collagen IV. SCLC cells were then added to the wells and incubated as
described above. Prior to [3H]-thymidine incorporation assessment, plates were
shaken using a benchtop vortex fitted with a plate holder adaptor head to loosen the
adherent cells. Cells were further loosened using a yellow tip (2 passes). Finally,
[3E1]-Thymidine incorporation was assessed as described above. At the end of the
assay procedure, each plate was studied by light microscopy to ensure the majority of
cells had been removed.
2.4.2 Liquid Growth Assay.
Cultures of SCLC cells at five days post-passage, were grown for two days in SITA
medium. Prior to experimentation, cells were centrifuged at 225 x g (4 minutes) and
washed twice in SITA medium before being resuspended in fresh SITA. Cells were
gently disaggregated by two passes through a 21 gauge needle into an essentially
single cell suspension as judged by light microscopy. Viability was determined by
trypan blue exclusion on a hsemocytometer and judged to be > 95%. Cells (1 x
107ml) were seeded into 24 well plates in SITA medium and incubated for 4 hours in
a humidified atmosphere of 5% CCb/ 95% air at 37°C prior to the addition of various
inhibitors (see appropriate figure legends). Cells were further incubated under the
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same conditions before being removed at various times, disaggregated into a single
cell suspension using a 21 gauge needle (two passes) (modified from (Carney et al.,
1980)) and cell number determined using a Coulter Cell Counter. Results are
expressed as % inhibition of cell number with respect to control cells (treated with
diluent only), or as fold increase in cell number with respect to initial number of cells
plated..
2.4.3 Clonogenic Assay.
Previous work by Freedman and Shin (1974) has demonstrated that the ability of
SCLC cells to form colonies in semi-solid media directly correlates to the
tumourigenicity of the cancer in vivo. This assay not only assesses the cells' ability to
proliferate, but also to survive within a 3-dimensional environment in a single cell
suspension.
SCLC cells 3-5 days post passage, were centrifuged at 225 x g for 4 minutes, washed
and resuspended in SITA medium. Cells were then disaggregated into a single cell
suspension by two passes through a 21 gauge needle. Viability was judged by trypan
blue exclusion to be greater than 95%. Cell number was determined using a Coulter
cell counter, before lxl04 cells (per ml) were mixed with SITA medium containing
0.3% (w/v) agarose and the specific agonist/inhibitor at the concentrations indicated
(see relevant figure legends). This was layered over a solid base of 0.5% (w/v)
agarose in SITA medium containing the same concentration of the relevant
agonist/inhibitor, in 35 mm plastic dishes (CorningCostar, UK.). The cultures were
incubated in a humidified atmosphere of 5% CCb/ 95% air at 37°C for 21 days prior
to being stained with the vital stain nitroblue tetrazolium. Colonies of >120 pm
diameter (16 cells) were counted by light microscopy (x40).
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2.5 Assessment of Small Cell Lung Cancer Cell
Apoptosis.
2.5.1 Acridine Orange, Ethidium Bromide Staining.
Washed SCLC cells (2x107ml) were seeded into 96 well plates in (200 pi) and
incubated in a number of different culture mediums for a defined time. A mixture of
ethidium bromide (100 pg/ml) and acridine orange (100 pg/ml) (1:1 v/v; 1 pi) diluted
in PBS (pH 7.2) was added to each well. The percentage of cells undergoing
apoptosis was then assessed using fluorescent microscopy (x 40) (BH2 Olympus) as
described previously (Cotter & Martin, 1996).
Table 2.3: Assessment Guidelines for Calculation of Cell Apoptosis Levels Using
Acridine Orange and Ethidium Bromide Staining.
Cell Stage
Viable Cells Bright green nucleus with intact structure.
Early Apoptotic Bright green nucleus showing condensation
of chromatin as dense areas in the nucleus
Late Apoptotic Orange nucleus showing condensation of
chromatin as dense orange areas.
Necrotic Orange nucleus with intact structure
Information from Cotter & Martin, 1996.
Essentially acridine orange and ethidium bromide excite green and orange
fluorescence bands respectively. Acridine orange is able to penetrate through an intact
plasma membrane therefore healthy cells appear green. When both acridine orange
and ethidium bromide enter the cell (late apoptotic and necrotic cells) the ethidium
bromide fluoresces stronger and the cells appear orange.
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2.5.2 ELISA Cell Death Detection.
SCLC cells were washed and quiesced for 24 hours prior to gentle disaggregation
into an essentially single cell population by 2 passes through a 21 gauge needle.
Approximately 5x1 CP cells/ml were plated out into 48 well plates (500 pl/well).
Cells were incubated at 5% C02/ 95% air, 37°C for 2 - 3 hours before addition of the
inhibitors (see relevant figure legends). After 24 hours cells (150 pi) were removed
for cytocentrifugation (see following method), and from the remaining cells 200 pi
were removed and assessed for apoptosis using a Cell Death Detection ELISA plus
kit (Boehringer and Mannheim, Germany).
The assay is a photometric enzyme-immunoassay which detects the presence of
cytoplasmic histone-associated-DNA-fragments which are produced during
programmed cell death (apoptosis). Essentially, the cells were washed and lysed
before the lysates were transferred into the streptavidin-coated ELISA plates
provided. A mixture of anti-histone (biotinylated) and anti-DNA (peroxidase-
conjugated) mouse monoclonal antibodies were added to the lysates and incubated
over 2 hours. During this period the anti-histone antibodies associated with the
histone components of the nucleosomes. These in turn became attached to the
streptavidin-coated plates (via its biotinylation). The anti-DNA antibodies then
reacted and associated with the DNA components of the nucleosomes. After removal
of any unbound antibody, the amount of nucleosomes bound to the plate was
quantified and determined photometrically using the substrate supplied (ABTSR).
Results are expressed as the increase in absorption (405 nm) of treated cells in
comparison to untreated cells (positive and negative controls are also provided with
the kit).
2.5.3 Morphological Assessment by Cytocentrifugation.
Cells that were treated with various inhibitors over 24 hours (see section 2.5.2) were
harvested from each well (150 pi approximately 7.5x104) and cytocentrifuged (300 x
g, 3 min) (Shandon, Cytospin 3) on to glass slides. The resulting slide preparations
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were air dried, fixed in methanol (5 minutes) and allowed to air dry again before being
stained with May-Grunwald-Giemsa stain. Covers slips were added to each slide
using DPX. Cell morphology was examined by objective light microscopy (x40), and
apoptotic SCLC cells defined as smaller cells containing more a darkly stained
condensed nuclei. For each condition examined, slides were prepared from triplicate
incubations and a total of at least 500 SCLC cells were counted over a minimum of
five random fields per slide. Figure 2.5 shows two representative SCLC cytopsins.
SCLC cells are mitotic cells (i.e. are continually dividing). One of the characteristics
of SCLC cells when spun for cytological examination is that mitosis is particularly
noticeable. Concerns are often expressed as to the visual differences between
apoptotic and dividing cells. During the dividing procedure the cells do condense but
the chromatin structure is more noticeable. The nuclei of dividing cells do not stain as
darkly as apoptotic nuclei, and often more cytoplasm is noticeable around the nucleus.
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Figure 2.5: Representative Cytocentifugation Slides which were used to assess
Small Cell Lung Cancer Cell Apoptosis levels.
Cells were assayed and cytocentrifuged (as described in material and methods section
2.5.3). The photographs above show representative SCLC cytospins.
UPPER: A cytospin of control SCLC cells incubated over 48 hours in quiescent
medium.
LOWER: A cytospin of SCLC cells treated with tyrphostin-25 (25 M) over 48
hours prior to assessment for apoptosis.
NOTE the apoptotic SCLC cells are more condensed and darkly stained ( -►).
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2.6 Immunoblotting.
Cell lysates were assessed using western blotting techniques to identify the presence
of a variety of different proteins throughout this thesis. Cell pellets were lysed on ice
in PI 3-kinase lysis buffer (50 pi) (section 2.3.1a) for 30 minutes before the protein
concentration of each cell lysate was measured using a Pierce BCA protein assay
(Section 2.7). Once equilibrated for total protein, the whole cell lysates were
separated by SDS-PAGE.
2 x Sodium dodecyl sulfate (SDS)-PAGE Sample Buffer : 250 mM Tris HC1 (pH 6.8),
4% SDS (v/v), 10% glycerol (v/v), 0.006% bromophenol blue (v/v) and 2% p-
mercaptoenthanol (v/v).
10% SDS Polyacrylamide Gels :
Resolving gel preparation: acrylamide solution (30%) (29% : 1% acrylamide : N',N'-
methylenebisacrylamide in dH20) (8.33 ml), separating gel buffer (1.5 M Tris base
(pEl 8.8), 10% SDS) (6.25 ml), dH20 (10.38 ml), 25% ammonium persulphate (100
pi) and temed (20 pi).
Stacking gel preparation: acrylamide solution (30%) (1.5 ml), stacking gel buffer (1.0
M Tris base (pEl 6.8), 10% SDS) (2.5 ml), dH20 (5.7 ml), 25% ammonium
persulphate (50 pi) and temed (10 pi).
Gel Electrophoresis Buffer: 25 mM Tris base (pH 8.3), 250 mM glycine, 0.1% SDS.
Blotting Buffer: 210 mM glycine, 24.7 mM Tris base and 20% methanol in dH20.
Washing Buffer: (Tris buffered saline (TBS)). 20 mM Tris/ElCl (pH 7.4), 150 mM
NaCl and 0.2 % (v/v) Tween 20.
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When immunoblotting whole cell lysates, 20 p.g of total protein was solubilised in an
equal volume of 2x SDS-PAGE sample buffer at 95°C for 3 minutes. Samples were
cooled, any undisolved material was pelleted (13,000 x g, 1 min) before equal
amounts of protein (20 pi) were resolved on 10% SDS polyacrylamide gels using a
tris-glycine gel electrophoresis buffer (Atto Electrophoresis gel apparatus, 80 - 120
volts, 3 - 4 hours at room temperature (or until broad range molecular weight markers
(Sigma, UK.) leading front reached the base of the gel)).
The separated proteins were transferred on to nitrocellulose membranes (HybondC,
Amersham UK.) in blotting buffer (Biorad Mini Protean II apparatus, 100 volts, 1
hour at 4°C). The resulting filters were blocked using 5% (w/v) non-fat milk in
washing buffer overnight at 4°C to prevent any antibodies binding to the
nitrocellulose membranes in a non-specific manner. Blots were then incubated with
primary antibody diluted in blocking buffer (washing buffer containing 5% (w/v) non¬
fat milk) for 1 hour at room temperature on a rocking platform. Between antibody
incubations, filters were washed in washing buffer (3 x 10 minutes) to ensure
thorough removal of any unbound antibody. After washing, the secondary antibody
(appropriate HRP-conjugated antibody) was incubated with the nitrocellulose
membrane for approximately 1 hour at room temperature on a rocking platform. Both
the primary and secondary antibodies were normally used at a 1:1000 in blocking
buffer (see figure legends for exact dilutions). Finally, the immunoreactive bands
were identified using enhanced chemiluminescence (ECL) (Amersham, UK.). ECL is
a high resolution, non-radioactive method of detecting specific immobilised antigens
that are conjugated (indirectly or directly), to horseradish-peroxidase labelled
antibodies.
To ensure that equal protein loading of gels occurred, duplicate gels were run and
stained for protein when blotting protein samples. Figure 2.6 represents an example
of a gel run and analysed for total protein. The protein bands were stained with
comassie blue (consisting of 0.25% (w/v) comassie blue in destain solution) for 1 hour
on a shaking platform. Excess stain was then removed from the gel by sequential
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washes of the gel in destain (40% (v/v) methanol, 10% (v/v) acetic acid in dl I20) and
the gel dried overnight under vacuum.
2.7 Protein Concentration Assessment.
The assay kit was purchased from Pierce, IL, USA. Essentially the protein present
within the test solution causes the reduction of copper2"1" - copper'+ in an alkaline
medium. The copper1 + is then detected colourmetrically (purple) by bicinchoninic
acid (BCA) (Smith et ah, 1985). The colour is produced by the chelation of BCA to
copper1" (2 : 1 ratio) and the protein concentration is assessed using a spectometer at
562 nm. The assay is able to measure protein concentrations accurately between 20
pg/ml and 2 mg/ml. The protein concentrations in each sample are calculated in
comparison to BSA standards made in the lysis buffer in which the samples to be
tested were lysed. The assays were carried out by incubating the mixtures at 37°C
for 30 minutes before allowing the plates to cool to room temperature and reading the
results on an automated plate reader (Dynatech, MR5000, Dynatech UK.). Each
assay point was read in triplicate and the average absorbance calculated.
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Figure 2.6: Representative SDS-polyacrylamide Gel Stained to Visualise all the
Protein Bands present in Whole Cell Lysates of a Number of Different Cell
Types.
A representative dried SDS-polyacrylamide (10%) gel stained with coomassie blue
(0.25% w/v) (section 2.6.1). Left - Right: Broad range molecular weight markers
(Ml), H510, H345, H69, A549, Swiss 3T3, PC12, BTSM, kaleidoscope molecular
weight markers (M2). Abbreviations BTSM - bovine trachea smooth muscle cells.
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2.8 Tissue Immunohistochemistry.
Small cell cancer lung resection specimens were collected from pathology files
(1989-1994) of the Department of Pathology, University of Edinburgh.
Representative sections were cut from formalin fixed and paraffin embedded blocks,
dewaxed in xylene and rehydrated through graded alcohols to water. Antigen
unmasking was performed by either pre-incubating sections in 0.1% trypsin (pH 7.6)
at 37°C for 15 minutes (fibronectin, laminin and tenascin) or microwave-oven
boiling for 15 minutes in 0.1 M citrate (pH 6.0) (collagen IV).
ECM expression was demonstrated using antibodies against fibronectin (1:100),
laminin (1:100, LAM-89) tenascin (1:100, BC-24) and collagen IV (1:100, Col-94).
All were purchased from Sigma UK. and were mouse monoclonal antibodies with the
exception of fibronectin (rabbit polyclonal). Sections were processed (by Dr R.C.
Rintoul) using a Techmate 500 (Dako, UK.). Antibody detection was performed
using a multilink streptavidin biotin complex method and visualisation achieved
using a di-amino benzidine chromagen method as per manufacturer's instructions
(Dako, UK.). The slides were counterstained using Harris' haematoxylin, dehydrated
through graded alcohols and mounted in xylene. Negative controls (sections
processed as above except the primary antibody was omitted) were incubated each
time the procedure was performed. Sections were used as their own positive controls
by ensuring that areas of each section that would normally be positive for each ECM
(e.g. blood vessel walls) were indeed positive. All slides were reviewed
independently by two people. The staining was graded on a semi-quantitative scale
as no staining, focal staining or extensive (> 50% of section area) staining.
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2.9 Adhesion Assay.
Laminin (Ln), fibronectin (Fn) (Gibco BRL, UK.) and collagen IV (C IV) (Sigma,
UK.) were used as substrates in the serum-free adhesion assays. All ECM proteins
were aliquoted and stored as per manufacturers instructions (-80°C). Fibronectin is
known to be very unstable, so when the protein was required it was flash thawed at
37°C prior to use. (This was to prevent the protein from immunoprecipitating out of
solution.)
Cells (5 x 10^ /ml) 3-5 days post passage were washed twice in RPMI and
disaggregated into essentially a single cell population (by two passes through a 21-
gauge needle) in quiescent medium. Tissue culture plates (96 well) were previously
incubated overnight with different ECM proteins (laminin. 10 pg/ml, fibronectin, 20
pg/ml and collagen IV, 10 pg/ml) and poly-L-lysine (25 pg/ml) (50 pl/well). The
following day, the plates were washed with sterile PBS to remove any unbound
proteins before being blocked with 1 mg/ml BSA (1-2 hrs at 37°C). After washing
the plates with sterile PBS, the SCLC cells (100 pi) were added to 96 well tissue
culture plates (CorningCostar UK.) and were allowed to attach for 45 mins at 37°C.
The non-adherent cells were then gently removed by aspirating off the media and
gently washing the wells with PBS. The remaining cells were fixed with 3%
formaldehyde for 1 hr at room temperature prior to centrifugation (225 x g, 5 mins).
The formaldehyde was removed and the attached cells were stained with 1%
methylene-blue. After 5 minutes, the wells were washed with distilled water to
remove any excess dye. 0.1N HC1 (100 pi) was added/well to release the internal
dye, and the resulting solution read at 630 nm on an automated plate reader
(Dynatech, MR5000, Dynatech UK.). The attachment of SCLC cells to wells coated
with 25 pg/ml poly-L lysine were designated as 100% adhesion. (Poly-L-lysine
causes enhanced non-specific charge-related adhesion.)
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Note: - In experiments when inhibitors were added, see figure legends for
concentrations and the time the cells were exposed to inhibitors prior to the adhesion
assay being performed. Times varied due to the efficiency of the specific inhibitor at
entering the cell and inhibiting the enzyme in question.
2.10 Confocal Microscopy.
Glass-cover slips were coated with specific ECM proteins or poly-L-lysine (10
pg/ml) overnight at 4°C. This was carried out by covering a large petri dish in
clingfilm. Approximately 50 pi (depending upon size of coverslip) of the coating
matrix solution was added to the clingfilm to form a small 'mound' of matrix
solution. Coverslips were gently placed on the top of the solutions enabling the
lower face of the coverslip to be in contact with the matrix solution. After overnight
incubation at 4°C, the coverslips were removed and placed in 12 or 24 well culture
plates with the matrix covered face of the coverslip facing upwards. The coverslips
were washed in SITA to remove any unbound ECM proteins prior to the addition of
SCLC cells to the wells.
Cells were gently disaggregated by passing twice through a 21-gauge needle. The
essentially single cell population of SCLC cells (in SITA) was allowed to attach to
the matrix coated coverslips for 45 mins in a humidified atmosphere of 5% COil95%
air, at 37°C. Unattached cells were gently removed, fresh SITA added (1 ml /well)
and the attached cells were allowed to adhere for a defined time. Finally, the SITA
medium was removed and the cells were fixed (3% para-formaldehyde in PBS) for
20 mins, washed before being quenched (50 mM NELjCl/PBS) for 10 mins to mop up
any excess formaldehyde present. Cells were permeabilised using 0.1% TX-100
(v/v) in calcium and magnesium free (CMF)-PBS for 4 mins. Permeabilised cells
were blocked using 0.2% (w/v) fish skin gelatin/CMF-PBS (3x5 mins) before being
stained with rhodamine phalloidin (1 : 400 dilution, Molecular Probes Europe BY)
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for 20 mins in the dark at room temperature for actin filament studies. (All the above
procedures were carried out in culture dishes.)
For the studies investigating the expression of tyrosine phosphorylated proteins (anti-
phosphotyrosine antibody 4G10, 1 : 150 dilution), the coverslips were inverted on
clingfilm on top of the primary antibody (diluted in blocking buffer) for 30 mins - 1
hour at room temperature (50 pl/coverslip). This was followed by three consecutive
washes of 5 minutes with blocking buffer in culture plates. The slides were finally
incubated inverted on clingfilm again with the secondary antibody (anti-mouse FITC,
1 : 25 dilution in blocking buffer) for 30 mins - 1 hour before being washed in sterile
PBS and air dried.
At the end of either staining procedure, the coverslips were mounted onto glass slides
(matrix and cell covered face facing the glass slide) using DPX.
Immunofluorescence was scanned using a BioRad MRC 600 laser confocal
microscope with a Zeiss 63X objective or by fluorescence microscopy using a
Olympus BH2 microscope.
Note: When cells were incubated in the presence of specific inhibitors, before being
allowed to adhere to the matrix coated coverslips, they were incubated in sterile
tissue culture flasks (5 ml cells/ flask) in the presence of the inhibitor for a defined
time (see appropriate figure legends) in a humidified atmosphere of 5% C02/95%
air, at 37°C. Cells were then washed in fresh SITA (containing the inhibitor), before
being gently disaggregated into an essentially single cell population. Cells were
finally allowed to adhere to the matrix coated coverslips (in media still containing the
inhibitor). Once the non-adhered cells were removed fresh SITA (containing the
inhibitor) was added and the experiment continued as described previously.
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2.11 Chemosensitivity Assay.
Cells grown in SITA 3-5 days post-passage were washed, resuspended in SITA
medium and seeded (5 x 10^ cells/200 pl/well) in 96 well plates in the presence or
absence of ECM (laminin or collagen IV 10 pg/ml and fibronectin 20 pg/ml, each
well coated overnight at 4°C, 50 pi matrix solution/well). Serial dilutions of the
cytotoxic agent were added to each well 1 - 2 hrs after seeding. When tyrphostin-25
(25 pM) was utilised, it was added along side the cytotoxic agent. After three days in
a humidified atmosphere of 5% C02/95% air, at 37°C, the cells were assayed for
either total cell number or apoptosis levels. When assaying for percentage apoptosis,
the cells detached from the plates, aspirated and cytospun onto glass slides, fixed in
methanol and stained using May-Grunwald-Geimsa stain (described in section 2.5.3),
or spun down directly onto the microtitre plate, fixed and stained for counting and
photography. Cell number was calculated by counting the number of cells in 5
random fields of an inverted light microscope at 100X magnification. The total
number of cells present in the well was then calculated mathematically as the size of
the whole well and each field counted was known.
NOTE: In every experiment each condition was carried out in quadruplicate and in
duplicate tissue culture plates.
In the experiments described throughout this thesis, the chemotherapy reagent
cyclophosphamide was often utilised. As cyclophosphamide is a pro-drug which has
to be metabolised in the liver before it becomes active (section 1.1.4.1), the active
form (cis-4-sulfoethylthio-cyclophosphamide) was utilised in the experiments
described within this thesis.
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2.12 Flow Cytometric Analysis of Integrin
Expression.
Monoclonal antibody labelling of intact cells was performed using an indirect
immunofluorescence technique. Briefly, cells (lxlO3) were added to a 96-well
flexible assay plate and washed in phosphate buffered saline containing 0.2% (w/v)
BSA and 0.1% (w/v) sodium azide (EPICS buffer). Cells were then incubated in
50 pi of saturating concentrations of primary antibodies (1 : 500 dilution) in EPICS
buffer, av (13C2, Dr Mike Elorton, St Bartholemew's Hospital), a2 (AK7), a3
(11G5), a4 (HP2/1), a5 (SAM-1) a6 (AF-10 (IgG2b)), p3 (PM6/13), p2 (MHM23,
Dako, UK.) or (31 (mAb 13 (rat IgG, Becton Dickinson, UK.)). All antibodies were
purchased from Serotec UK. unless otherwise stated. Cells were incubated for
30 min on ice, washed twice in EPICS buffer and incubated with 1:25 dilution of
FITC conjugated anti-mouse secondary antibody (Dako, UK.) (with the exception of
the pi antibody where a FITC conjugated anti-rat secondary antibody was used) for
30 min on ice. Cells were washed and resuspended in EPICS buffer and analysed by
flow cytometry using an EPIC profile II (Coulter Electronics, UK.). All
photomultiplier settings were standardised throughout the study. Measured mean
fluorescence intensity (arbitrary units (AU)) was recorded for each sample.
2.13 Materials.
Monoclonal p85-SH3 PI 3-kinase antibody, and the S40 peptide substrate were from
TCS (Buckingham, UK.). Polyclonal p70s6k antibody was obtained from Santa Cruz
Biotechnology (Santa Cruz, USA). Adenosine 3' 5'-cyclic monophosphate-dependent
protein kinase inhibitor, tyrosine kinase inhibitors genistein and tyrphostin-25, MAP
kinase (MEK 1) inhibitor PD 098059 and LY294002 were from Calbiochem-
Novabiochem Corp (Nottingham UK.). Mouse monoclonal phosphotyrosine antibody
4G10 was purchased from Affinity UK. [3-P]y-ATP (3000 pCi/mmol), [6-3H]-
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thymidine (20-30 Ci/mmol) and Hybond C nitrocellulose membranes were purchased
from Amersham International (Amersham UK.). CIS-4-sulfoethylthio-
cyclophosphamide (pro-drug of cyclophasphamide) was purchased from Astra
Pharmeceuticals (UK). Cell culture antibiotics (Penicillin and Streptomycin),
Trypsin/EDTA (IX) (in Hanks buffered salt solution without calcium and
magnesium), 30% acrylamide solution and the extracellular matrix proteins
fibronectin and laminin were obtained from Gibco BRL (UK.). Horse radish
peroxidase (HRP)-conjugated antibodies were obtained from Dako UK. The May-
Grunwald-Giemsa stain (Diff Quick solution: Soliution I - Eosin G in phosphate
buffer pH 6.0 and solution II - Thiazime blue in phosphate buffer pH 6.0) was
purchased from Baxter healthcare Ltd, Scotland, UK..
PKBa, y, PH domain antibodies were a kind gift from Dr D.R. Alessi and Professor P
Cohen, University of Dundee, UK. The integrin function blocking antibody P5D2
was kindly given to us by Dr. P. Hughes, Scripps Research Institute, La Jolla, USA.
All reagents not specified along with RPMI 1640, BSA agarose, IgG protein agarose,
foetal calf serum, collagen IV, chemotherapy reagents, cytochalasin D, rapamycin and
wortmannin were purchased from Sigma (Poole, UK.). All reagents were of the
purest grade available.
2.14 Statistical Analysis and Pharmacological
Definitions.
All statistical analysis carried out within this thesis used the Instat computer package
(version 3.0). One way analysis of variance (ANOVA) was performed followed by
the Student-Newman-Keuls multiple correlation post test. (ANOVA compares the
means of 3 of more groups of data. Student-Newman-Keuls test compares the mean
of each set of data with all the others.)
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All IC50 concentrations and curve fits were calculated using the Macintosh Curve Fit
Package - Kaleidograph version 2.3.1.
Definitions of pharmacological abbreviations used in this thesis:
IC50 - Where a compound causes an inhibitory response, the IC50 is the molar
concentration which produces 50% of its maximum possible inhibition.
EC50 - The molar concentration of an agonist which produces 50% of the maximum
possible response for that agonist.
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CHAPTER 3
Phosphoinositide 3-kinase Activity is Elevated
in Small Cell Lung Cancer Cells and Regulates
Ribosomal Protein S6 Kinase Activity In Vitro.
3.1 Introduction.
The majority of cancer patients die as a result of tumour invasion and secondary
metastatic deposits. Thus, the ability of cancer cells to grow in an inappropriate
environment is central to cancer-related death. The actual mechanisms of how SCLC
cells overcome anchorage-dependence and metastasise are unclear.
Research to date has revealed that a large number of neuropeptides are secreted by
SCLC cells (reviewed Moody & Cuttitta, 1993), and that these neuropeptides
promote SCLC clonal growth (Carney et al., 1987, Sethi & Rozengurt, 1992). This
ability to grow in the absence of exogenously provided mitogens, via autocrine
growth loops, enables SCLC cells to become serum-independent and survive in an
inappropriate environment (i.e. whilst metastasising).
Studies performed in different cell types have shown that overexpression of focal
adhesion kinase (FAK), ras and src can lead to anchorage-independence, serum-
independence and cell transformation (Frisch et al., 1996a, Ihle & Kerr, 1995, Frisch
& Francis, 1994, Khwaja et al., 1997). Results showed that after constitutive
activation of ras, MDCK cells were able to survive when detached from tissue
culture plates (Khwaja et al., 1997). Detachment-induced apoptosis was also
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abrogated in epithelial cells when they were transformed with either v-Ha-ras or v-
src (Frisch & Francis, 1994). However, in SCLC cells, none of these proteins have
been shown to be either overexpressed or constitutively active (Tallett et ah, 1996,
Suzuki et ah, 1990, Budde et ah, 1994). Therefore, other proteins, yet to be
identified, must regulate SCLC cell anchorage-independence and aid in SCLC cell
transformation.
Previous studies have shown that activation of the lipid/tyrosine kinase
phosphoinositide 3-kinase (PI 3-kinase) (reviewed section 1.6) is required to enable
many processes involved in tumourigenesis to occur. These include cell
proliferation, inhibition of apoptosis and anoikis, and invasion (Yao & Cooper, 1995,
Shaw et al., 1997, Keely et al., 1997, Khwaja et al., 1997). Shaw and co-workers
noted that activated PI 3-kinase was required to enable breast carcinoma cells to
become invasive. Additionally, Keely and co-workers showed that PI 3-kinase
activation was required to enable transformed breast epithelial cells to become motile
and invasive. Finally, Khwaja and co-workers (1997) showed that adhesion to ECM
proteins caused an increase in PI 3-kinase activation levels in MDCK cells.
Detachment of these cells led to anoikis. However, in genetic mutation studies,
constitutively activated PI 3-kinase could prevent anoikis from occurring via a PKB-
dependent mechanism.
Thus, in response to the above observations, we went on to examine the potential role
of PI 3-kinase in regulating different cellular functions in SCLC cells. The aim of
the work presented in this chapter was to investigate whether the expression and
activation of PI 3-kinase was significantly altered in any way in comparison to




3.2.1 Expression of Phosphoinositide 3-kinase in Small Cell Lung
Cancer Cells.
The expression of the p85a subunit of PI 3-kinase was examined in a number of
different cell types. Swiss 3T3 cells are often used as model cells to investigate the
mechanisms behind SCLC cell proliferation and survival, and thus provided a
comparable cell system in which to examine the relative expression of PI 3-kinase.
A549 cells are derived from a different lung cancer type (adenocarcinoma) and were
used to examine the possibility that differences observed might relate to more than
one type of lung cancer. Rat pheochromocytoma cells (PC 12) cells were tested along
side SCLC cells, as they are of neuroendocrine origin. SCLC cells are known to
exhibit a large number of neuroendocrine markers.
Using western blotting techniques, the presence of the p85a PI 3-kinase subunit in
SCLC cells was demonstrated (Figure 3.1). In comparison to Swiss 3T3 cells, A549
cells and PC 12 cells, high levels of p85a PI 3-kinase were observed under normal
culture conditions in SCLC cell lines H69 and H345. Slightly lower levels of PI 3-
kinase expression were seen in the SCLC cell line H510.
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H510 H345 H69 A549 PC12 3T3
Figure 3.1: Western Blot of the p85a Protein Subunit of Phosphoinositide 3-
kinase.
Cells were grown 3-5 days post passage prior to being lysed in PI 3-kinase lysis
buffer. Lysates were equilibrated for protein, separated by SDS-PAGE and probed
with a p85-SH3 PI 3-kinase mouse monoclonal antibody (1:1000 dilution). The blot
represents one experiment carried out in duplicate (n = 4).
Abbreviations: H69, H345, H510 - SCLC cell lines, A549, adenocarcinoma cell line,
PC12, rat pheochromocytoma cell line, 3T3, Swiss 3T3 mouse fibroblasts.
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3.2.2 Activity Levels of Phosphoinositide 3-kinase in Small Cell
Lung Cancer Cell Lines under Different Culture Conditions.
Figure 3.1 demonstrates the relatively high expression levels of p85a PI 3-kinase in
SCLC cells, but does not provide any information on its activity status. The ability
of PI 3-kinase to be activated in response to the addition of various neuropeptides or
growth factors was examined in the SCLC cells. Quiesced/ basal SCLC cells were
classified as cells grown overnight in quiescent (Q) medium (section 2.1), before
being washed and incubated in warmed PBS prior to experimentation. This
procedure was performed to remove any exogenous or autocrine growth factors
which may stimulate the cells, as it has been proposed that SCLC cells proliferate by
autocrine/paracrine growth factor and neuropeptide stimulation. Given that addition
of growth factors which have previously been shown to stimulate p85a/pl 10 PI 3-
kinase activity in other cell types should theoretically result in the activation of PI 3-
kinase in SCLC cells, foetal calf serum was initially used as it contains a variety of
mitogenic factors known to stimulate PI 3-kinase including LPA, NGF and IGF-1
(Zhang et al., 1995, Vemuri & Rittenhouse, 1994, Soltoff et al., 1996, Carter &
Downest, 1996, Kotani et al., 1994). However, PI 3-kinase activity levels could only
be increased by a modest amount in H69 (51 ± 19.4% (mean ± S.D., n = 2)) and
H510 (82.9 ± 22% (mean ± SEM, n = 4)) SCLC cell lines in comparison to quiesced
SCLC cells upon the addition of 10% (v/v) foetal calf serum over 10 minutes.
The neuropeptide insulin has been shown to be important in the proliferative
properties ofmany SCLC cell lines (Bepler et al., 1988, Nakanishi, 1988). Addition
of insulin (1 pM) for 5 minutes was unable to induce a large increase in the
activation of PI 3-kinase. A modest increase in PI 3-kinase activity was observed in
all three SCLC cell lines including H345 cells (e.g. average PI 3-kinase activity per
mg of total protein; Basal = 12080 cpm and insulin (1 pM) = 17680 cpm
(corresponds to a 46% increase in PI 3-kinase activity above control values)).
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In view of the above results, further studies were performed under basal conditions to
establish that SCLC PI 3-kinase activity levels were elevated. SCLC cells were
grown in either quiescent growth medium (devoid of all growth factors and
neuropeptides) or in serum-free SITA medium (supplied with a number of known
key proliferation stimulators of SCLC cells). Under these conditions, similar levels
of PI 3-kinase activity were seen (Figure 3.2). The activity levels of PI 3-kinase per
mg of total protein were SITA 55140 ± 3143 cpm, quiescent 49685 ± 4173 cpm and
10% (v/v) FCS 83405 ± 16181 cpm (mean ± SD, n=2 in duplicate) for H69 SCLC
cells.
Further investigations have examined the basal levels of PI 3-kinase activity in a
larger number of SCLC cell lines (H69, H345, H510, DMS79 and LS274) (Moore et
ah, 1998). Elevated basal PI 3-kinase activity levels were observed in all the SCLC
cell lines examined in comparison to a number of different cell types including Swiss
3T3 fibroblasts and A549 cells (Figure 3.3). All cells were quiesced and washed in
PBS prior to experimentation to remove all exogenous mitogens.
Thus, under strict conditions where every effort was made to remove the presence of
all exogenous/autocrine growth factors and neuropeptides (by extensive washing and
the incubation of SCLC cells in PBS), high basal PI 3-kinase activity levels were
observed in SCLC cells only. These results suggested that the elevation in PI 3-
kinase activity was not caused by the external stimulation of growth factor/G-protein
coupled receptors in SCLC cells. This was corroborated by the observation that the
PI 3-kinase activity levels of SCLC cells incubated in either quiescent or serum-free
SITA medium were not statistically different. However, elevated PI 3-kinase basal




Figure 3.2: Changes in Phosphoinositide 3-kinase Activity levels in H69 Small
Cell Lung Cancer Cells under Different Culture Conditions.
Cells were washed and cultured in either serum-free SITA or quiescent medium (Q)
overnight prior to being re-washed, plated in warmed PBS and assayed for PI 3-
kinase activity. 10% FCS indicates cells were cultured in Q medium and then
stimulated with 10% (v/v) FCS for 10 minutes prior to lysis. 3-phosphorylated lipids
were resolved using TLC, autoradiography and quantified by liquid scintillation
counting. Results are the mean ± SD. of two independent experiments carried out in
duplicate. Representative autoradiograph shows the 3'-phosphorylated lipid product
(PI3P) for each condition in duplicate. Results are expressed as % change in activity
in comparison to SITA (control). SITA activity levels were taken to equal 100% PI
3-kinase activity.
Average cpm/mg total protein/min 2757 cpm (SITA = 100%), 2484 ± 209 cpm (Q)
and 4171 ±810 cpm (10% (v/v) FCS).
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Figure 3.3: Phosphoinositide 3-kinase Activity in a Number of Different Cell
Types.
Cells were quiesced before being washed in PBS and lysed in PI 3-kinase lysis
buffer. After the lysates were equilibrated for protein concentration, they were
assayed for PI 3-kinase activity. Results are the mean cpm ± S.D. of 2 independent
experiments performed by Dr R.C. Rintoul.
Abbreviations: HBE, human bronchial epithelial cells, 3T3, Swiss 3T3 fibroblasts.
BTSM. bovine trachea smooth muscle cells, A549, human type II alveolar epithelial
cells. All other cell types were SCLC cell lines.
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3.2.3 Inhibition of Phosphoinositide 3-kinase Activity in Small Cell
Lung Cancer Cells using Wortmannin.
Due to the above observation that PI 3-kinase is activated under basal cell culture
conditions in SCLC cells, the ability to inhibit this activity was examined using a
well documented and specific PI 3-kinase inhibitor, wortmannin. Wortmannin is a
non-competitive inhibitor of PI 3-kinase which is able to inhibit PI 3-kinase activity
by irreversibly binding to the ATP binding site present on the pi 10 catalytic subunit
of the p85/pl 10 heterodimer (Arcaro & Wymann,1993, Wymann et ah, 1996).
Pretreatment of the SCLC cells with increasing concentrations of wortmannin
(DMSO < 0.001% (v/v)) for 20 minutes prior to cell lysis caused a concentration-
dependent inhibition of basal PI 3-kinase activity in all three cell lines (graphs with
representative autoradiographs for H69 and H345 cell lines shown - Figure 3.4). The
IC50 values for wortmannin were 8.0 ±2.1 nM (mean ± S.D., n = 2), 0.27 ±1.1 nM
(mean ± SEM, n = 3) and 6.55 ± 1.49 (mean ± SEM, n = 4) for H69, H345 and H510
SCLC cells respectively. The IC50 values obtained using wortmannin are similar to
those previously published (Powis et al., 1994 (IC50 = 3 nM)). Maximal inhibition
was observed with the addition of 100 nM wortmannin (75 ± 3.3%, 82 ± 7% and
79.33 ± 10.33% for H345, H69 and H510 SCLC cells respectively).
3.2.4 Inhibition of Phosphoinositide 3-kinase Activity in Small Cell
Lung Cancer Cells using LY294002.
To clarify that basal SCLC cell PI 3-kinase activity could be inhibited, an alternative
PI 3-kinase inhibitor was utilised. LY294002 is structurally different to wortmannin
and inhibits PI 3-kinase activity in an alternative manner (Vlahos et ah, 1994).
LY294002 is a competitive inhibitor of PI 3-kinase activity, whilst wortmannin is a
non-competitive inhibitor. LY294002 associates with a region of PI 3-kinase
common to the agonist (ATP in this case) without activating the enzyme. Whilst





Figure 3.4: Effect of Wortmannin on Phosphoinositide 3-kinase Activity in
Small Cell Lung Cancer Cells H345 (left) and H69 (right).
Pre-washed SCLC cells were inhibited with increasing concentrations ofwortmannin
for 20 minutes prior to lysis and assaying for PI 3-kinase activity (see section 2.3.1a)
using phosphoinositide (PI) as the substrate. Values shown are the mean ± SD (H69)
and SEM (H345) for 2 - 3 independent experiments carried out in duplicate. Basal
(control) PI 3-kinase activity was taken as 100% (no inhibitor added). 3-
phosphorylated lipids were resolved by TLC, visualised by autoradiography and
quantified by liquid scintillation counting. Above, representative autoradiographs
showing the 3-phosphorylated lipid product (PI3P) are shown for each condition.
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non-competitive inhibitors covalently bind to their target forming a stronger bond.
The competitive association/binding of an inhibitor can often be overcome by
increasing the concentration of agonist (ATP) with respect to the inhibitor. This
results in an increased probability of the agonist binding to the site in relation to the
inhibitor. Also continual washing of the enzyme following immunoprecipitation
may cause dissociation and loss of the inhibitor.
Pretreatment of the SCLC cells with LY294002 had no effect on basal PI 3-kinase
activity (Figure 3.5). However, addition of LY294002 to PI 3-kinase
immunoprecipitates caused a concentration-dependent inhibition of PI 3-kinase
activity (Figure 3.6). As with the inhibition of SCLC cell PI 3-kinase using
wortmannin, LY294002 produced IC50 values for all three cell lines similar to those
previously published (Vlahos et al., 1994 (1.4 pM)). The IC50 values for the
inhibition of PI 3-kinase activity by LY294002 in H69, H345 and H510 cells were
3.4 ± 1.4 pM (mean ± SEM, n = 5), 0.85 ± 0.41 pM (mean ± SEM, n = 4) and 1.27 ±
0.55 pM (mean ± SD, n = 2) respectively. LY294002 (100 pM) was maximally
effective causing 98 ± 0.9%, 98 ± 3% and 95 ± 1.46% inhibition of PI 3-kinase
activity in H345, H69 and H510 SCLC cells respectively.
In summary, PI 3-kinase activity was shown to be elevated under basal growth
conditions in all SCLC cell lines examined. Under these conditions, the PI 3-kinase
activity levels observed in SCLC cells were significantly higher than in any of the
other cell types examined. However, this elevated activity could be significantly
inhibited upon the addition of either wortmannin or LY294002. These data taken
together suggests that in SCLC cells PI 3-kinase is constitutively activated. This is
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Figure 3.5: Representative Autoradiograph of the POP Lipid Product produced
in a Whole Cell Phosphoinositide 3-kinase Activity Assay in the Presence of
Increasing Concentrations of LY294002.
SCLC cells were pre-incubated with increasing concentrations of LY294002 for 20
minutes prior to cell lysis. Lysates were assayed for PI 3-kinase activity as described
in the materials and methods section. Autoradiograph shows the formation of the 3'-
phosphorylated lipid product (PI3P) from a single experiment representative of at
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Figure 3.6: Concentration-dependent Inhibition of Phosphoinositide 3-kinase
Activity by LY294002 in Small Cell Lung Cancer Cell Lines H345 (left) and H69
(right).
Untreated SCLC whole cell lysates were immunoprecipitated using a p85-PI 3-kinase
antibody (2.5 pg/mg protein). The immunoprecipitates were washed and treated with
increasing concentrations of LY294002 immediately prior to assaying for in vitro
phosphoinositide 3-kinase activity using PI as the lipid substrate. The resulting lipid
products were separated by TLC before [ 2P]y-ATP incorporation was assessed by
liquid scintillation counting. Values shown are mean ± SEM for 4 - 5 independent
experiments performed in duplicate. Untreated SCLC cell lysate activity was taken
to equal 100% (control value). Above: representative autoradiographs showing the




To investigate whether the presence of this constitutive PI 3-kinase activity in SCLC
cells resulted in the increased activity of potential downstream signalling targets,
ribosomal protein s6 kinase (p70s6k) activity was assessed. This enzyme has been
shown to reside downstream of PI 3-kinase in many cell types (Chung et ah, 1994,
Weng et al., 1995) using a number of different techniques including the use of
pharmacological inhibitors as well as enzyme and receptor mutants (section 1.6.2.2).
3.2.5 Expression of p70s6k in Small Cell Lung Cancer Cells.
Using western blotting techniques, the serine/threonine protein p70s6k was shown to
be expressed in all three SCLC cell lines (Figure 3.7).
Seufferlein and Rozengurt (1996) have previously shown that in the SCLC cell lines,
p70s6k is constitutively phosphorylated, and that this phosphorylation could be
inhibited by the addition of rapamycin. However, research by different research
groups has shown that p70s6k contains a number of phosphorylation sites and exists in
various phosphorylation states. It is not until a number of crucial sites are
phosphorylated that the enzyme becomes active (Ferrari et al., 1992, Pearson et al.,
1995, Moser et al., 1997). Therefore, in the case of p70s6k, phosphorylation levels as
a whole may not reflect enzymic activity. To investigate the activity of p70s6k in
SCLC cells, an in vitro kinase assay technique was utilised.
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Figure 3.7: Western Blot Demonstrating the Expression of p70s6k in Small Cell
Lung Cancer Cell Lines H69, H345 and H510 and Swiss 3T3 Fibroblasts.
Cells were grown 3-5 days post passage prior to lysis, protein equilibration and
separation by gel electrophoresis. Levels of p70s6k were assessed using a rabbit
polyclonal anti-p70s6k antibody (1:1000 dilution) followed by an anti-rabbit HRP
conjugate (1:1000) (Dako, UK.). The blot was visualised by ECL. Autoradiograph
is representative of a single experiment carried out four times.
Figure 3.8: Effect of Rapamycin and Foetal Calf Serum on p70s6k Activity in
Small Cell Lung Cancer Cells.
Cells were incubated with either rapamycin (Rap) (20 min), 10% (v/v) FCS (10 min)
or in combination before being lysed and assayed for p70s6k activity using the S40
peptide as the enzyme substrate. Results are expressed as % activity of p70sbk in
relation to cells treated with diluent only (control = 100% (DMSO < 0.001% v/v)).
Each bar is representative of the mean (± range) of a single experiment carried out in
duplicate of at least 3 experiments in H345 SCLC cells.
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3.2.6 p70s6k Activity in Small Cell Lung Cancer Cells.
Initial results demonstrated the presence of a significant level of p70s6k activity in
basal SCLC cells which could be both stimulated by the addition of 10% (v/v) FCS
and maximally inhibited by the addition of rapamycin (Figure 3.8). Prior addition of
rapamycin to incubated whole cells could prevent the stimulation of p70s6k by serum.
Addition of rapamycin to the immunoprecipitated p70s6k enzyme did not inhibit
enzyme activity confirming that its mechanism of action is to inhibit an upstream
regulator of the enzyme (Chou & Blenis, 1995) (Figure 3.9).
3.2.7 Regulation of p70s6k Activity by Phosphoinositide 3-kinase.
To investigate whether p70s6k was situated downstream of PI 3-kinase in SCLC cells,
p70s6k in vitro kinase assays were performed in the presence of wortmannin and
LY294002. Cells were pre-treated with increasing concentrations of wortmannin or
LY294002 for 20 minutes prior to cell lysis. This resulted in a concentration-
dependent inhibition of p70s6k activity by both inhibitors in all three SCLC cells lines
tested (Figure 3.10). The IC50 values in the three SCLC cell lines tested were 1.3 ±
0.73 nM (mean ± SEM, n = 4), 14.6 + 5.5 nM (mean + SEM, n = 3) and 4.1 nM (n =
1) for wortmannin, and were 0.9 ± 0.68 pM (mean ± SEM, n = 4), 4.2 ± 1.2 pM
(mean ± SEM, n = 3) and 1.0 pM (n = 1) for LY294002 in H69, H345 and H510
cells respectively. These results are similar to the IC50 values obtained using both
wortmannin and LY294002 to inhibit PI 3-kinase activity (Table 3.1). Whilst
performing these experiments, it was noticed that both LY294002 and wortmannin
were unable to fully inhibit p70s6k activity. The addition of either inhibitor was only
able to achieve between 65 and 70% inhibition of p70s6k activity at maximally
effective concentrations.
Additional experiments were performed to clarify that both LY294002 and
wortmannin are unable to inhibit p70s6k directly. The incubation of either inhibitor
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with immunoprecipitated p70s6k was shown to have no effect on enzyme activity
(Figure 3.9).
In summary, p70s6k activity is regulated in a PI 3-kinase -dependent and -independent
manner. However, inhibition of mTOR activation completely prevents p70s6k










Figure 3.9: Effect of Various Inhibitors on Immunoprecipitated p70s6k Activity.
H345 SCLC cells were washed and lysed prior to immunoprecipitation of p70s6k
using a p70s6k rabbit polyclonal antibody (2 pg/assay point). Immunoprecipitates
were incubated with specific inhibitors (Rap, rapamycin; WM, wortmannin or LY,
LY294002) for 20 minutes before assaying for p70s6k activity. In comparison to
control values (cell lysates treated with diluent alone (DMSO < 0.01% (v/v)), results





Figure 3.10: Ribosomal p70s6k Activity in Small Cell Lung Cancer Cells in the
Presence ofWortmannin and LY294002.
Well washed H69 (upper) and H345 (lower) SCLC cells were inhibited with
increasing concentrations ofWortmannin (left) and LY294002 (right) for 20 minutes
prior to lysis. Cell lysates were immunoprecipitated using a p70s6k antibody (2.0
pg/assay point) and assayed for p70s6k activity using a S40 synthetic peptide
substrate. Results are expressed as mean values ± SEM for 3 - 4 independent
experiments carried out in duplicate. Control cells (cells received diluent alone
(DMSO < 0.01% (v/v)) were expressed as 100% activity. (Basal/ control H69
activity level was 4317 ± 346 cpm with non-specific background counts of 698 ± 158
cpm. For H345 cells basal/ control level was 4417 ± 897 cpm with non-specific
background levels of 392 ± 90 cpm.)
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3.2.8 Presence of Protein Kinase B Isoforms in Small Cell Lung
Cancer Cell Lines H69, H345 and H510.
Over the last few years protein kinase B (PKB) has been shown to be situated
downstream of PI 3-kinase in many different cell types (discussed in section 1.6.2.1).
PKB is a product of the v-akt oncogene and has been shown to be overexpressed in a
number of different cancers including ovarian and breast cancer (Cheng et ah, 1992,
Bellacosa et ah, 1995).
Western blot analysis was performed to investigate the presence of the different PKB
isoforms in SCLC cells (Figure 3.11). Whole cell lysates were separated by SDS-
PAGE and western blotted using polyclonal antibodies to the different isoforms of
PKB. Antibodies raised against the pleckstrin homology (PH) domain of PKB
recognised a number of proteins upon western blotting. This may be due to the
polyclonal antibody recognising the PH domains of other proteins within the cell. To
date, over 100 different proteins are known to contain PH domains (Shaw, 1996).
In view of the fact that only the a and y PKB isoforms were initially shown to be
expressed in the SCLC cells (Figure 3.11), further experimentation investigating the
presence of the PKBp isoform was performed using a higher concentration of the
PKBp antibody. Using an elevated concentration of the PKBp antibody (8 pg/ml), a
band was identified at the molecular weight corresponding to PKBp (approx. 57
kDa) (Figure 3.12). In addition, other proteins were detected by this antibody at the
higher concentration. This may be due to the polyclonal PKB antibody recognising
other epitopes on a variety of proteins.
In protein equilibrated samples, similar levels of PKBa were observed in both the
SCLC and Swiss 3T3 cells (Figure 3.13). Two bands were consistently observed in












Figure 3.11: Western Blots Demonstrating the Presence of the Different Protein
Kinase B Isoforms in Small Cell Lung Cancer Cells.
Cells grown for 3 - 5 days post passage were lysed in PI 3-kinase lysis buffer.
Proteins were separated by SDS-PAGE and the resulting nitrocellulose blots were
visualised with various antibodies to the different protein kinase B isoforms (a, P, y
and PH - antibody recognising the pleckstrin homology domain present in PKB).
Primary antibodies (sheep polyclonal) were used at a concentration of 2 pg/ml. The
secondary antibody (1:1000) was a donkey anti-sheep HRP (SAPU UK.). (Note
'corresponds to the PKB isoform present in that specific lane.) Results are
representative of individual experiments carried out at least 3 times in each SCLC
cell line.





Figure 3.12: Western Blot of Small Cell Lung Cancer Cells Probed with a
Protein Kinase B (3 Antibody.
Lysates were produced as previously described (section 2.6), and probed with a sheep
polyclonal anti-PKBp antibody (8 pg/ml) (secondary antibody donkey anti-sheep
HRP (1:1000)). Immunoreactive bands were visualised by ECL. Western blot is
representative of an individual experiment performed 2 times.
3T3 H69 H345 H510
Figure 3.13: Expression of Protein Kinase B a in Small Cell Lung Cancer Cell
Lines H69, H345 and H510 and Swiss 3T3 cells.
Cells were cultured for 3 - 4 days in liquid culture media prior to whole cell lysis.
Cell lysates were equilibrated for protein, and proteins separated by SDS - PAGE.
Levels of PKBa present were assessed using a PKBa sheep polyclonal antibody
(0.15 pg/ml). (Secondary antibody donkey anti-sheep 1:1000 (SAPU UK.)). Bands
were visualised by ECL. The western blot is representative of an individual




Initial experiments revealed high protein levels of the p85a regulatory subunit of PI
3-kinase in the SCLC lines examined. This led us to examine the activity status of
this enzyme in SCLC cells. The observation that the basal PI 3-kinase activity levels
seen in all three SCLC cell lines were sustainable after washing and incubation in
warmed PBS (devoid of all growth factors), suggested that this activity was
independent of any exogenous mitogenic stimulus including autocrine growth factor
stimulation.
Further studies have shown that basal PI 3-kinase activity levels in SCLC cells are at
least 4 fold higher than in Swiss 3T3 mouse fibroblast cells, A549 cells and BTSM
cells when equilibrated for total protein. The basal activity levels of PI 3-kinase in
Swiss 3T3 cells could be markedly lowered by thorough washing and incubation of
cells in quiescent media (personal communication Dr R.C. Rintoul).
A concentration-dependent inhibition of basal PI 3-kinase activity was achieved
using the PI 3-kinase inhibitors wortmannin and LY294002. These inhibitors were
shown to be maximally effective at concentrations of 100 nM for wortmannin and
100 pM for LY294002. The IC50 values obtained using wortmannin and LY294002
were similar to those previously reported in other cell types; 0.27 -11.1 nM and 0.85
-3.4 pM for wortmannin and LY294002 respectively in the three SCLC cell lines
(Table 3.1). This data indicates that in unstimulated SCLC cells, PI 3-kinase activity
is elevated, and the inhibitors wortmannin and LY294002, are selectively able to
significantly inhibit this elevated PI 3-kinase activity.
These results demonstrate for the first time, the presence of constitutively active PI 3-
kinase in any human cancer cell.
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Table 3.1: IC50 Values for Wortmannin and LY294002 on PI 3-kinase, PKB*
and p70s6k Activity.
Assay H69 H345 H510
PI 3-kinase
Wortmannin (nM) 8.0 ± 2.1 0.27 ± 1.1 6.55 ± 1.49
LY294002 (pM) 3.4+1.4 0.85 ±0.41 1.27 ±0.55
Protein Kinase B *
Wortmannin (nM) 2.0 ±0.6 ND ND
LY294002 (pM) 2.7 ±0.1 ND ND
p70s6k
Wortmannin (nM) 1.3 ±0.73 14.6 ±5.5 4.1
LY294002 (pM) 0.9 ±0.68 4.2 ± 1.2 1.0
* Experiments performed by Dr. R.C. Rintoul (presented in Moore et al., 1998). (ND
= not determined.)
In view of the fact that PI 3-kinase mediates a large number of key cellular responses
including cell proliferation and cell survival (Table 1.2), understanding the cellular
consequences of this elevated activity in SCLC cells may help in identifying specific
targets to aid in the treatment of SCLC (initial functional results shown in chapter 4).
There are a number of possible reasons why PI 3-kinase is constitutively activated in
SCLC cells. Previous studies performed in different cell types, have shown that PI 3-
kinase can be activated by a number of intracellular signalling intermediates
including FAK, src and ras (Chen & Guan, 1994b, Rodriguez-Viciana et ah, 1994
and 1997). These three proteins have been shown to cause anchorage-independence
and transform cells when overexpressed or mutated (Frisch & Francis, 1994, Frisch
et ah, 1996, Khwaja et al., 1997, Guan & Shalloway, 1992). PI 3-kinase may
therefore be activated in SCLC cells due to high levels of any of these three proteins
leading to anchorage-independence and cell transformation. However, under basal
conditions, Tallett and colleagues (1996) have shown that FAK is not tyrosine
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phosphorylated and therefore activated in SCLC cells. Further studies show that
there is no evidence to suggest the presence of activated ras mutations in SCLC cells
(Mitudomi et al., 1991, Suzuki et al., 1990). pp60src activity has also been shown to
be low in SCLC cells (Budde et al., 1994).
In view of the above data, it can be hypothesised that the elevated basal PI 3-kinase
activity observed in the SCLC cells maybe due to a novel mechanism of PI 3-kinase
activation, or due to the mutation of a receptor/ligand which is constitutively
switched on causing PI 3-kinase activation. An example of receptor mutation was
described by Moscatello and colleagues (1998). Moscatello observed that on
transfection ofNIH 3T3 cells with a mutated epidermal growth factor receptor, PI 3-
kinase became increasingly activated. However, this increased activation could still
be inhibited on the addition of either wortmannin or LY294002. Finally, there is the
possibility that the PI 3-kinase enzyme itself could be mutated in the SCLC cells
resulting in constitutive PI 3-kinase activity, enabling the enzyme to be switched on
with or without an activation signal. Sequencing of the p85/p 110 heterodimer
present in SCLC cells may reveal an enzyme which is either missing some regulatory
sites, or some conformational restraints causing constitutive activity. Further
experimentation is required to determine why PI 3-kinase is constitutively activated
in SCLC cells.
3.3.2 Phosphoinositide 3-kinase Inhibitor Specificity.
Wortmannin is a fungal metabolite which is known to display anti-inflammatory and
immunosuppressive effects in experimental animal models. Wortmannin was
initially shown to inhibit neutrophil cellular responses to receptor activation
(Baggiolini et al., 1987). However, further experimentation indicated that the fungal
metabolite was a specific inhibitor of PI 3-kinase activity (IC50 = 3 nM). It has since
been shown to bind irreversibly to the pi 10 catalytic subunit of PI 3-kinase, and
remain associated after repeated washing (Yano et al., 1993), suggesting that it is
able to covalently bind to PI 3-kinase (Thelen et al., 1994). Initial research
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demonstrated that a short pre-incubation with micromolar concentrations of
wortmannin caused the inhibition of the myosin light chain (IC50 1.9 pM) (Nakanishi
et al., 1992). Additionally, Protein kinase C, cAMP-dependent protein kinase,
cGMP-dependent protein kinase and calmodulin-dependent protein kinase II were
shown to be minimally effected by concentrations of wortmannin as high as 10 pM.
Protein kinase A, C and G were subsequently reported to be unaffected by
concentrations ofwortmannin up to 1 pM (Okada et al., 1994, Yano et al., 1993). In
view of these data wortmannin was said to be a specific inhibitor of PI 3-kinase at
nanomolar concentrations.
Since these first studies were performed, it has been suggested that wortmannin can
cause inhibition of other proteins in the nanomolar range including a novel PI 4-
kinase [3 protein with an IC50 of approximately 150 nM (Meyers & Cantely, 1997)
and PLA2 (Cross et al., 1995). Brunn and colleagues (1996) reported that
wortmannin inhibited the activity of the protein mammalian target of rapamycin
(mTOR) (also known as FRAP) (discussed in section 1.6.2.2). mTOR contains a PI
3-kinase-related catalytic domain (Helliwell et al., 1994). However, mTOR has not
been shown to exhibit lipid kinase activity. Brunn and colleagues addressed the idea
that mTOR may act as a protein kinase within the cell, and that serine autokinase
activity of the enzyme may be inhibited by the addition ofwortmannin (Brown et al.,
1995). Wortmannin, directly added to purified mTOR from rat brain extracts was
shown to cause a concentration-dependent inhibition of mTOR autokinase activity
(IC50 around 200 nM). However, a maximal inhibition of autokinase activity was not
achieved. After further experimentation, Brunn concluded that mTOR activity was
inhibited by wortmannin in the nanomolar range, but that mTOR was over a 100 fold
less sensitive to wortmannin than the p85/pl 10 PI 3-kinase protein. Conversely
Brown and colleagues (1995) showed that in Jurkat T cells, rapamycin was able to
prevent mTOR autophosphorylation (therefore prevent p70s6k activation) (IC50
between 10 and 15 nM), where as the addition of wortmannin (50 nM and 500 nM)
was unable to affect autophosphorylation of mTOR. In view of this recent data, it
can be concluded that wortmannin does have a degree of selectivity for PI 3-kinase
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over any of the other proteins examined to date, but at high nanomolar concentrations
it may loose its specificity.
Initial studies investigating the potential biological uses of the naturally occurring
bioflavinoid quercetin revealed that the compound was a potent inhibitor of PI 3-
kinase activation (Matter et al., 1992). However, quercetin had previously been
shown to inhibit other enzymes such as PI 4-kinase (Nishioka et al., 1989). Using
quercetin as a model compound, several similar compounds were synthesised by
Vlahos and co-workers (1994) whilst attempting to synthesise a more selective PI 3-
kinase inhibitor. One of the compounds synthesised, LY294002, was shown to be
more selective towards PI 3-kinase as it did not inhibit cytosolic MAP kinase, p70s6k,
PKA, DAG kinase or pp60,src activity at concentrations up to 35-fold greater than the
IC50 for PI 3-kinase inhibition (IC50 of 1.4 pM). In view of this data, LY294002 has
been classified as a PI 3-kinase specific inhibitor at low micromolar concentrations.
3.3.3 Ribosomal Protein S6 Kinase.
The hypothesis that p70s6k may lie downstream and be regulated by the PI 3-kinase in
SCLC cells was investigated. Primarily p70s6k was shown to be expressed in all three
SCLC cell lines examined. To further the observation that p70s6k is constitutively
phosphorylated in SCLC cells (Seufferlein & Rozengurt, 1996), the activity of p70s6k
in basal SCLC cells was seen to be elevated as rapamycin was able to fully inhibit
basal p70s6k activity. Results suggested that, although p70s6k was highly
phosphorylated and active under basal conditions, additional activation occurred in
the presence of FCS. Addition of 10% (v/v) FCS to SCLC cells caused a 50 - 100%
increase in PI 3-kinase activity, where as addition of an identical amount of FCS for
the same period of time caused over a 150% increase in p70s6k activity. This suggests
that either an alternative signalling pathway maybe involved in regulating p70s6k
independently of PI 3-kinase activation, or that the signal emanating from PI 3-
kinase becomes amplified further downstream. The suggestion that p70s6k might be
activated by both PI 3-kinase-dependent and -independent signalling pathways was
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strengthened by the observation that concentrations of both LY294002 and
wortmannin that were able to maximally inhibit PI 3-kinase activity, were only able
to partially inhibit p70s6k activity where as rapamycin could fully inhibit p70s6k
activity. A similar observation was made by Chung and co-workers (1994). In
HepG2 cells they showed that wortmannin (up to 1 pM) could not fully inhibit p70s6k
activity, where as rapamycin could.
From the observations described in this chapter, it could be hypothesised that the
mTOR signalling pathway acts parallel to the PI 3-kinase regulated pathway in
SCLC cells. Parallel activation of these two signalling pathways has previously been
shown to occur by Cheatham and co-workers (1995) and Weng and co-workers
(1995). A rapamycin resistant p70s6k was shown be sensitive to wortmannin-
mediated inhibition of enzyme activity. Upstream regulators of the mTOR signalling
pathway have yet to be established. It is therefore possible that the alternative
signalling pathway causing an increase p70s6k activity in response to FCS may signal
via mTOR. The presence of this residual p70s6k activity could also be due to an
alternative pathway activating p70s6k' e.g. the protein kinase C (PKC) pathway. In
other cell types, PKC isoforms have been shown to activate p70s6k (Tudan et al.,
1998, Chou & Blenis, 1995, Chung et al., 1994) independently of PI 3-kinase.
Chung and co-workers (1994) showed that PLC-dependent activation of p70s6k was
PKC-dependent, where as PI 3-kinase-mediated p70s6k activation was PKC-
independent. The suggestion that a PLC/PKC signalling pathway may regulate
p70s6k independently of PI 3-kinase is strengthened by the observation that phorbol
esters have been shown to cause p70s6k activation in cultured cells (Erikson, 1991).
Further experiments will have to be performed using SCLC cells to discover the
additional pathway(s) able to stimulate p70s6k in a PI 3-kinase-independent manner.
It must be noted that previous experiments studying the phosphorylation patterns of
p70s6k, have shown that mTOR activity is required to phosphorylate specific serine
residues on p70s6k before the enzyme becomes fully active (Chou & Blenis, 1995).
This is demonstrated by the observation that rapamycin is able to fully inhibit p70s6k
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activity even when PI 3-kinase is constitutively activated. In relation to this
observation, it could be hypothesised that the mTOR signalling pathway is required
to be active to allow p70s6k to be basally phosphorylated. On further phosphorylation
(e.g. via PI 3-kinase) the protein becomes fully activated allowing downstream
targets to be stimulated/inhibited.
3.3.4 Protein Kinase B.
Initial experiments confirmed the presence of all three isoforms of PKB in SCLC
cells. In addition to the observations of constitutive PI 3-kinase activity in SCLC
cells, high basal activity levels of PKBa have been reported in H69 SCLC cells in
comparison to Swiss 3T3 cells (Moore et al., 1998). As in the case of PI 3-kinase,
this basal activity could only be increased by 1.5 - 2 fold with the addition of 10%
(v/v) foetal calf serum. Additionally, the potent SCLC mitogen IGF-1 (100 ng/ml)
could only increase PKBa levels by 1.5 - 2 fold. This stimulation was relatively
small in comparison to 5 - 10 fold increases in PKBa kinase activity in Swiss 3T3
cells using IGF-1 (Dr R.C. Rintoul personal communication).
The addition of either wortmannin or LY294002 was able to completely abolish the
activation of basal PKBa in H69 cells with an IC50 value of 2.0 ± 0.6 nM and 2.7 ±
0.1 pM respectively (mean ± SEM, n = 3) (Moore, et al., 1998, experiments
performed by Dr. R.C. Rintoul). Complete inhibition of PKBa was observed at
concentrations ofwortmannin and LY294002 specific to PI 3-kinase inhibition. This
suggested that the elevated PKBa activity in basal SCLC cells is most likely a direct
downstream consequence of constitutive PI 3-kinase activity, and is entirely PI 3-
kinase-dependent. Thus studies performed by Moore and colleagues show the
presence of a constitutively activated signalling pathway in SCLC cells which
emanates from PI 3-kinase and involves both PKB and p70s6k.
The presence of p70s6k downstream of PKB remains controversial. Burgering and
Coffer (1995) demonstrated that stimulation of PKB causes activation of p70s6k
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upstream of the rapamycin inhibition site. More recently PKB has been shown to
activate p70s6k in co-transfection assays (Reif et al., 1997, Kohn et al., 1996).
However, there is contradictory evidence that PKB is unable to phosphorylate p70s6k,
by the failure of a kinase dead PKB to prevent p70s5k stimulation (Burgering &
Coffer, 1995).
Additional data indicating that PKB and not p70s6k, mediates the PI 3-kinase-
dependent survival of rat-1 fibroblasts and neurons (Dudek et al., 1997, Kauffmann-
Zeh et al., 1997, Kulik et al., 1997), and that PKB and p70s6k are differentially
regulated by calcium (Conus et al., 1998) suggests that either these two proteins can
be differentially regulated by various signalling input, or that PKB activates p70s6k
when cells have been stimulated and the intracellular calcium levels are appropriate
for the activation of both enzymes. Another reason may be that these observed
variations in how PKB potentially regulates p70s6k activation is due to alterations in
the signalling cascades of different cell types. Finally PKB and p70s6k may both be
situated on the same pathway as well as parallel pathways within a cell, and
depending upon the stimulation or environmental factors surrounding the cell, either




















Figure 3.14: Potential Signalling Pathways Originating from Phosphoinositide
3-kinase which cause p70s Activation in Small Cell Lung Cancer Cells.
Abbreviations: Phosphoinositide 3-kinase, PI 3-kinase; wortmannin, WM;
PI(3,4,5)P3-dependent kinase, PDK1; protein kinase B, PKB; protein kinase C, PKC;
FK506 binding protein 12, FKBP12 and mammalian target of rapamycin, mTOR.
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3.4 Summary.
In this chapter it has been reported that the anchorage-independent SCLC cell lines
H69, H345 and H510 exhibit constitutive PI 3-kinase activity which results in
elevated PKB and p70s6k activity. This increased activity was shown not to be due to
the proposed auto/paracrine growth factor loops thought to underlie SCLC cell
survival and proliferation. These data represent the first description of constitutively
activated PI 3-kinase in any human cancer. Constitutive activation of this enzyme
which is known to be activated both in an integrin-dependent manner and by a
number of proteins which are able to cause anchorage-independence, may account
for the anchorage-independent phenotype of SCLC cells, and help explain the highly
metastatic nature of this human cancer.
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CHAPTER 4
Role of Phosphoinositide 3-kinase in Small Cell
Lung Cancer Cell Proliferation and Survival.
4.1 Introduction.
The enzyme PI 3-kinase has been shown to be important in the regulation of a wide
range of cellular processes including mitogenesis and apoptosis (reviewed Table 1.2,
Duronio et al., 1998, Vanhaesebroeck et al., 1997, Carpenter & Cantley, 1996).
Activated PI 3-kinase was shown to be required to enable cells to proliferate in
response to PDGF receptor stimulation (Carpenter & Cantley, 1990, Parker &
Waterfield, 1992). Additionally, Yao and Cooper (1995) noted that to rescue PC12
cells from undergoing apoptosis in response to serum deprivation, PI 3-kinase
activation was required. Finally, IGF-1 has been shown to prevent fibroblasts from
undergoing UV-induced apoptosis. This was shown to be mediated via a PI 3-
kinase-dependent mechanism as the addition of wortmannin blocked the anti-
apoptotic effect (Kulik et al., 1997).
Research has demonstrated a number of possible cellular functions for the cytosolic
protein p70s6k. The inhibition of p70s6k activation is known to effect the proliferative
and cell cycle properties of a number of different cell types. Using the
immunosuppressant rapamycin, inhibition of p70s6k activity causes G1 arrest in T-
lymphocytes and delays the entry of fibroblasts into the S phase of the cell cycle
(Chung et al., 1992, Kuo et al., 1992, Price et al., 1992). In relation to the apoptotic
capabilities of p70s6k, p70s6k has been shown to exhibit either no effects or anti-
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apoptotic effects in different cell types. Studies by Yao and Cooper (1996) noted that
p70s6k inhibition did not effect the apoptosis levels of serum-independent cell types.
Conversely Shi and co-workers (1995) showed that the addition of rapamycin
enhanced cell apoptosis in T cells, HL-60 cells and fibroblasts. Cells were also seen
to be more sensitive to cis-platin-induced apoptosis when p70s6k activity was
inhibited.
In view of the fact that the balance between cell proliferation and cell death regulates
tumour mass, the role of these two cellular functions was investigated in SCLC cells




4.2.1.1 Effect of Exogenous Growth Factors on Small Cell Lung Cancer Cell
Growth in Liquid Culture.
SCLC is a cancer which displays both serum- and anchorage-independence in vitro.
SCLC cells have been shown to synthesise and secrete a large number of peptides
(reviewed Moody & Cuttitta, 1993, Belper et al., 1988) and hormones (Sorenson et
al., 1981) which sustain SCLC cell growth via autocrine and paracrine growth loops
(Carney et al., 1987, Sethi & Rozengurt, 1992).
The requirement of specific growth factors for the growth of SCLC cells in vitro has
been extensively studied (Simms et al., 1980, re-evaluated and revised Nakanishi,
1988). Nakanishi (1988) concluded that the growth factors selenium, insulin and
transferrin (SIT) are required to allow efficient proliferation of SCLC cells in liquid
culture to occur.
Figure 4.1 demonstrates that the presence of selenium, insulin, transferrin (plus
bovine serum albumin, A) (SITA) reduced the length of the lag phase of SCLC cells
growing in liquid culture, in comparison to cells grown in the absence of these
growth factors. To carry out these experiments, the cells were plated at a relatively
low density to allow the experiment to run over a number of days without the cells
exhausting the media. In view of the fact that the SCLC cells used in this study have
doubling times of between 55 and 72 hours, it took 2-3 days before the full effect of
the proliferative environment could be assessed. The results obtained suggested the
possibility that, the cells plated in the absence of all exogenous growth factors were
required to synthesise more of their own 'autocrine' growth factors to mimic the
SITA growing conditions. However, the results show that although the number of
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Figure 4.1: Increase in Small Cell Lung Cancer Cell Number with the Addition
of Specific Mitogens.
H345 SCLC cells were incubated overnight in either quiescent (Q) media or serum-
free SITA medium. Cells were washed and disaggregated into an essentially single
cell population (cell viability was assessed by trypan blue exclusion > 95%). Cells
were plated (500 pl/well, 2 x 107ml), in 24 well culture dishes in either quiescent or
SITA media. Cells were incubated in a humidified atmosphere, 5 % C02/95% air at
37°C. After a defined time, cells were removed and gently disaggregated. Cells
(200 pi) were removed for apoptotic assessment (Figure 4.5) and remaining cell
number counted using a Coulter Counter. Results are expressed as fold increase in
cell number in comparison to the number of cells initially plated. Each point is the
mean (± SEM) of 3 independent experiments carried out in triplicate. * p<0.05, ***
p<0.001 (Student-Newman-Keuls ANOVA post test).
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cells plated in SITA medium increased by the greatest amount, cells in the absence of
the exogenous growth factors were still able to significantly increase in number over
9 days.
4.2.1.2 Small Cell Lung Cancer Cell Proliferation is Phosphoinositide 3-kinase-
dependent.
The importance of PI 3-kinase activity in SCLC cell proliferation was investigated
using the PI 3-kinase specific inhibitor LY294002.
Figure 4.2a shows the concentration-dependent inhibition of [/H]-thymidine
incorporation in H510 SCLC cells 72 (left) and 96 (right) hours after treatment with
LY294002. Addition of 100 pM LY294002 caused maximal inhibition of DNA
synthesis (95.8 ± 2.15% and 95.7 ± 2.34% mean ± SEM, n = 3 for 72 and 96 hours
respectively). The IC50 values obtained for LY294002 were 22.1 ± 7.4 pM and 30.2
±11.2 pM for 72 and 96 hours respectively (mean ± SEM, n = 3). LY294002 was
also shown to inhibit H69 SCLC cell proliferation by preventing [3H]-thymidine
incorporation (Figure 4.2b) (IC50 at 96 hours, 15.6 ± 1.22 pM (mean ± S.D., n = 2 of
replicates of five)).
These studies demonstrated that SCLC cell proliferation in liquid media is dependent
upon signalling pathways which emanate from the constitutively activated enzyme PI
3-kinase. In view of the knowledge that PI 3-kinase is constitutively activated in
SCLC cells, it could be hypothesised that the proliferation signal in SCLC cells is
permanently switched on. This may help to explain why SCLC cells are the fastest
growing lung cancer cell type.
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LY294002 (|iM)
Figure 4.2a: Effect of Increasing Concentrations of LY294002 on [3H]-
Thymidine Incorporation in H510 Small Cell Lung Cancer Cells.
SCLC cells were grown for 24 hours in quiescent medium before being washed and
re-plated in SITA medium (5 x 104/ml, 200 pl/well) in the presence of increasing
concentrations of LY294002. After 48 (left) or 72 hours (right), ['H]-thymidine was
added (0.1 pCi/well) and the cells incubated for a further 24 hours. Cells were
finally harvested and [3H]-thymidine incorporation counted on a beta plate reader
(see section 2.4). Each point represents the mean ± SEM percentage [3H]-thymidine
incorporation in comparison to control cells (received diluent alone = 100%) of three
independent experiments carried out in replicates of five, (average control cpm =
46817)
LY294002 (jiM)
Figure 4.2b: Effect of Increasing Concentrations of LY294002 on [3H]-
Thymidine Incorporation in H69 Small Cell Lung Cancer Cells.
SCLC cells were grown for 24 hours in quiescent medium before being washed and
re-plated in SITA medium (5 x 104/ml, 200 pl/well) in the presence of increasing
concentrations of LY294002. After 72 hours [3H]-thymidine was added (0.1
pCi/well) and the cells incubated for a further 24 hours. Cells were finally harvested
and [3H]-thymidine incorporation counted on a beta plate reader (section 2.4.1).
Each point represents the mean ± S.D. percentage [3H]-thymidine incorporation in
comparison to control values (diluent alone = 100%) of two independent experiments
carried out in replicates of five.
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4.2.1.3 Phosphoinositide 3-kinase-dependent Small Cell Lung Cancer Cell
Proliferation is Mediated via Both p70s6k-independent and -dependent
Signalling Pathways.
Results described in chapter 3 indicate that in SCLC cells, p70s6k activity is regulated
in a PI 3-kinase-dependent and -independent manner. Using the p70s6k specific
inhibitor rapamycin, p70s6k has been shown to reside downstream of PI 3-kinase in
many cell types, and has been shown to be important in the regulation of cell
proliferation and the cell cycle (Chung et ah, 1992, Marx et ah, 1995). In view of
these observations, the relative contribution of p70s6k in the PI 3-kinase mediated
SCLC cell proliferation pathway was investigated.
Previous studies by Seufferlein and Rozengurt (1996) assessed the role of p70s6k in
SCLC cell growth in liquid culture (via inhibition of the enzyme using rapamycin).
They indicated that addition of rapamycin alone caused a slight concentration-
dependent inhibition in cell number (IC50 concentration around 0.3 - 1 nM and
maximal inhibition concentration of around 10 nM). A maximally effective
concentration was however only able to achieve 55% growth inhibition in liquid
culture. (Experiments were performed over 7-11 days).
Figure 4.3 shows that in further studies in SCLC cell line H69, a maximally effective
concentration of rapamycin (100 nM) caused a 33 - 39% inhibition in [ 'H]-thymidine
incorporation over 3-4 days. At a concentration close to the IC50 (20 pM),
LY294002 caused a 50.4 ± 5.55% and 46 ± 9.45% inhibition of [3El]-thymidine
incorporation at 72 and 96 hours respectively (mean ± SEM, n = 3). In combination,
LY294002 (20 pM) and rapamycin (100 nM) caused a 64.3 ± 5.7% and 65.3 ±
6.35% inhibition of ['Hj-thymidine incorporation at 72 and 96 hours respectively.
These results indicate that addition of a maximally effective concentration of
rapamycin significantly inhibited DNA synthesis in SCLC cells grown in liquid
culture in comparison to cells grown in the absence of any inhibitor. This inhibition
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of [JH]-thymidine incorporation could be significantly increased by the co-incubation
of SCLC cells with LY294002 (IC50) and rapamycin (max). However, this inhibition
was shown not to be additive. Thus, the data implies that PI 3-kinase regulates
SCLC cell proliferation in serum-free liquid culture. Downstream of PI 3-kinase the
signalling pathway splits with a proportion of the proliferation signal acting through
p70s6k.
4.2.1.4 Inhibition of Small Cell Lung Cancer Cell Colony Formation by
LY294002.
One of the key characteristics of a cells transformed phenotype is its anchorage-
independent ability to proliferate. The majority of SCLC cells grow in liquid culture
as free floating aggregates highlighting their transformed phenotype. The ability of
transformed SCLC cells to form colonies in semi-solid medium has been well
documented and a positive correlation between cloning efficiency, the histological
involvement and the invasiveness of SCLC tumour specimens has been reported
(Freedman & Shin, 1974).
Figure 4.4 highlights the ability of SCLC cells to form colonies in semi solid
medium. This ability is enhanced by the addition of different neuropeptides. This
corresponds to the previous work carried out by Sethi and Rozengurt (1991 and
1992) showing that neuropeptides stimulate SCLC cell colony formation by
activating multiple autocrine and paracrine growth loops. Addition of LY294002 (10
pM) to SCLC cells both in the presence and absence of additional neuropeptides
inhibited colony formation. Thus, active PI 3-kinase is required to enable SCLC
cells to grow and survive in a semi-solid media environment. This suggests that PI
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Figure 4.3: Effects of LY294002 and Rapamycin Either Alone or in
Combination on Small Cell Lung Cancer Cell [3H]-thymidine incorporation.
H69 SCLC cells 3-5 days post passage were incubated in quiescent medium for 24
hours before being washed and incubated (5 x 104/ml, 200 pl/well) in serum-free
SITA medium for 48 (upper) or 72 (lower) hours in the presence of various
inhibitors. [3H]-thymidine (0.1 pCiAvell) was added and the cells incubated for a
further 24 hours prior to being assessed for [3H]-thymidine incorporation (see section
2.4.1) in comparison to control cells that received diluent alone (SITA). Each point
represents the mean (± SEM) of three independent experiments carried out in
replicates of five. Average counts for the control values were 35156 cpm (72 hours)
and 43067 cpm (96 hours). Abbreviations: LY - LY294002, IC50 20 pM, max 100
pM, Rap - rapamycin IC50 2 nM, max 100 nM. In comparison to SITA - ** p < 0.01.















Figure 4.4: Small Cell Lung Cancer Cell Clonal Growth is Dependent upon
Phosphoinositide 3-kinase Activity.
Cells were washed and plated in SITA medium (1 x 104 cells/ml) containing 0.3%
agarose on top of a base of 5% agarose in culture medium (see section 2.4.3). Both
layers contained either no additional neuropeptides (black bars) or vasopressin, 50
nM (VP), bombesin, 50 nM (Bom), or gastrin, 100 nM (G) (grey bars), in the
absence (-) or presence (+) of LY294002, 10 pM (LY). After 21 days colonies > 16
cells were counted. Results are expressed as the mean number of colonies/dish for 2
independent experiments carried out in triplicate (± S.D.)
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4.2.2 Cell Survival.
4.2.2.1 Role of Exogenous Growth Factors in Small Cell Lung Cancer Cell
Survival.
In order to assess the role of certain growth factors on SCLC cell survival, SCLC cell
apoptosis levels were examined in serum-free SITA media and quiescent media over
a period of 9 days. Figure 4.5 demonstrates that in SCLC cell line H345, the addition
of selenium, insulin and transferrin (SIT) did not effect the apoptosis levels over the
first three days. However, from day 5, the rate of apoptosis in quiesced cells was
higher than the levels observed in the cells incubated in SITA medium. These results
show that in the presence of specific growth factors, the levels of SCLC cell
apoptosis in liquid culture are lowered.
When examining the results in figure 4.5 alongside the parallel growth studies
(Figure 4.1), it can be seen that the cells in SITA exhibit both a decrease in apoptosis
levels as well as an increase in growth rates in comparison to cells grown in
quiescent media. However, when studying the increases in absolute live cell number
in both SITA and quiescent medium (taking into account apoptosis rates), cells in
either media significantly increased in number over time. In conclusion, these
experiments indicate that the presence of selenium, transferrin and insulin enables
SCLC cells in liquid culture to increase in number at a faster rate than cells grown in
the absence of these growth factors. However, in the absence of these exogenous
growth factors, SCLC cells still have the ability to survive and grow. This
observation highlights their ability to survive and grow in a foreign environment in
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Figure 4.5: H345 Small Cell Lung Cancer Cell Apoptosis Levels over 9 days
Under Different Culture Conditions.
H345 cells (2 x 105/ml, 500 pl/well) were washed thoroughly prior to being
incubated in the presence of either quiescent medium (Q) or serum free SITA
medium over 9 days and assessed for apoptosis. Apoptosis was assessed by the
addition of ethidium bromide (100 pg/ml) and acridine orange (100 pg/ml) (1:1 v/v;
1 pi) to the SCLC cells (200 pi) and examined using fluorescent microscopy as
described in section 2.5.1. Each point represents the fold increase in apoptosis in
relation to the levels observed at day 0 (between 8 & 11 %). Each point is the mean
(± SEM) of three experiments carried out in triplicate. * p< 0.05 (Student-Newman-
Keuls ANOVA post test).
136
As expected there was a small basal turnover of apoptosis observed in SCLC cells
(basal apoptosis at day 0 = 8-11 %). This basal apoptosis was observed in the
cultured cells during all of the following experiments but remained between
approximately 1 and 8%.
4.2.2.2 Small Cell Lung Cancer Cell Survival is Modulated in Part by
Phosphoinositide 3-kinase.
The results described in this chapter have so far indicated that PI 3-kinase plays a
crucial role in regulating SCLC proliferation and tumourigenicity. As tumour mass
is a balance between cell growth and death (via apoptosis and necrosis), the role of PI
3-kinase in SCLC cell apoptosis was assessed. PI 3-kinase has also been shown to
inhibit apoptosis (and anoikis) in many cells types (often via PKB activation)
(Downward, 1998, Eves et ah, 1998, Khwaja et ah, 1997, Franke et ah, 1997).
The effect of the PI 3-kinase inhibitor LY294002 on SCLC apoptosis was assessed
using two different experimental methods. Primarily, cells were quiesced for 24
hours prior to experimentation. After 24 hours figure 4.6 demonstrates that addition
of LY294002 caused a concentration-dependent increase in the level of H69 SCLC
cell apoptosis as assessed by cytocentrifugation (morphological assessment) (upper)
and ELISA (immunoassay assessment of DNA fragmentation) (lower). (During the
experiment cell viability was assessed by trypan blue exclusion to be > 95%.) In
comparison to control cells (received only diluent), results show that LY294002
causes a 300 - 400 % increase in apoptosis as assessed by morphological techniques
(section 2.5.3). The mean control apoptosis rates as assessed by cytocentrifugation



























Figure 4.6: Effect of LY294002 on Small Cell Lung Cancer Cell Apoptosis.
SCLC cells, 3-5 days post-passage were quiesced overnight, washed thoroughly
and plated in quiescent media (2.5 x 107500 pl/well) in the presence of increasing
concentrations of LY294002. After 24 hours, cells (150 pi) were removed and
assessed for apoptosis by cytocentrifugation (upper). From the remaining cells 200
pi was removed and assessed for apoptosis by ELISA (lower) (see section 2.5).
Results are expressed as percentage increase (upper) and increase in absorbency
(lower) in relation to control cells (-) cultured in quiescent medium (received diluent
only). The results show the mean ± SD. for two separate experiments performed in
triplicate. Student-Newman-Keuls ANOVA not performed as n = 2 (see section
2.14).
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The effects of LY294002 were confirmed using an ELISA based technique. The
antibodies utilised in the ELISA based assay bind to histones and the cleaved single
and double-stranded DNA in the cells. Results highlighted in figure 4.6 (lower)
show that on the addition of increasing concentrations of LY294002, an increase in
DNA fragmentation was observed (occurs after cell-induced cell death).
4.2.2.3 Role of Ribosomal p70s6k in Phosphoinositide 3-kinase-mediated Small
Cell Lung Cancer Cell Apoptosis.
It was noted earlier that the proliferative effect of PI 3-kinase in SCLC cells is
regulated via a p70s6k-dependent and -independent pathway. Yao and Cooper (1996)
showed that inhibition of p70s6k in both serum-dependent and -independent cells had
no effect on cell survival. Therefore, to examine the role of p70s6k in the apoptotic
response in SCLC cells, rapamycin was added using a maximally effective
concentration causing 100% inhibition of enzyme activity. Apoptosis was assessed
by ELISA (section 2.5.2) in the presence of LY294002 (10 pM), rapamycin (100
nM) and tyrphostin-25 (25 pM). Figure 4.7 demonstrates that in H69 cells,
rapamycin caused an increase in apoptosis levels. This increase was similar to the
increase observed using the IC50 concentration of LY294002. However, a maximally
effective concentration of LY294002 is able to further increase apoptosis levels
(Figure 4.6). This implies that the increase in SCLC cell apoptosis emanating from
PI 3-kinase inhibition is mediated via both a p70s6k-dependent and -independent
mechanism.
The effect of both LY294002 and rapamycin on basal SCLC cell apoptosis levels
were however less that the increases in apoptosis levels caused by the tyrosine kinase
inhibitor tyrphostin-25 (Figure 4.7 and 4.8). This suggests that signalling pathways
not involving either PI 3-kinase or p70s6k are also involved in the control of SCLC
apoptosis.
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4.2.2.4 Effect of Increased Exposure of Small Cell Lung Cancer Cells to
LY294002.
Tallett and colleagues (1996a) recently reported that addition of the protein tyrosine
kinase inhibitor tyrphostin-25, caused an increase in SCLC cell apoptosis. This
increase was both concentration and time-dependent (maximal inhibition seen after
approximately 72 hours). Figure 4.8 shows that LY294002 was unable to produce a
further increase in apoptosis level over an extended time period (72 hours). This
shows that LY294002 causes SCLC cell apoptosis within 24 hours, and that the rate
of apoptosis is constant over time.
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Figure 4.7: Effect of the Phosphoinositide 3-kinase Inhibitor (LY294002), p70s
Inhibitor (Rapamycin) and Tyrosine Kinase Inhibitor (Tyrphostin-25) on
Apoptosis in H69 Small Cell Lung Cancer Cells.
Quiescent cells (2.5 x 107500 pl/well) were washed and plated in fresh quiescent
media in the presence of LY294002 (LY) 10 pM, rapamycin (Rap) 100 nM and
tyrphostin-25 (Tyr-25) 25 pM for 24 hours. Cells were then assayed for apoptosis
using the ELISA method (see section 2.5.2). Each bar represents the mean (± S.D.)
of two separate experiments performed in triplicate.
Control LY Tyr-25
Figure 4.8: The Effect of Increasing the Exposure Time of Small Cell Lung
Cancer Cells to Different Inhibitors on Apoptosis.
Cells (H345) (2.5 x 107500 pl/well) were washed and incubated in quiescent media
in the presence of various inhibitors LY294002 (LY) 10 pM, or Tyrphostin-25 (Tyr-
25) 25 pM. After 24 and 72 hours, cells (100 pi) were removed and assessed for
apoptosis by cytocentrifugation (see section 2.5.3). Each bar represents the mean of




SCLC cells have the fastest growth rates of the four main lung cancer cell types.
Discovery of a potential signalling pathway that regulates SCLC cell growth, would
be of benefit in the design of new therapies in the treatment of SCLC.
LY294002 caused a concentration-dependent inhibition of SCLC cell [3H]-thymidine
incorporation. A maximally effective concentration of LY294002 (100 pM) which is
able to cause approximately 100% inhibition in PI 3-kinase activity, fully inhibited
SCLC cell proliferation as assessed by [3H]-thymidine incorporation studies. The
slight increases in the LY294002 IC50 values obtained from the proliferation studies
(chapter 4) in comparison to the enzyme activity studies (chapter 3, Table 3.1) may
be due to the fact that the enzyme activity experiments were carried out in cell free
conditions.
In the presence of a maximally effective concentration of rapamycin, the inactivation
of p70s6k caused a significant decrease in [3H]-thymidine incorporation (SCLC cell
proliferation). Additionally, this inhibition in [3H]-thymidine incorporation was
shown to be regulated upstream by a PI 3-kinase-dependent mechanism. This was
demonstrated by the observation that the addition of a maximally effective
concentration of rapamycin and LY294002 (IC50) together did not cause an additive
inhibitory effect on ['Hj-thymidine incorporation in comparison to the effects
observed in the presence of rap (max) and LY294002 (IC50) alone. Parallel studies
were performed investigating the role of p70s6k and PI 3-kinase in SCLC liquid
growth studies (Moore et al., 1998). Similar results were obtained showing that PI 3-
kinase-dependent cell growth was mediated downstream by both p70s6k-dependent
and -independent signalling pathways. Over 50% of the growth signal was shown to
be able to bypass the requirement of p70s6k activation. The observation that PI 3-
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kinase-regulated signalling bifurcates upstream of p70s6k has previously been
suggested by Chung and co-workers (1994). Wortmannin was shown to inhibit
insulin-dependent GLUT4 translocation (Kanai et ah, 1993), where as inhibition of
p70s6k using rapamycin had no effect on this process. This suggested that PI 3-kinase
was able to mediate events independently of p70s6k activation even though
wortmannin was still able to inhibit p70s6k activation.
There are a number of possible signal transduction pathways which may regulate
SCLC cell growth in liquid culture via a PI 3-kinase-dependent mechanism. In
addition to p70s6k being involved, three other pathways have been identified in
different cell types and under different cell conditions. Firstly, calcium-independent
and atypical PKC isoforms have been shown to be activated by the 3'-
phosphorylated lipid products of PI 3-kinase (section 1.6.2.4, Nakanishi et ah, 1993,
Toker et ah, 1994 and 1995, Zheng et ah, 1995) leading to cell growth. A second
pathway involves the activation of the small protein Rac. Rac activation has been
shown to cause activation of the JNK/stress activated protein kinase cascade leading
to DNA synthesis (Hawkins et ah, 1995, Klippel et ah, 1996, Kyriakis et ah, 1995,
Minden et ah, 1995). Finally, the MAP kinase pathway has been shown to be
activated by PI 3-kinase in a number of different cell types. PI 3-kinase has also
been shown to be required for MAP kinase activation via the neuropeptide and
hormones vasopressin, insulin-like growth factor 1 and insulin (DePaolo et ah, 1996,
Cross et ah, 1994, Uehara et ah, 1995).
There are number of mechanisms by which cells may activate the MAP kinase
pathway in a PI 3-kinase-dependent manner. PI 3-kinase is known to associate with
ras via its pi 10 catalytic domain leading to co-activation of the MAP kinase
signalling pathway. PI 3-kinase may also mediate the activation of the MAP kinase
cascade via the serine-threonine protein raf independently of ras. The cytosolic
protein rafmay associate with the 3'-phosphorylated lipid products of PI 3-kinase via
its cysteine rich domain. These lipids are associated with the plasma membrane
causing targeting of raf to the plasma membrane where it can associate with other
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downstream proteins causing activation of the MAP kinase pathway (Leevers et al,
1994). Another potential mechanism whereby PI 3-kinase may cause raf activation is
via association with members of the PKC family. The PKC isoforms s and a have
been shown to cause MEK-1 activation via raf (Cai et al., 1997).
King and co-workers (1997) showed that adhesion of COS-7 cells to fibronectin (not
poly-L-lysine), caused integrin activation resulting in the accumulation of 3'-
phosphorylated phospholipids, as well as activation of PKB, Raf-1, MEK-1 and
ERK-1. Addition of either LY294002 or wortmannin caused over a 80% inhibition
of these kinases, but was unable to inactivate ras suggesting that PI 3-kinase was
present downstream of ras in the MAP kinase signalling cascade when stimulated by
integrins. Cross and co-workers (1994) also showed that addition of wortmannin to
rat skeletal L6 cells blocked the activation of the MAP kinase pathway between ras
and raf. Additionally, previous work by Mcllroy and co-workers (1997) has shown
that both p70s6k and the MAP kinase signalling pathways are involved in serum
stimulated, PI 3-kinase-mediated regulation ofDNA synthesis in CHO cells using the
selective pharmacological inhibitors rapamycin and PD 098059. Finally Grammer
and Blenis (1997) suggested that PI 3-kinase might have a role in the MEK-
dependent and -independent activation of the MAP kinase cascade via growth factor
stimulation. In kinetic studies, the initial activation of MAP kinase by PDGF was
shown to be MEK-dependent and PI 3-kinase-independent. Further studies carried
out in Swiss 3T3 cells, suggested that prolonged activation ofMAP kinase by PDGF
mainly occurred via a MEK-independent mechanism. This stimulation of MAP
kinase was however seen to be dependent upon PKC and PI 3-kinase activation.
Grammer and Blenis also showed that a number of different cell types (e.g. T-
lymphocytes and NIH 3T3 cells) were dependent upon PI 3-kinase stimulation for
the activation ofMAP kinase.
Initial observations (Moore, unpublished observations) have indicated that serum-
free SCLC cell proliferation is partially mediated via a MAP kinase-dependent
pathway. In H69 SCLC cells, addition of the MEK1 specific inhibitor PD 098059
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(Alessi et al., 1995, Dudley et al., 1995) caused a maximal inhibition of SCLC
growth after 8 days of 46 ± 6 % (mean ± SEM, n = 3), in comparison to cells that
received diluent alone (DMSO < 1% (v/v)). DMSO at a concentration of 1% (v/v)
was shown not to effect SCLC growth in liquid culture. The mean IC50 obtained
from these experiments was 2.7 ± 2.3 pM. A similar observation was seen by
Seufferlein and Rozengurt (1996a), where a maximally effective concentration of PD
098059 (20 pM), inhibited SCLC cell growth in liquid culture by approximately
50%. Previous work by Alessi and co-workers (1995) has shown that PD 098059 is
a selective non-competitive inhibitor of MEK1 activation in both whole cell and cell
free assay systems. In an in vitro cell free cell assay system, PD 098059 was shown
to have an IC50 between 2-7 pM. To date, a link between the MAP kinase pathway
and PI 3-kinase has not been investigated in SCLC cells. However, p42MAPK
activation has been shown to occur via the stimulation ofG-protein coupled receptors
(Seufferlein & Rozengurt, 1996a); and G-protein coupled receptor-mediated
neuropeptide SCLC cell colony formation has been shown to be inhibited by the
addition of LY294002 (chapter 4).
The above observations along with the results described in this chapter, indicate that
although both the p70s6k and the MAP kinase cascade have been repeatedly shown to
be important in cell growth, the potential upstream enzyme PI 3-kinase maybe
critical to SCLC cell growth. It was only on addition of the PI 3-kinase inhibitor

















Figure 4.9: Potential Signalling Pathway(s) mediated by Phosphoinositide 3-
kinase, Causing Small Cell Lung Cancer Cell Proliferation.
Abbreviations: phosphoinositide 3-kinase, PI 3-kinase, protein kinase B, PKB, MAP
Kinase, mitogen activated protein kinase, FK506 binding protein 12, FKBP12 and
mammalian target of rapamycin, mTOR.
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Finally, studies have shown that there is a positive correlation between SCLC cell
cloning efficiency in vitro and the invasiveness of SCLC cells in vivo (Freedman &
Shin, 1974). It appears from the data described in this chapter, that active PI 3-
kinase may play a crucial role in sustaining the clonal growth of SCLC cells in vitro.
From this it can be hypothesised that PI 3-kinase plays a key role in the invasiveness
of SCLC cells in vivo and that inhibition of this enzyme (shown to be basally active
in SCLC cells) may inhibit the tumourigenicity of this highly metastatic tumour in
vivo. Work performed in breast cancer cells has shown that PI 3-kinase activation is
required to enable the cells to migrate on ECM proteins and become invasive in
character (Keely et al., 1997, Shaw et ah, 1997). Thus, the role of PI 3-kinase in
SCLC cell migration and invasion needs to investigated further.
4.3.2 Cell Survival.
In many cell types (e.g. PC12 cells, MDCK cells and CHO cells), PI 3-kinase has
been linked to an anti-apoptotic mechanism of cell survival (Yao & Cooper, 1995
and 1996, Kennedy et al., 1997, Khwaja et al., 1997). The downstream protein
kinase PKB has been studied over the past 3-4 years in greater detail, and its role in
cell survival has become apparent. PI 3-kinase regulation of cell survival appears
often to be mediated via PKB (review Marte & Downward, 1997, Hemmings, 1997,
Eves et al., 1998, section 1.6.2.1). Conversely, studies performed by Yao and
Cooper (1996) noted that serum-independent cells did not require PI 3-kinase
activation for protection against apoptosis by growth factor withdrawal.
Results showed that in SCLC cells, a maximally effective concentration of
LY294002 (-100% inhibition of PI 3-kinase activity and proliferation (100 pM)),
caused approximately a 400% increase in the basal apoptosis levels of H69 SCLC
cells (1.5 - 8% and 3 - 12 % in two separate independent experiments). This modest
but consistent increase in apoptosis suggests a small but significant role for PI 3-
kinase in basal SCLC cell survival.
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Experiments using the phosphotyrosine kinase inhibitor tyrphostin-25, have
previously shown that tyrosine kinase activation is required for SCLC cell survival
(Tallet et al., 1996a), cell proliferation and clonal growth (Seckl & Rozengurt, 1996).
Tyrphostins are a series of compounds that specifically act as competitive inhibitors
at the protein tyrosine kinase substrate subsite (Gazit et ah, 1989). They selectively
inhibit both membrane bound (e.g. EGF and PDGF receptors) (Lyall et al., 1989,
Bilder et al., 1991), and cytosolic protein tyrosine kinases (e.g. pp6Cbrc) (Anafi et
al., 1992, O'Dell et al., 1991). Addition of tyrphostin-25 caused increased SCLC cell
apoptosis in comparison to LY294002. This suggests that additional tyrosine kinase
enzymes (not present downstream of PI 3-kinase) may also aid in the regulation of
basal SCLC cell apoptosis. Additional apoptosis experiments described in the
following chapter show that the addition of chemotherapeutic agents such as
etoposide and doxorubicin can induce much higher levels of SCLC cell apoptosis.
For example etoposide (50 pg/ml) and doxorubicin (100 pM), are able to induce
apoptosis levels of 75% in H345 and H510 SCLC cells respectively over 3 days
(Figure 5.15). Additionally, etoposide (25 pg/ml) was seen to induce apoptosis
levels of approximately 80% (Figure 5.16) in H69 SCLC cells over 3 days. This data
suggests that the inhibition of PI 3-kinase does not effect a major signalling pathway
that is required for SCLC cell survival in liquid culture.
An alternative explanation may be that in SCLC cells 'cross talk' between the major
signalling cascades involved in the onset of cell apoptosis occurs. If one specific
pathway is blocked, alternative signals from other pathways become involved
preventing apoptosis. It is only when a number of the major pathways are inhibited
that a larger percent of cells undergo apoptosis. This hypothesis relates to the recent
observation noted by Murray (1998). Addition of wortmannin (100 nM) over 6
hours did not cause an increase in neutrophil apoptosis levels as assessed by
morphology (2.7 ± 0.7%) (Basal rate 1.7 ± 0.6%). Addition of TNFa (12.5 ng/ml)
over 6 hours caused 7.4 ± 2.3% apoptosis in neutrophils. The addition of
wortmannin and TNFa in combination, greatly increased neutrophil apoptosis levels
(30.6 ± 2%) (mean + SEM, n = 3). This suggested that in neutrophils, inhibition of
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PI 3-kinase alone is insufficient to activate an apoptotic signalling pathway.
However, in combination with TNFa, the TNFa apoptotic pathway is activated
along with the activation of a pro-apoptotic, or suppression of an anti-apoptotic
signal causing a marked increase in neutrophil apoptosis.
In addition, the reasoning behind why LY294002 only has a modest effect upon
SCLC cell apoptosis levels, but is able to completely inhibit PI 3-kinase activation
and SCLC cell growth in liquid culture may be answered by a recent observation by
Moore and colleagues (1998). Recent studies (Moore et al., 1998) have shown that
addition of LY294002 causes an inhibition in the number of cells undergoing cell
division. An increase in the number of cells in the G1 phase of the cell cycle was
observed after the cells were incubated with LY294002 over 24 hours. This indicates
that the large anti-proliferative effects of LY294002 noted, may be due to a
combination of effects; the PI 3-kinase inhibitor is able to cause SCLC cell cycle
delay and a modest increase in apoptosis levels. However, due to the presence of
constitutively activated PI 3-kinase in SCLC cells, it is unlikely that the cells will
ever be in an environment where activity is suppressed in vivo. Therefore, SCLC
cells will continually proliferate, and this phenomenon may go some way to
describing why SCLC has the highest growth rate of the four main types of lung
cancer.
Variations occurred in the 'fold increase' in apoptosis observed on the addition of
LY294002 throughout the cell survival studies. These variations may have been due
to the different experimental techniques applied in studying the cells. Also
morphological assessment of apoptosis can be difficult and variations may have
occurred due to more than one person counting the cytocentrifugation slides. (This
allowed us to say that although the increase was small it was however consistent.)




SCLC cells are known to be able to survive and grow in the absence of exogenous
growth factors. However, SCLC cell proliferation in vitro requires the activation of
PI 3-kinase. This proliferation pathway signals via a p70s6k-dependent and -
independent mechanism, with the majority of the signal bypassing p70s6k. As PI 3-
kinase is constitutively activated in SCLC cells, they are able to continually grow and
this may account for the rapid doubling times seen in SCLC cells.
In this chapter it was demonstrated that constitutive PI 3-kinase activity regulates
proliferation, tumourigenicity and in part apoptosis. Recent studies by Shaw and co¬
workers (1997) and Keely and co-workers (1997), indicate that PI 3-kinase activation
induces integrin-mediated cell motility and invasiveness. Given that serum- and
anchorage-independent survival are important in the maintenance of a transformed
phenotype, and to the ability of a cell to metastasis within the body, an understanding
of the mechanisms regulated by this constitutive PI 3-kinase activity could be of
benefit in designing novel therapies for the treatment of SCLC.
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CHAPTER 5
Extracellular Matrix Proteins: Protection of
Small Cell Lung Cancer Cells from
Chemotherapy-Induced Apoptosis.
5.1 Introduction.
Studies have shown that after primary chemotherapy treatment, the majority of
SCLC patients relapse within 1 year. On relapse, SCLC cells become resistant to
further chemotherapy treatment, thus the patient two year survival rate remains less
than 5% (Smyth et ah, 1986). The mechanisms underlying why SCLC cells become
resistant to chemotherapy are unclear. It is now thought that chemotherapy reagents
exert their cytotoxic effects by causing cells to undergo apoptosis (Hannun, 1997,
Walker et al., 1991, Kaufmann, 1989). Therefore, it may be hypothesised that after
primary treatment, SCLC cells become resistant to chemotherapy-induced apoptosis.
In view of the fact that tumour mass is a balance between cell proliferation and cell
death (apoptosis and necrosis), the factors effecting this balance will have a profound
effect on tumour growth.
In untransformed epithelial and endothelial cells, cell adhesion to ECM proteins has
been shown to protect the cells from undergoing apoptosis (Meredith et al., 1993,
Boudreau et al., 1995, Frisch & Francis, 1994). The integrin family of receptors are
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the major extracellular matrix receptor. On activation, integrins stimulate a large
number of intracellular signalling processes including tyrosine phosphorylation, cell
migration, cell survival and regulation of the cell cycle (Hynes, 1992, Guadagno et
al., 1993, Khawaja et al., 1997). Tumour cells are known to adhere to different ECM
proteins (Terranova et al., 1982). This adherence (via integrins) has been shown to
cause the activation of a number of intracellular signalling pathways including the
stimulation of cell migration on the ECM proteins and cell invasion (Shaw et al.,
1997, Keely et al., 1997, Bredin et al., 1998, Shibata et al., 1997).
In view of the above information, studies were performed to investigate if ECM
proteins were expressed within the local environment of SCLC cells in vivo, and to
examine if this local micro-environment could provide an anti-apoptotic signal, or
suppress an apoptotic signal resulting in SCLC cell resistance to chemotherapy.
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5.2 Results.
5.2.1 Expression ofExtracellular Matrix Proteins In Vivo.
5.2.1.1 The Presence of Increased Amounts of Extracellular Matrix Proteins
around Small Cell Lung Cancer Cells In Vivo.
SCLC lung sections were stained using an immunohistochemical technique (section
2.8) for the presence of ECM proteins laminin, fibronectin, collagen IV and tenascin.
Normal areas of the lung showed staining for laminin and collagen IV in the
basement membranes of alveoli, blood vessels and bronchial glands as expected.
Fibronectin stained weakly positive in a diffuse fashion throughout the pulmonary
interstitium without accentuation along the basement membrane (Figure 5.1a). The
ECM protein tenascin was not present in normal lung tissue.
In SCLC lung tissue specimens, ECM protein staining fell under three categories,
either no staining, extensive staining (> 50% of section area) or focal staining.
Extensive and focal areas of dense staining were observed for collagen IV,
fibronectin and tenascin (Figure 5.1a & b). In summary, between 90 and 100% of
the tissue specimens examined (23 specimens) had either focal or extensive staining
for fibronectin, collagen IV or tenascin (Sethi et ah, 1999). Staining for these three
ECM proteins was mainly observed in areas of patient reactive tissue. This was seen
as extensive areas of scarring or as stromal bands delineating packets of SCLC
tumour cells. SCLC lung sections also possessed thickened alveolar basement
membranes in comparison to normal lung tissue. These membranes showed
increased expression of laminin, fibronectin and collagen IV.
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Figure 5.1a: Photographs of Small Cell Lung Cancer and Normal Lung Sections
Stained for Collagen IV (upper) and Fibronectin (lower).
Lung sections of normal (left) and SCLC (right) lung tissues were stained using
immunohistchemical techniques (section 2.8) (primary antibodies 1: 100 dilution).
Brown staining shows strong immunoreactivity and marks the presence of the
extracellular matrix protein being studied. (x40 magnification.)
Sections were processed by Dr R.C. Rintoul.
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Figure 5.1b: Photographs of Small Cell Lung Cancer Lung Sections Stained for
Laminin (upper) and Tenascin (lower).
SCLC lung tissues were stained using immunohistchemical techniques (section 2.8)
form the presence of laminin (upper) and tenascin (lower) (primary antibodies 1:100
dilution).
Brown staining shows strong immunoreactivity and marks the presence of the
extracellular matrix protein being studied.
Sections were processed by Dr R.C. Rintoul.
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Further results highlighted by Sethi and colleagues (1999), showed that a proportion
of the SCLC cells in the SCLC lung tissue samples stained positive for either
fibronectin or laminin (26% and 16% respectively). This observation suggested that
a percentage of the cells were able to synthesise and potentially secrete both laminin
and fibronectin into the surrounding tissue. Thus, in vivo, SCLC cells were shown to
be surrounded by an ECM rich micro-environment. The physiological relevance of
this observation was examined further.
5.2.2 Regulation of the Adhesion of Small Cell Lung Cancer Cells to
Extracellular Matrix Proteins In Vitro.
5.2.2.1 Adherence of Small Cell Lung Cancer Cells to Extracellular Matrix
Proteins In Vitro is Mediated via a pllntegrin-dependent Mechanism.
Adhesion of cells to ECM proteins is widely accepted to occur via the binding of
integrin dimers to specific polypeptide sequences on proteins. To clarify the
presence of different integrin subunits on the SCLC cell lines H69 (Figure 5.2), H345
and H510, the relative expression of the integrin subunits was assessed by flow
cytometry (section 2.12). As shown previously by Falcioni and colleagues (1994)
and Feldman and colleagues (1991), high expression of the pi integrin subunit was
observed in comparison to the other p integrin subunits examined (Table 5.1).
When studying the a subunits (Table 5.1), a3 was highly expressed on all three cell
lines. Similar levels of av were observed in the three cells lines tested. a6
expression was significantly elevated in all three SCLC cell lines examined in
comparison to background fluorescence levels. Only H510 cells expressed
significant amounts of the a2 subunit. Expression levels of all the other a subunits
examined were similar to background control levels (2.4 ± 0.2 AU). In conclusion,
the SCLC cell lines predominately expressed integrin dimers that were involved in
the binding of laminin (a2pi, a3pi and a6pi), fibronectin (a3pi and avpi) and
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collagen (a2pi, a3pi and a6pi) (Hynes, 1992, Elices et al., 1991, Vogel et al.,
1990).
Table 5.1: Integrin Subunit Expression on Small Cell Lung Cancer Cell Lines
H69, H345 and H510.
Relative Expression Values (AU)
Integrin subunit H69 H345 H510
(31 30.8 ±3.5 17.1 ± 1.4 42.3 ±3.9
(32 5.0 ±0.3 1.4 ±0.2 4.2 ±0.4
(33 6.8 ±0.5 6.8 ±0.6 4.5 ±0.7
(34 6.7 ±0.9 4.6 ±0.5 6.0 ±0.1
(35 5.6 ±0.8 3.8 ±0.2 6.8 ±0.6
(36 5.6 ±0.6 5.9 ±0.4 2.5 ±0.1
al 4.3 ±0.2 6.1 ±0.5 4.9 ±0.8
a2 2.3 ±0.3 7.1 ±0.6 17.4 ±2.2
a3 36.4 ±2.5 38 ±2.2 30± 1.8
a4 5.7 ±0.4 6.5 ±0.3 3.2 ±02
a5 3.0 ±0.2 2.4 ±0.4 4.4 ± 0.4
a6 32.4 ±2.8 22.5 ±2.5 17.1 ±2.9
av 20.6 ±3.1 14.7 ±2.8 26.3 ± 1.2
Expression of the c ifferent integrin subunits was determined by flow cytometric
analysis using an indirect immunofluorescent technique (section 2.12). Each value
represents the mean fluorescence intensity (AU - arbitrary units) ± SEM of 3 - 4
independent experiments carried out in duplicate. (Background control AU = 2.4 ±
0.2)
In response to the above observations, all SCLC cells lines were shown to adhere to
laminin, fibronectin and collagen IV in a dose dependent manner (Figure 5.3). The
EC50 values for the three ECM proteins were 20 p.g/ml (fibronectin), 10 qg/ml
(laminin) and 12 pg/ml (collagen IV) in H69 SCLC cells.
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Negative control (mouse) Negative control (rat)
Figure 5.2: Representative Examples of Integrin Profiles as Assessed by Flow
Cytometry for Small Cell Lung Cancer Cell Line H69.
Cells (1 x 106/ml. 100 pl/well) were washed in PBS containing azide (EPICS buffer)
and incubated sequentially with saturating concentrations of the primary integrin
antibodies (1: 500 dilution) for 30 minutes on ice. Cells were washed in EPICS
buffer and then incubated with species-specific FITC conjugated secondary
antibodies (1: 25 dilution) for 30 minutes on ice. Labelled cells were examined by
flow cytometric analysis. The above histograms are representative of a single














Figure 5.3: Adhesion of H69 Small Cell Lung Cancer Cells to Different
Extracellular Matrix Proteins.
Cells (5 x 107ml, 100 pl/well) were washed in RPMI medium and plated on culture
dishes previously coated with increasing concentrations of ECM proteins. Cells were
incubated at 37°C in a humidified atmosphere of 5% C02/95% air for a period of 40
minutes before the non-adherent cells were removed. The remaining cells were fixed
(3% formaldehyde) and stained with 1% methylene blue. Residual dye was removed
and the cells lysed to release the internal stain. The absorbance values were read at
630 nm, and the relative number of adhered cells was calculated in relation to cells
adhered to 10 pg/ml of poly-L-lysine (PLL) (taken to be 100% adherence). Each
graph represents the mean (± SEM) of 3 - 6 independent experiments carried out in
duplicate.
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Further experimentation confirmed that the SCLC cells adhered to the different ECM
proteins in a pi integrin-dependent manner. Addition of a function pi-blocking
antibody (P5D2) to the SCLC cells before plating them on to ECM coated microtitre
plates (section 2.9), prevented the cells from adhering (Figure 5.4). The non-specific
adhesion of SCLC cells to poly-L-lysine (PLL) and BSA was unaffected. Therefore,
although SCLC cells are known to be anchorage-independent in vitro, they are able
to adhere to different ECM proteins in a pi integrin-dependent manner.
Residual adherence of the SCLC cells to collagen IV was noted in the presence of the
pi-function blocking antibody. This may be due to the SCLC cells being able to
bind to collagen IV in a non-pl-mediated fashion, or due to contaminants in the
collagen IV (extracted from human placenta (Sigma, UK)).
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Figure 5.4: Effect of the (31 Integrin Function Blocking Antibody (P5D2) on
H510 Small Cell Lung Cancer Cell Adhesion to Different Extracellular Matrix
Proteins.
H510 cells (5 x 105/ml, 100 pl/well) were added to BSA blocked (1 mg/ml BSA, 1
hour, 37°C) microtitre plates which were previously coated with different
extracellular matrix proteins overnight at 4°C (50 pl/well). Cells were added to the
96 well microtitre plate in the presence and absence of the (31 function blocking
antibody P5D2 (10 pg/ml). Cells were allowed to adhere for 45 minutes prior to the
removal of non-adhered cells and fixing of the remaining cells using 3%
formaldehyde. Adhered cells were stained with 1% methylene blue, lysed and
analysed using a plate reader at 630 nm. Absorbance of poly-L-lysine (in the
absence of P5D2) (25 pg/ml) was taken to be equal to 100% adhesion (control).
Each bar is representative of the mean one experiment performed 3-4 times in
duplicate. Abbreviations: - poly-L-lysine (25 pg/ml), PLL, Bovine Serum Albumin
(1 mg/ml), BSA, Laminin (10 pg/ml), Ln, fibronectin (20 pg/ml), Fn, collagen IV
(10 pg/ml), C IV.
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Figure 5.5: Effect of the Divalent Cation Manganese and EDTA on H69 Small
Cell Lung Cancer Cell Adhesion to Extracellular Matrix Proteins.
As described above, cells were incubated on pre-coated microtitre plates in the
presence of Manganese (Mn 2+) (1 mM) or EDTA (1.8 mM). Cells were allowed to
adhere for 45 minutes prior to washing, fixing and staining. Once lysed, the
percentage of cells adhered to the wells was assessed colourmetrically in comparison
to SCLC cells adhered to poly-L-lysine (10 pg/ml) (control). Each bar represents the
mean (± SEM) of 3 - 6 independent experiments carried out in duplicate.
Abbreviations: - Laminin (10 pg/ml), Ln, Fibronectin (20 pg/ml), Fn, collagen IV
(10 pg/ml), C IV.
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5.2.2.2 The Adhesion of Small Cell Lung Cancer Cells to Different Extracellular
Matrix Proteins is Dependent on the Presence of Functional Cations.
The cation-dependence of integrins has been studied by many groups (reviewed
Humphries, 1996). The cations magnesium and manganese have been implicated in
the stimulation of ligand binding, whereas calcium has been seen to have an
inhibitory effect. Studies have found that the majority of integrins contain a number
of cation binding sites (these differ between integrins), which exhibit distinct
preferences to the different types of cations available.
To investigate the role of cations in SCLC cell adhesion to ECM proteins, cells were
co-incubated with the divalent cation manganese and the cation chelator EDTA.
Figure 5.5 demonstrates that the adhesion of H69 SCLC cells to ECM protein
laminin, collagen IV and fibronectin increased in the presence ofmanganese (1 mM).
Addition ofEDTA (1.8 mM), inhibited integrin-induced adhesion of SCLC H69 cells
to the ECM proteins (Figure 5.5). These experiments were carried out in quiescent
cell culture medium (RPMI 1640, 25 mM HEPES, Sigma, UK.) which contains both
calcium (0.65 mM Ca(N03)2'4H20) and magnesium (0.54 mM Mg(S04) 7H20). This
enabled the cells to adhere in the presence of no additional cations (-). Addition of
manganese to the cell culture medium enhanced the binding ability of the SCLC cells
to the different ECM proteins. This may have been due to changes in the different
integrin heterodimer preferences and affinities to the manganese cations in
comparison to the magnesium cations already present.
These observations were in agreement with the previous studies performed by Elices
and co-workers (1991). These studies highlighted the different affinities displayed
by the a3pl integrin on binding to fibronectin in the presence of calcium (low
binding), magnesium (6.6 fold increase) and manganese (30 fold increase). Binding
of the H69 SCLC cells to collagen I was shown to decrease in the presence of
calcium. Addition ofmagnesium or manganese caused a 1.2 and 1.7 fold increase in
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a3(31 binding respectively. All cations caused optimal binding at a concentration
between 0.5-1 mM.
5.2.2.3 Inhibition of Specific Intracellular Signalling Molecules has No Effect on
Small Cell Lung Cancer Cell Adhesion to ExtracellularMatrix Proteins.
To investigate if the inhibition of intracellular signalling proteins or cytoskeletal
structure organisation could effect SCLC cell adhesion to ECM proteins, various
enzyme/protein inhibitors were added to cell cultures prior to, and during the
adhesion assay. PI 3-kinase and tyrosine kinase activation has been shown to be
elevated on cell adhesion to different ECM proteins (Schwartz, 1997). To investigate
if the stimulation of these intracellular proteins was a requirement for cell adhesion,
or a consequence of cell adhesion, cells were incubated in the presence of specific
enzymic inhibitors and plated onto different ECM proteins. Results indicated that
the addition of the PI 3-kinase inhibitor wortmannin (100 nM), and the tyrosine
kinase inhibitors tyrphostin-25 (25 pM) and genistein (100 pM) did not effect ECM
induced SCLC cell adhesion (Figure 5.6).
To investigate if a functional actin cytoskeleton was required to allow the SCLC cells
to adhere, SCLC cells were incubated in the presence of the inhibitor cytochalasin D.
Cytochalasin D causes capping of the f-actin fdaments and therefore prevents actin
polymerisation. Pre-incubation of the SCLC cells with cytochalasin D (200 pM) was















Figure 5.6: Adhesion of H69 Small Cell Lung Cancer Cells to Different
Extracellular Matrix Proteins in the Presence of Various Inhibitors.
Cells were assessed for adhesion to different matrices poly-L-lysine PLL (25 pg/ml),
laminin Ln (10 pg/ml), fibronectin Fn (20 pg/ml), collagen IV C IV (10 pg/ml) and
plastic as described in section 2.9. Before, and during the washing and assaying
procedure, cells were incubated in the presence of either no inhibitor (C),
wortmannin, WM (100 nM) (1 hour before plating), tyrphostin-25, Tyr-25 (25 pM)
(24 hours prior to plating), cytochalasin D, CD (20 pM) (1 hour before plating) or
genistein, Gen (100 pM) (24 hours prior to plating). Results are expressed as the
percentage change in adhesion in comparison to poly-L-lysine (25 pg/ml, 100%
adhesion (control)), in the presence of diluent alone (DMSO < 0.01% (v/v)). Each
bar is representative of the mean (± SEM) of four independent experiments carried
out in duplicate.
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5.2.3 Morphological Alterations in Small Cell Lung Cancer Cells on
Adhesion to Extracellular Matrix Proteins.
Whilst studying the adhesive capabilities of the SCLC cells, the adherence of H69
(and H345) SCLC cells to both laminin (Figure 5.7) and collagen IV (Figure 5.8) was
shown to induce the formation of membrane ruffles and microspikes. This change
was noticeable after 40 minutes. The ability of the SCLC cells to spread and produce
neurite-like processes (microspikes) was unable to occur on non-specific cell
adhesion to poly-L-lysine (Figure 5.7). Immunostaining of f-actin using rhodamine
phalloidin showed the presence of a large number of actin filaments within the cells.
H510 SCLC cell spreading was much less pronounced on adherence to laminin or
collagen IV in comparison to H69 and H345 SCLC cells.
The addition of cytochalasin D prevented the cells from forming membrane ruffles
and microspikes (Figure 5.8). This observation was in agreement with previous
studies in other cell types (particularly fibroblasts). It has been shown that cell
protrusions such as membrane microspikes or lamellipodia are dependent upon the
dynamic remodelling of the actin cytoskeleton.
The presence of the tyrosine kinase inhibitor genistein also prevented the formation
of the large microspikes and membrane ruffles (Figure 5.9). Cells adopted a more
rounded morphology as though they were unable to flatten out along the ECM. As
the intracellular protein Rho is known to cause the production of microspikes (Nobes
& Hall, 1995) and regulate genistein-sensitive proteins (Ridely & Hall, 1994), this
observation was not surprising.
In summary, the data shows that SCLC cell lines H345 and H69 adhere to laminin
and collagen IV in a (31 integrin-dependent manner causing the cells to flatten and
spread on the ECM proteins. Cell spreading was observed in the formation of
membrane ruffles, and microspikes (Figure 5.7). Activated tyrosine kinases and a
mobile actin cytoskeleton are required to enable the SCLC cells to produce these
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neurite-like processes. However, further investigations are required before the




Figure 5.7: Confocal Image of Small Cell Lung Cancer Cells Adhered to Poly-L-
lysine (Left) and Laminin (Right).
H69 SCLC cells were incubated in SITA medium before being gently disaggregated
and allowed to adhere to cover slips (previously coated with either poly-L-lysine (10
pg/ml) or laminin (10 (ag/ml) overnight at 4°C). Cells were allowed to adhere for 45
minutes before gently aspirating off any unadhered cells and adding fresh SITA
medium. The cells were then allowed to adhere and spread for a total of 4 hours
before being fixed, permeablised and stained using rhodamine phalloidin (1 : 400) to
visualise the actin structure within the cell. Confocal imaging was used to visualise
the actin structure near the base of the cells where they adhered to the coating matrix.
Each picture is representative of a single independent experiment carried out at least
10 times.
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Figure 5.8: Immunofluorescence Image of Small Cell Lung Cancer Cells H69
Adhered to Collagen IV in the Presence of Cytochalasin D.
SCLC cells were incubated in small sterile culture flasks in the absence or presence
of the inhibitor cytochalasin D (200 pM) for one hour. Cells were then washed,
disaggregated and plated onto the coverslips pre-coated in collagen IV (10 pg/ml) in
SITA medium in the absence (upper) and presence (lower) of cytochalasin D. Cells
were allowed to adhere for 45 minutes before non-adhered cells were gently
aspirated off and the remaining cells allowed to attach and spread for a total of 4
hours in the absence or presence of cytochalasin D (200 pM). After 4 hours,
coverslips were washed, fixed, permeablised and stained using rhodamine phalloidin
(1: 400). Cells were examined under fluorescence microscopy (BH2 Olympus
microscope). Image taken using a x 40 objective. Each photograph is representative
of single independent experiments carried out 4 times in SCLC cells lines H345 and
H69.
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Figure 5.9: Immunofluorescence Images of H345 Small Cell Lung Cancer Cells
Adhered to Laminin in the Absence (upper) or Presence (lower) of
phosphotyrosine Kinase Inhibitor Genistein.
Cells in SITA medium containing either genistein (100 pM) or diluent only, were
incubated in sterile culture flasks for 24 hours in a humidified atmosphere 5%
CC>2/95% air at 37°C. Cells were allowed to adhere (in the presence/absence of
genistein) to coverslips pre-coated with laminin (10 pg/ml) for 45 minutes in a
humidified atmosphere 5% COi/95% air at 37°C. Non-adhered cells were gently
removed and the remaining cells incubated for a total of 4 hours in fresh SITA in the
absence (upper) or presence (lower) of genistein (100 pM). Cells were fixed and
permeablised, before being stained with rhodamine phalloidin (1: 400 dilution) and
visualised by immunofluorescent microscopy. Images were photographed using a x
40 objective lens (BH2 Olympus microscope). Results are representative of a single
independent experiment performed 4 times.
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5.2.4 Increase in Phosphoinositide 3-kinase Activity on Adhesion to
Laminin.
The protein PI 3-kinase has been shown to be activated on cell adhesion to different
ECM proteins (King et ah, 1997. Khwaja et al., 1997, Chen et al., 1996, Wary et ah,
1996). The attachment of MDCK cells to matrix led to the rapid elevation of PI 3-
kinase lipid products (Khwaja et ah, 1997). COS-7 cells were also seen to adhere to
the matrix protein fibronectin causing increased PI 3-kinase activity (King et ah,
1997). Additionally, Shaw and co-workers (1997) showed that PI 3-kinase activity
was required to enable breast carcinoma cells to invade surrounding tissue. In view
of the fact that SCLC cells are highly metastatic and are able to adhere to different
ECM proteins, experiments were performed to investigate if SCLC cell adhesion to
laminin was able to further increase SCLC cell constitutive PI 3-kinase activity.
Adhesion of the SCLC cells to the ECM protein laminin was shown to cause an
increase in basal PI 3-kinase activity levels (143 ± 83% (H69, mean ± SEM, n= 3)
and 128 ± 25% (H510, mean ± S.D., n = 2), Figure 5.10 preliminary observations).
Addition of the PI 3-kinase inhibitors wortmannin and LY294002 was still able to
inhibit PI 3-kinase activity to below basal levels.
These observations indicate that although SCLC cells are anchorage-independent and
the enzyme PI 3-kinase is constitutively activated within the cells, adhesion to
laminin (via a pi integrin-dependent mechanism) causes PI 3-kinase activity levels to
be elevated further.
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Figure 5.10: Phosphoinositide 3-kinase Activity in Small Cell Lung Cancer Cell
Line H510 on Adherence to Laminin, in the Presence or Absence of
Wortmannin and LY294002.
Quiesced H510 SCLC cells (approximately 8 x 106/ml) were washed in warmed PBS
before being disaggregated into an essentially single cell population. Cells were
allowed to adhere to 12 well culture dishes pre-coated with laminin (10 pg/ml, 500
pl/well, overnight at 4°C) or no coating matrix (control, C) for a total of 40 minutes.
Cells were incubated in the presence ofwortmannin (WM, 100 nM, 20 minutes) and
10% (v/v) foetal calf serum (FCS, 5 minutes). Cells were lysed in PI 3-kinase lysis
buffer before the assay was performed as previously described in section 2.3.1a. As
with previous PI 3-kinase experiments LY294002 (LY, 100 pM) was only added
immediately prior to carrying out the actual in vitro kinase assay.
Results are expressed as the mean percentage PI 3-kinase activity with respect to
control cells (plated in the absence of laminin and received diluent alone (DMSO <
0.001% (v/v)). Each bar represents the mean (± S.D.) of two independent
experiments carried out in duplicate.
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5.2.5 The Effect of Small Cell Lung Cancer Cell Adhesion on Cell
Growth and Tumourigenicity.
5.2.5.1 The Effects of Small Cell Lung Cancer Adhesion to Extracellular Matrix
Proteins on Cell Proliferation.
Whilst the adhesion of SCLC cells to laminin and other ECM proteins has been
reported by a number of groups, its relationship with SCLC cell growth is unclear.
Initial experiments were undertaken to corroborate previous findings by Giaccone
and co-workers (1992a) and Fridman and co-workers (1990). Integrin-mediated
adhesion on its own is said not to be sufficient to induce cell mitogenesis. Giaccone
and co-workers (1992a), reported no change in the proliferation doubling times of
SCLC cells plated on laminin by MTT assay, cell counting and [3H]-thymidine
incorporation. Fridman and co-workers (1990) also noted that adhesion of SCLC
cells to laminin did not alter the growth rate of the cells in both MTT and ['H]-
thymidine assays. Nakanishi (1988) demonstrated that elevated levels of laminin (30
pg/ml) actually had an inhibitory effect on SCLC cell proliferation.
Preliminary studies indicated that the adhesion of H510 SCLC cells to laminin (10
pg/ml) did not effect SCLC [3H]-thymidine incorporation (e.g. SITA = 100 % [3H]-
thymidine incorporation, laminin (10 pg/ml) = 94.4 ± 7.5% [3H]-thymidine
incorporation, mean ± S.D., n=2 from replicates of five).
As a number of studies have examined the role of laminin in SCLC cell proliferation,
we went on to examine the role of the basement membrane protein collagen IV in
SCLC cell proliferation. As with laminin, SCLC cells had previously been shown to
adhere to collagen IV via a (31 integrin-dependent mechanism and produce
membrane ruffles and microspikes on adherence. Results described in figure 5.11
indicate that SCLC cell proliferation is not significantly increased on adhesion to
collagen IV. Proliferation studies indicated that in comparison to control cells
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Figure 5.11: Effects of Small Cell Lung Cancer Cell Adhesion to Collagen IV on
[3H]-Thymidine Incorporation in the Absence and Presence of Phosphoinositide
3-kinase Inhibitor LY294002.
H69 (upper) and H510 (lower) SCLC cells (1 x 107ml, 200 pl/well) were incubated
in flat-bottomed 96 well microtitre plates previously coated with collagen IV (C IV)
overnight at 4°C (50 pl/well) at various concentrations. Cells were incubated at
37°C in a humidified atmosphere 5% C02/95% air for 48 hours in the absence and
presence of LY294002. [3H]-thymidine (0.1 pCi/well) was added, and the cells
incubated for a further 24 hours prior to assessment for [3H]-thymidine incorporation.
Results are expressed as the mean percentage ["H]-thymidine incorporation in
comparison to control cells that received diluent alone. UPPER: Each bar represents
the mean (± SEM) of 3 independent experiments carried out in replicates of five.
Average basal counts per minute (cpm) = 40160 cpm. LOWER: Each bar represents
the mean (± range) of one experiment carried out in replicates of five. Average basal
cpm = 41078.
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(plated in the absence of collagen IV), lower concentrations of collagen IV (1 - 10
pg/ml) caused a slight increase in [3H]-thymidine incorporation, but this increase was
not statistically significant (p > 0.05). In H69 SCLC cells 100% adhesion (control
cells) was increased to 117 ± 13 % in the presence of collagen IV (10 pg/ml).
LY294002 was added to SCLC cells in the presence of collagen IV to investigate if
cell adhesion effected the ability of LY294002 to fully inhibit cell proliferation as PI
3-kinase had previously been shown to be elevated further on pi integrin-dependent
adhesion to ECM proteins. LY294002 was still able to inhibit [_1H]-thymidine
incorporation in the presence of collagen IV. Addition of 20 pM LY294002 (close to
the IC50 value obtained in Figure 4.2) caused an average 55% inhibition in [3H]-
thymidine incorporation and 100 pM LY294002 95% inhibition.
5.2.5.2 Increases in Small Cell Lung Cancer Cell Colony Formation in the
Presence of Different Extracellular Matrix Proteins and Neuropeptides.
The ability of cells to form colonies in semi-solid medium has been shown to
correlate with their tumourigenic capabilities (Freedman & Shin, 1974). Figure 5.1
demonstrates the increased deposition of ECM proteins in the micro-environment
surrounding SCLC cells in vivo. In view of this, studies were performed to
investigate if this increased ECM deposition may aid in SCLC cell tumourigenicity,
and help explain why SCLC cells are highly metastatic.
The addition of neuropeptides to SCLC cells grown in semi-solid agar is known to
enhance colony formation (Sethi & Rozengurt, 1991 and chapter 4). Figure 5.12
demonstrates an increase in the number of colonies formed by SCLC cells H69 in the
presence of ECM proteins laminin and fibronectin. This increase in colony number
was furthered by the addition of neuropeptides. Laminin and fibronectin caused a 3.2
and 2.2 fold increase in colony formation respectively. Bradykinin and galanin a 2.5
and 2.4 fold increase respectively. When added along side laminin and fibronectin,
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bradykinin and galanin caused a 4.5 and 3.6 fold increase in colony formation
respectively. The exact mechanisms underlying this synergistic increase in colony
formation are unclear, however, the presence of both ECM and neuropeptides either
alone or in combination significantly increase the tumourigenic properties of SCLC
cells.
Previously, the ability of lung cancer cells to form colonies in semi-solid medium
was shown to increase in the presence of matrigel (Yoshida, et al., 1997).
Additionally preliminary studies by Fridman and co-workers (1990) examined the
effect of matrigel on SCLC cell tumour growth in an in vivo enivronment. They
subcutaneously injected a combination of SCLC cells and matrigel into athymic nude
mice. Results confirmed the hypothesis that the presence of ECM alongside SCLC
cells aids in SCLC cell tumourigenicity, as the resulting tumours in the mice co-




Figure 5.12: The Effect of Extracellular Matrix Proteins Fibronectin and
Laminin on H69 Small Cell Lung Cancer Colony Formation in the Presence
and Absence ofNeuropeptides Bradykinin and Galanin.
H69 cells (1 x 104/ml) were plated in agarose (3%) as described in section 2.4.3, in
the presence and absence of laminin (Ln) (10 pg/ml) or fibronectin (Fn) (20 pg/ml)
and the neuropeptides bradykinin (BK) (10 nM) or galanin (Gal) (50 nM). After 21
days incubation at 37°C, cells were stained with a vital stain (tetrazolium blue).
Colony number was assessed by counting colonies >16 cells in size by light
microscopy. Each bar represents the mean (± S.D.) of two experiments performed in
triplicate.
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5.2.6 Resistance to Chemotherapy.
The majority of chemotherapy reagents are thought to trigger cell death by causing
cells to undergo apoptosis (Hannun, 1997). The adhesion of different cell types to
ECM proteins or to pi integrin antibodies, has been shown to protect cells from
undergoing apoptosis (known as anoikis) (Meredith et ah, 1993, Frisch & Francis,
1994). On serum withdrawal, endothelial cells were prevented from undergoing
apoptosis when immobilised on integrin (31 antibodies, or when treated in suspension
with the tyrosine phosphatase inhibitor sodium pyrophosphate (Meredith et ah,
1993). Studies in epithelial cells indicated that if the epithelial cell-matrix interaction
was disrupted, the cells underwent anoikis. This could be prevented by
overexpression of the anti-apoptotic protein Bcl-2, by cellular transformation with v-
Ha-ras or v-src, or by treatment with phorbol esters (Frisch & Francis, 1994). In
view of some of the above observations that pi integrin/ECM interactions aided in
cell survival, we went on to investigate whether the presence of, and adhesion to,
ECM proteins was able to effect SCLC cell number / apoptosis levels when
incubated in the presence of different chemotherapeutic agents.
5.2.6.1 Effects of Chemotherapeutic Agents on Small Cell Lung Cancer Cell
Number In Vitro.
Our initial results showed that in the presence of chemotherapeutic agents, the
number of surviving cells was significantly higher when the SCLC cells were plated
in the presence of different ECM proteins (Figure 5.13). When F1345 SCLC cells
were adhered to Fn, the IC50 value of Cyclophosphamide increased from 1 pM to 200
pM, and IC50 value of Cis-Platinum from 92 pg/ml to 450 pg/ml. This suggested
that the adhesion of SCLC cells to the ECM proteins triggered a signalling pathway
that either aided in SCLC cell proliferation (thought not to be the case (Figure 5.11)),
or in the prevention of chemotherapy-induced SCLC cell death. In view of these
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Figure 5.13: Changes in Small Cell Lung Cancer Cell Number when
Adhered/Not-Adhered to Fibronectin in the Presence of Chemotherapy
Reagents.
H345 cells (5 x 107ml, 200 phwell) were plated on microtitre plates pre-coated with
no coating matrix (□ ) or fibronectin (•) (20 pg/ml, overnight at 4°C). Cell were
allowed to adhere for 1 - 2 hours prior to the addition of increasing concentrations of
Cyclophosphamide (pM) (left) or Cis-Platinum (pg/ml) (right). After 3 days
incubation (5% C02/95% air, 37°C), total live cell number was assessed as described
in the materials and methods section (section 2.11). Each point represents the mean
(± SEM) of three independent experiments performed in quadruplicate.
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results, the role of ECM adhesion on SCLC cell chemotherapy-induced apoptosis
was investigated.
5.2.6.2 Extracellular Matrix Proteins Protect Small Cell Lung Cancer Cells
from Apoptosis via a pi Integrin-dependent Mechanism Resulting in Increased
Resistance to Chemotherapeutic Agents.
Figure 5.14 indicates that in vitro adhesion of SCLC cells to different ECM proteins
protects them from undergoing chemotherapy-induced apoptosis. In comparison to
the apoptosis levels observed in SCLC cells in the absence of any chemotherapy
agents, lower levels were seen in the presence of both etoposide and
cyclophosphamide when the cells were plated onto ECM proteins (except at very
high concentration levels). For example, the addition of etoposide to H345 SCLC
cells in the absence of any ECM protein produced an IC50 of 12.5 pg/ml. This
concentration caused approximately 50% apoptosis. Plating the SCLC cells onto
ECM proteins prior to the addition of etoposide (12.5 pg/ml), caused a decrease in
the percent apoptosis observed (+ laminin 10%, + fibronectin 20%). The IC50 values
of etoposide in the presence of these ECM proteins were also raised (+ laminin IC50
63 pg/ml, and + fibronectin IC50 58 pg/ml).
When comparing the protective effects of the different ECM proteins in the presence
of various chemotherapy reagents, no major differences between the relative
protective effects of each of the ECM proteins could be found. This indicated that
adhesion to any of the ECM proteins examined was able to prevent SCLC cells from
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Figure 5.14: Effect of Extracellular Matrix Proteins on Chemotherapy-induced
Apoptosis in Small Cell Lung Cancer Cells.
Approximately (5 x 105/ml, 200 pl/well) cells were washed and plated in serum-free
SITA medium into 96 well microtitre plates (pre-coated with either fibronectin (20
pg/ml) (•), laminin (10 pg/ml) (♦), collagen IV (10 pg/ml) (ji) or in the absence of
any ECM protein (□)). Cells were allowed to adhere over approximately 1 - 2 hours
before chemotherapy reagents were added at various concentrations. Cells were
incubated for a further 3 days in a humidified atmosphere (5% C02/95% air, 37 °C)
prior to being assessed for apoptosis morphologically by cytocentrifugation (section
2.4). Each point represents the mean (± SEM) of 2 - 4 experiments carried out in
quadruplicate.
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Further investigations were performed to assess if this protective effect was pi
integrin-mediated. This hypothesis was suggested as it had previously been shown
(Figure 5.4) that SCLC cells adhered to the ECM proteins in a pi-dependent manner.
In the presence of a pi-function blocking antibody (P5D2), SCLC cells incubated in
the presence of collagen IV could not be protected against etoposide-induced
apotosis. Additionally, the non-specific adhesion of SCLC cells to poly-L-lysine
could not protect the cells from undergoing chemotherapy-induced apoptosis (Figure
5.15). Thus, SCLC cell resistance to chemotherapy-induced apoptosis must be a
consequence of either the stimulation a cell survival signal, or the repression of a pro-
apoptotic signal that is dependent upon pl-integrin activation.
During these experiments, differences between the relative resistance of the different
SCLC cell lines to various chemotherapy reagents was noted. An example of this
can be seen in figures 5.14 and 5.15. Etoposide, at a concentration of 25 pg/ml
caused approximately 56% apoptosis in SCLC cell line H345 (Figure 5.14), and
approximately 80% apoptosis in SCLC cell line H69 (Figure 5.15). These
differences where thought to be a cell specific phenomenon. Although the
differences could not be explained experimentally, the effect of the ECM proteins
remained the same. They were all able to cause a 3 - 6 fold decrease in apoptosis
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Figure 5.15: Extracellular Matrix Protein Mediated Small Cell Lung Cancer Cell
Resistance to Chemotherapy-Induced Apoptosis is Mediated via a (31 Integrin-
dependent Mechanism.
A) H69 SCLC cells were plated in 96 well microtitre plates (5 x 105/ml, 200 pl/well)
pre-coated with either collagen IV (10 pg/ml), poly-L-lysine (25 pg/ml) (PLL), or no
coating matrix (-). SCLC cell apoptosis was assessed in the presence and absence of the
pi integrin functional blocking antibody P5D2 (1 : 25 dilution) (added to cells as plated
into microtitre plates). After allowing the cells to adhere for 1 - 2 hours, etoposide (25
pg/ml) was added and the cells incubated for 3 days (5% C02/95% air, 37 °C) before
being assessed for apoptosis using morphological techniques (section 2.5.3). Each bar
represents the mean of 3 experiments carried out in quadruplicate (± SEM). B)
Representative cytocentrifugation samples of H69 SCLC cells under the above
conditions (A) are shown stained with May-Grunwald-Giemsa stain and examined using
an Olympus BH-2 microscope.
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5.2.6.3 Extracellular Matrix Protein-mediated Small Cell Lung Cancer Cell
Resistance to Chemotherapy-induced Apoptosis Requires the Activation of
Tyrosine Kinase Enzymes.
Attempts were made to begin to understand the signalling mechanism(s) behind this
apparent (31 integrin-mediated resistance to chemotherapy-induced apoptosis. Initial
observations by Sethi and colleagues (1999) indicated that on adhesion to ECM
proteins, there was an increase in the number of tyrosine phosphorylated proteins in
SCLC cells. Additionally, Tallett and colleagues (1996a) had previously
demonstrated the requirement of tyrosine kinase activity in the suppression of SCLC
cell apoptosis in the absence of ECM protein adhesion. Finally, Meredith and co¬
workers (1993) noted that in endothelial cells, detachment-induced apoptosis could
be prevented by the addition of the tyrosine phosphatase inhibitor sodium
pyrophosphate. This indicated that tyrosine kinase activation may be stimulated on
cell adhesion to (31 integrins. Thus, the role of tyrosine kinase activation in SCLC
cell resistance to chemotherapy-induced apoptosis was investigated.
As previously demonstrated, the presence of Ln, Fn and C IV caused an increase in
the IC50 values of etoposide (Figure 5.16). This inhibition of chemotherapy-induced
apoptosis was abolished by the addition of the tyrosine kinase inhibitor tyrphostin-
25. For example, in the presence/absence of Fn, the IC50 values for etoposide were
18 pg/ml and 3 pg/ml respectively. In the presence of tyrphostin-25, the IC50 values
were lowered to 4.9 pg/ml and 3.9 pg/ml +/- Fn respectively. Therefore, the results
indicated that on adhesion to ECM proteins, the intracellular signalling mechanism
which enables the SCLC cells to become resistant to chemotherapy-induced
apoptosis, requires tyrosine kinase activation.
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5.3 Discussion.
5.3.1 Extracellular Matrix Protein Expression.
In the initial studies we established the increased presence of a number of different
ECM proteins in the local environment surrounding SCLC cells in vivo. These
results corresponded to previous studies performed by Wetzels and co-workers
(1992), where they showed that all the SCLC tissue specimens they examined were
surrounded by the ECM protein laminin. Paakko and co-workers (1990) also
demonstrated the presence of both laminin and collagen IV around all types of lung
cancer tissues including SCLC. Further work has indicated that both the primary
tumours and their matched metastatic lymph nodes express elevated levels of ECM
proteins (Sethi et al., 1999) suggesting that these observations are characteristic of
SCLC throughout the body.
The origin of these ECM proteins has yet to be established. However, preliminary
observations described by Sethi and colleagues (1999) suggest that in vivo, SCLC
cells themselves are capable of synthesising and secreting ECM proteins, and thereby
altering their own microenvironment. This was in agreement with studies by
Mastroianni and co-workers (1993), who noted that 15% of the SCLC tissue samples
they studied were positive for intracellular cytoplasmic staining of laminin. Other
possibilities include the suggestion that the ECM proteins may be produced as a
consequence of autocrine and paracrine interactions involving fibroblasts and other
surrounding cells such as epithelial cells.
An important observation was the presence of the ECM protein tenascin in SCLC
lung tissue. The exact function of tenascin is not clear, however, it is known to be
expressed in adult tissues which are actively remodelling, where it is often co-
expressed with different matrix metaloproteinases (Jones et al., 1997). In the
presence of tenascin. the adhesion of fibroblasts to fibronectin has been shown to
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cause alterations in gene expression (Tremble et al., 1994). Tremble suggested that
co-expression of fibronectin and tenascin may regulate the expression of genes
involved in cell invasion and tissue remodelling. Roskelley and co-workers (1995)
also noticed that the adhesion of breast epithelial cells to ECM proteins caused
alterations in cell gene expression. These data imply that the adhesion of SCLC cells
to ECM proteins may cause alterations in gene expression possibly leading to SCLC
invasion and metastasis.
Tenascin expression has been shown to increase in the presence of the cytokine
transforming growth factor p (TGF-P). TGF-P has been has been shown to be
secreted by a number of tumour cell types including breast (Butta, et al., 1992) and
colon (Coffey et al., 1986). TGF-P has previously been shown to be constitutively
secreted by SCLC cell line NCI-N417. Further studies by Fischer and co-workers
(1994) confirmed that 4/8 of the SCLC cell lines examined secreted TGF-p. This
work is in agreement with our initial observations indicating that TGF-P is secreted
by all three SCLC cell lines examined (H69, H345 and H510 (personal
communication Dr. R. Streiter)).
TGF-P has been shown to be a key mediator in wound healing as it causes an
increase in collagen formation in experimental wounding models (Sporn et al., 1983).
Additionally, TGF-P is able to regulate the alternative splicing of fibronectin at the
mRNA level (Borsi et al., 1990). This can lead to the production of other ECM
proteins such as laminin and tenascin. Finally, secretion of TGF-P by wound
heterophils and macrophages causes the increased deposition of ECM proteins
(Keski-Oja et al., 1988, Sporn et al., 1987).
In view of these data, it can be hypothesised that SCLC cells, in conjunction with
surrounding cells, may secrete a number of growth factors and cytokines which cause
the formation of an ECM rich enviroment around SCLC cells in vivo.
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5.3.2 Integrin Profiling and Adhesion to Extracellular Matrix
Proteins.
ECM proteins are known to associate with cells via the integrin family of cell surface
receptors. SCLC cells have previously been shown to possess laminin receptors
(Feldman et ah, 1991, Pellegrini et ah, 1994) and adhere to laminin and matrigel (a
multi-protein preparation rich in laminin, collagen IV, heparan sulphate
proteoglycan, TGF -P, and IGF-1) (Fridman et ah, 1990). However, to understand
the role of integrins in tumour behaviour, information on the pattern of integrin
expression is required in relation to normal cell counterparts. SCLC cells were
shown to express the same integrin subunits as bronchial epithelial cells, although
they do not express the a5 integrin subunit (Koukoulis et ah, 1997). Decreases in
a5pi expression have often been observed to correlate with increased cancer cell
aggressiveness (Giancotti & Ruoslathi, 1990, Schreiner et ah, 1991), suggesting that
the loss of a5pi integrin expression may aid in the metastatic capabilities of SCLC
cells in vivo. To further the hypothesis that the integrin profde of SCLC cells is
favourable towards a metastatic cell type, expression of the integrin dimers a2pi,
a3pi, and avp3 (Schadendorf et ah, 1993, Danen et ah, 1994) have been shown to
be present on a wide variety of malignant melanomas (including the SCLC cell lines
examined). Studies by Vink and co-workers (1993) showed that a2pi/avp3 integrin
expressing cells colonised the lungs, where as cells expressing both the a2pi and
a6pi integrin heterodimers colonised both the lungs and extrapulmonary sites.
Additionally, the pi integrin has previously been shown to be important in the
angiogenic properties of teratoma growth (Bloch et ah, 1997). Migration and
invasion of a number of SCLC cell lines has also been shown to be dependent upon
pi-mediated integrin signals (Bredin et ah, 1998). Thus, the data described above
suggests that SCLC cells express an integrin profile which is favourable towards the
production of a metastatic cancer.
The results obtained in this chapter suggest that to allow SCLC cells to adhere to
ECM proteins, a functional pi integrin is required. However, the activation of
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certain intracellular proteins are not required to enable the cells to adhere. These
results agree with previous studies performed by Tachibana and co-workers (1996).
They showed that the adherence of SCLC cell line CADO LC6 was pi integrin-
dependent but did not require tyrosine kinase activity. This was concluded, because
addition of the phosphotyrosine inhibitor herbimycin A could not prevent adhesion.
Additionally, observations by Shaw and colleagues (1997) showed that breast
carcinoma cells adhered to ECM proteins in a PI 3-kinase-independent manner.
5.3.3 Alterations in Small Cell Lung Cancer Cell Characteristics on
Adhesion to Extracellular Matrix Proteins.
Classification of lung cancers has always been complex. Pathologists have often
observed the presence of mixed SCLC/NSCLC morpholological characteristics in
patients. These mixed NSCLC-like changes have frequently been observed after
chemotherapy and are often linked with chemoresistance and a poorer prognosis
(Matthews & Gazdar, 1981, Radice et al., 1982, Piehl et ah, 1988). Studies carried
out by a number of laboratories have shown that the induction of NSCLC
phenotypical characteristics can occur on the oncogenic transformation of SCLC
cells (Doyle, 1993). Transfection and transformation of SCLC cells with c-myc and
v-Ha-ras were associated with a move towards a more large cell
morphology/NSCLC phenotype. Additionally, Barr and co-workers (1996) showed
that transfection of the myc or ras oncogene, cell aggregation and attachment to
laminin aided in the transition between SCLC and NSCLC phenotypes. These
transitions could however be reversed on re-suspension of these cells suggesting that
a number of factors such as gene expression, and cell adhesion/environment are key
to phenotypic transformation.
As NSCLC cells are known to be adherent under tissue culture conditions, the
adhesion of SCLC cells to ECM proteins may cause a shift towards a more NSCLC-
like phenotype. However, studies by Sethi and colleagues (1999) showed that on
adhesion to ECM proteins, there were no alterations in the expression levels of the
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neuroendocrine markers chromogranin A, dopa-decarboxylase and neuron-specific
enolase. Fridman and co-workers (1990) also indicated that there were no alterations
in the expression of specific NSCLC proteins on the adherence of H345 SCLC cells
to laminin. Thus, the data suggests that the ability of SCLC cells to transform into a
more NSCLC-like phenotype requires more than just adhesion. A number of
additional factors such as an alteration in cell gene expression are required. The
suggestion that all lung cancer cell types originate from bronchial epithelial cells, and
that NSCLC cell types such as adenocarcinoma cells may be formed from SCLC
cells after additional genetic alterations, was hypothesised by Mabry and co-workers
(1991). They suggested that normal maturation of a bronchial cell led to the
production of a pluirpotent undifferentiated cell. This cell was then able to
differentiate into epithelial or endocrine cell types. As a consequence of chronic
injury these cells were hypothesised to lead to unrestrained growth and autocrine
growth loop activation (hyperplasia). Eventually transformation may occur due to
genetic alterations. These included deletion of a section of the 3p chromosome and
the oncogenic transformation of other oncogenes including ras and myc.
5.3.4 Small Cell Lung Cancer Growth and Survival.
Initial results indicated that adhesion to either collagen IV or laminin was unable to
significantly induce SCLC growth above control levels. These results were in line
with previous observations by Fridman and co-workers (1990), Giaccone and co¬
workers (1992a) and Nakanishi (1988). In contrast, the presence of ECM proteins
laminin and fibronectin were able to induce SCLC tumourigenicity in synergy with
neuropeptide-mediated SCLC clonal growth in semi-solid media. This indicates that
the presence of increased ECM deposition around SCLC cells in vivo aids in SCLC
tumourigenicity producing a more aggressive cell phenotype.
Further results demonstrated that SCLC cell resistance to chemotherapy is due to the
cells becoming resistant to chemotherapy-induced apoptosis when adhered to ECM
proteins. As shown by Meredith and co-workers (1993), ECM-mediated prevention
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of apoptosis occurred via a pi integrin-dependent mechanism. This observation was
strengthened by the fact that adhesion to poly-L-lysine was unable to rescue the cells
from chemotherapy-induced apoptosis. Fridman and co-workers (1990) first
observed laminin-induced chemoresistance in SCLC cells. The data described in this
chapter goes on to show that this initial observation is a more general property of a
number of ECM proteins that are found to be expressed in elevated amounts around
the SCLC cells in vivo. Also this protection from chemotherapy-induced apoptosis
occurs via a pi integrin-mediated signalling pathway that requires tyrosine kinase
activation.
Further studies examining ECM-induced cell survival mechanisms have shown that
both matrix adhesion, and ras transformation in suspended cells, are both able to
prevent anoikis/apoptosis via a PI 3-kinase-dependent mechanism (Khwaja et ah,
1997). It may therefore be hypothesised that the constitutively activated PI 3-kinase
present in SCLC cells is able to mimic ras transformation and enable SCLC cells to
become anchorage-independent. However, further investigations are required before
the potential role of PI 3-kinase in chemotherapy-induced apoptosis has been
established; although it was noted that on adhesion to laminin PI 3-kinase activation
was elevated.
Studies by Simizu and co-workers (1996 and 1998), and Tallet and colleagues
(1996), have shown that in SCLC cells grown in liquid culture, the induction of
apoptosis can be triggered via the inhibition of tyrosine kinase activation. This
induction of apoptosis was shown to be mediated via a caspase-3-like protease.
Caspase-3 is a member of the ICE protease family, and exhibits high percentage
homology and substrate specificity with the pro-apoptotic protein ced-3 (Nicholson
et ah, 1995). Caspase-3 is known to induce apoptosis via the cleavage of
poly(ADP)ribose polymerase (PARP). Further work by Simizu and co-workers
(1998) revealed that the activation of caspase-3 induced an increase in the expression
levels of the pro-apoptotic protein Bax. Thus, these data suggests that one of the
possible signalling mechanisms able to induce SCLC cell apoptosis is dependent
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upon the inhibition of tyrosine kinases and the activation of ICE-like protease
caspase-3.
Chemotherapy-induced apoptosis has been shown to be inhibited by the prevention
of PARP cleavage (Nicholson et ah, 1995, Chen et al., 1996, Dubrez et al., 1996).
When examining chemotherapy-induced apoptotic mechanisms, etoposide was
shown to cause DNA damage leading to cell cycle delay and activation of caspase-3.
Data described by Sethi and colleagues (1999) indicates that cell cycle delay and
caspase activation can be prevented by the inhibition of tyrosine phosphatase
activation, and by the adhesion of SCLC cells to ECM proteins. This inhibition of
etoposide-induced apoptosis was dependent upon tyrosine kinase activation and a (31
integrin-mediated signal. Thus, from the data described by both Simizu and co¬
workers (1998) and Sethi and colleagues (1999), it can be hypothesised that
etoposide-induced cell cycle delay is regulated by tyrosine kinase activity. On
adhesion to ECM proteins, additional tyrosine phosphorylation/activation occurs
resulting in cell cycle initiation. The activation of caspase-3 becomes abrogated
leading to a down-regulation of cellular apoptosis. It can therefore by hypothesised
that due to this process of events, SCLC cells surrounded by ECM proteins in vivo
are able to escape chemotherapy-induced apoptosis.
Thus, from the in vivo and in vitro data described in this chapter, it seems likely that
the adhesion of SCLC cells to ECM proteins plays a critical role in SCLC cell
tumourigenicity and resistance to chemotherapy-induced apoptosis. Understanding
how the local environment is formed around SCLC cells in vivo, and the exact
mechanism which enables specific proteins to be activated/inhibited on adhesion to




One of the main causes of death in cancer patients is the development of secondary
metastatic deposits at sites remote from the primary tumour. SCLC has the highest
metastatic potential of any of the solid tumours with over 90% of patients having
widespread metastases at initial presentation. When first diagnosed, patients respond
well to chemotherapy. However, despite this initial sensitivity to chemotherapy, the
tumour almost invariably relapses and becomes resistant to further chemotherapy
treatment; thus the patient two year survival rate remains between 3 - 8% (Elias,
1997). In this thesis we aimed to begin to unravel possible signalling mechanisms
which regulate SCLC cell growth, tumourigenicity and resistance to chemotherapy-
induced apoptosis.
6.1 Major Findings of this Thesis.
The novel findings described within this thesis are that in SCLC cells the
lipid/tyrosine kinase PI 3-kinase is constitutively activated resulting in high levels of
p70s6k activity. Inhibition of PI 3-kinase activity was shown to fully inhibit SCLC
cell proliferation in liquid culture, and prevent both basal and neuropeptide-
stimulated colony formation in semi-solid medium. We show that PI 3-kinase-
mediated proliferation is regulated by at least two signalling cascades, with one of
these pathways signalling via p70s6k. The observed inhibition of SCLC cell growth in
liquid culture has since been shown to be regulated by a combination of factors. We
show that inhibition of PI 3-kinase activity causes a small but consistent increase in
SCLC cell apoptosis. This observation, coupled with the recent observation (Moore
et al., 1998) that PI 3-kinase inhibition causes a delay in the SCLC cell cycle at Gl,
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helps to explain why the PI 3-kinase inhibition prevents SCLC cells from undergoing
mitosis. Thus in SCLC cells, the downstream signalling pathways regulated by the
constitutively activated PI 3-kinase, are important in SCLC cell anchorage-
independent growth and tumourigenicity.
Studies investigating the mechanism(s) underlying SCLC cell resistance to
chemotherapy-induced apoptosis, indicated that in vivo, SCLC cells were surrounded
by an extensive stroma of ECM proteins. In vitro SCLC cells were shown to adhere
to these ECM proteins predominantly via a pi integrin-dependent mechanism
causing the cells to become more resistant to chemotherapy-induced apoptosis. This
resistance was shown to involve activated tyrosine kinase enzymes, but the exact
enzymes have yet to be established. This survival effect could not be mimicked by
the non-specific adhesion of SCLC cells to poly-L-lysine. Additionally, the presence
of ECM proteins was shown to increase the tumourigenic properties of the SCLC
cells by increasing the number of clonies formed in semi-solid medium. Thus,
despite SCLC cells being anchorage-independent, the adhesion of SCLC cells to
ECM proteins via a pi integrin-dependent mechanism, protected the cells from
chemotherapy-induced apoptosis, and resulted in enhanced tumourigenicity.
6.2 Discussion.
Results from chapter 3 indicate that PI 3-kinase is basally activated by a mechanism
yet to be established. This is the first time PI 3-kinase has been shown to be
constitutively activated in any human cancer. In view of this novel finding, the role
of PI 3-kinase in SCLC cell growth and survival was investigated further.
Previous studies have indicated that the proliferation of SCLC cells is driven by
multiple autocrine and paracrine growth loops involving calcium mobilising
neuropeptides (Sethi & Rozengurt. 1991 and 1992). This mitogenic signalling is
thought to enhance SCLC cell tumourigenicity (clonal growth studies) and explain
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why the tumour is serum-independent. A wide range of mitogenic signalling
cascades have been shown to involve PI 3-kinase (Chung et ah, 1994 (PDGF),
Vemuri & Rittenhouse, 1994 (NGF), Kotani et al., 1994 (IGF-1), DePaolo et al.,
1996, Cross et al., 1994, Uehara et al., 1995 (vasopressin, IGF-1 and insulin),
reviewed Toker & Cantley, 1997). Given that PI 3-kinase is constitutively activated
in SCLC cells, it maybe hypothesised that the presence of PI 3-kinase may explain
the serum-independence observed in these cells. The constitutive activation of PI 3-
kinase observed in quiescent SCLC cells was shown to be stimulated further upon
the addition of FCS or insulin. In view of this, the combination of constitutive PI 3-
kinase activation and the presence of autocrine mitogens may explain why SCLC
cells are the fastest growing lung cancer cell type. The growth signal within the cell
may be permanently switched on due to PI 3-kinase activation. However, when the
cells are stimulated via autocrine growth promoting mitogens, the cells become fully
activated maximising their growth signal without the requirement for exogenously
added mitogens.
The major role of PI 3-kinase in SCLC cell growth was highlighted by the
observations that on the inhibition of PI 3-kinase activity, SCLC cells were unable to
proliferate in liquid culture. This growth signal was seen to signal via p70s6k and at
least one other pathway independently of p70s6k. Studies have shown that inhibition
of the MAP kinase signalling cascade in SCLC cells causes approximately a 50%
inhibition in cell proliferation in liquid culture. PI 3-kinase has been shown to
regulate MAP kinase activation in a number of cells types (Hawes et al., 1996,
Lopez-Ilasaca et al., 1997, King et al., 1997). King and co-workers (1997) noted that
PI 3-kinase and PKB regulated integrin-mediated MAP kinase signalling. They
suggested that this occurred either via the PI 3-kinase-dependent activation of PKC
causing an increase in raf-1 activation, or by the 3-phosphorylated lipid products of
PI 3-kinase activating raf-1. Hawes and co-workers (1996) demonstrated that the
inhibition of PI 3-kinase activation in COS-7 cells prevented MAP kinase activation.
One hypothesis could therefore be that downstream of PI 3-kinase the proliferation
signal splits with one pathway signalling via p70s6k and the other via MAP kinase.
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Further experimentation is required before it can be established whether in SCLC
cells, MAP kinase activation can be regulated by growth factor/integrin-dependent PI
3-kinase activation and whether this underlies the signalling processes that mediate
SCLC cell growth.
Transformation of adherent cells using the cytoplasmic oncogenes ras and src has
been shown to enable cells to grow in suspension (become anchorage-independent)
(Frisch & Francis, 1994, Khwaja et ah, 1997). Epithelial cells have been seen to
overcome anchorage-dependent apoptosis (anoikis). The mechanism underlying this
observation was shown to involve the proteins PI 3-kinase and PKB (Khwaja et al.,
1997). Given that both ras and src are not highly expressed or activated in SCLC
cells (Mitsudomi et al., 1991, Suzuki et al., 1990, Budde et al., 1994), the presence of
constitutively activated PI 3-kinase in SCLC cells may mimic ras or src
transformation. PI 3-kinase has been shown to be stimulated on integrin activation
(King et al., 1997, Chen & Guan, 1994b), therefore constitutive PI 3-kinase activity
may cause the stimulation of signalling cascades within the SCLC cells which are
normally activated on integrin binding enabling the cells to become anchorage-
independent.
This hypothesis was strengthened by recent evidence indicating that growth factors
alone were unable to induce DNA synthesis in NIH 3T3 cells in the absence of
integrin activation (Renshaw et al., 1997). This appeared to result from the inability
of growth factors to activate the MAP kinase pathway in the absence of integrin
activation and cause the stimulation and production of integrin-mediated second
messenger signals. In NIH 3T3 cells Renshaw and co-workers (1997) noted that
activation of the classical MAP kinase signalling cascade could only trigger DNA
synthesis when the cells were allowed to adhere. In transformed cells (transfected
with constitutively active ras or rafmutants), the activity of p42MAPK remained low
in suspended cells in comparison to the activity observed in untransfected cells that
were allowed to adhere. However, the p42MAPK activity in the suspended
transformed cells was approximately 40% higher than that measured in serum-
195
stimulated untransformed cells. Thus, using this analogy, it could be hypothesised
that in SCLC cells, the constitutive activation of PI 3-kinase may mimic the
transformation changes observed by Renshaw. Renshaw suggested that the presence
of the ras transformation overcame the requirement for cell adhesion by causing the
production of integrin-mediated second messengers in the absence of integrin
activation. Hence for SCLC cells in suspension, the constitutive activation of PI 3-
kinase may cause a stimulation of the 'integrin-mediated' downstream signalling
second messengers. This enables the SCLC cells to maintain their 'growth signal' in
the absence of integrin adhesion and become anchorage-independent.
Preliminary investigations into the composition of the micro-environment
surrounding SCLC cells in vivo, indicated that due to possible auto and paracrine
interactions, SCLC cells were surrounded by a micro-environment enriched in
different ECM proteins. Although SCLC cells are anchorage-independent, in the
presence of different ECM proteins, they were shown to adhere via a pi integrin-
dependent mechanism. On adhesion, an increase in the tyrosine phosphorylation of
intracellular proteins (Sethi et al., 1999) was observed. Additionally, the adhesion of
the SCLC cells to ECM proteins was shown not to cause a significant increase SCLC
cell proliferation in liquid growth media, but cause the production (or inhibition) of a
signal which resulted in an increase in SCLC resistance to chemotherapy-induced
apoptosis. Moreover, SCLC cell PI 3-kinase activity was shown to increase on
adhesion to Laminin. This final observation mimics the observation by Renshaw and
co-workers (1997) who noted a 2.5 fold increase in p42MAPK activity in adhered
transformed cells in comparision to non-adhered transformed cells. In view of this,
the activation of additional signalling proteins (including PI 3-kinase) on SCLC
adhesion to ECM proteins may therefore enable SCLC cells to become resistant to
chemotherapy-induced apoptosis.
Further studies both described in chapter 5 and performed by Sethi and colleagues
(1999), have highlighted that the mechanism underlying SCLC cell resistance to
chemotherapy-induced apoptosis is regulated by a tyrosine kinase-dependent
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mechanism. The adhesion of SCLC cells to an ECM protein via a pi integrin-
dependent mechanism, protected the SCLC cells from etoposide-induced caspase-3
activation and apoptosis by activating tyrosine kinase signalling downstream ofDNA
damage (as adhesion did not significantly alter either the expression or activity of
topoisomerase II). Activation of the tyrosine kinase-dependent signalling
mechanisms abrogated cell cycle arrest at the G2/M and S phase. Additional work
indicated that the caspase inhibitor Z-VAD prevented the cleavage of pro-caspase-3
and therefore chemotherapy-induced apoptosis. The addition of Z-VAD did not
effect DNA damage or cell cycle delay indicating the caspase-3 activation was a
downstream event in etoposide-induced SCLC cell death.
Therefore, although SCLC cells are thought of as anchorage-independent, this may
not be strictly true. SCLC cells may be able to survive and proliferate whilst in
suspension (e.g. whilst moving around the body in the blood stream, or lymphatic
system), however to maximise their tumourigenic and metastatic capabilities, they
may prefer to be adhered to proteins such as ECM proteins via integrin-dependent
mechanisms. For a cell to invade and metastasis it has to adhere and degrade ECM
(Clezardin, 1998). This enables the cells to intravasate from the primary tumour site
into the blood stream/lymphatic system. From there the cells would then have to be
able to adhere to the vessel wall and extravastate and form a secondary ectopic
deposit. Tumour cells are known to migrate via integrin-dependent mechanisms
(Bredin et ah, 1998, Fridman et ah, 1990), become more invasive in the presence of
laminin (Shaw et ah, 1997, Keely et al., 1997) and become increasingly tumourigenic
both in vitro and in vivo (chapter 5, Fridman et al., 1990) in the presence of laminin
or matrigel.
Thus, the constitutive activation of PI 3-kinase may be mimicking the effects of an
'activated oncogene' enabling the SCLC cells to become both serum- and anchorage-
independent in culture. The activation of PI 3-kinase in SCLC cells appears to be
crucial in a number of important cellular functions and may regulate the cell growth,
anchorage-independence, serum-independence and tumourigenic properties of SCLC
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cells. Along with the ECM/integrin-mediated cell signalling events described above,
these observations may help explain why partial responses and the local reoccurrence
of SCLC is often seen after chemotherapy.
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6.3 Future Directions.
Many questions still need to be addressed in relation to the role of PI 3-kinase in this
highly aggressive and metastatic cancer.
i) The use of different strategies to clarity our published observations.
The work presented throughout this thesis has centred upon experiments utilising a
number of different pharmacological inhibitors. As discussed with respect to the PI
3-kinase inhibitors wortmannin and LY294002 (section 3.3.2), there have been a
number of published cases suggesting that as research progresses, these
pharmacological inhibitors are seen to be less enzyme specific. To overcome this, a
number of groups now perform experiments in parallel with enzyme inhibitor
experiments using molecular genetic approaches. For example when investigating PI
3-kinase, researchers have used dominant negative and constitutively activated PI 3-
kinase enzyme mutants to investigate/clarify specific observations they have seen.
Researches suggest that using these more direct approaches which target specific
proteins, there is less chance of non-specific effects from occurring, like the
inhibition of a related protein. To clarify our pharmacologically based observations
that PI 3-kinase is constitutively activated in SCLC cells and is required for growth, a
dominant negative PI 3-kinase mutant should be transfected into SCLC cell lines and
the results assessed in parallel to the data described within this thesis.
ii) The mechanism underlying the constitutive activation of PI 3-kinase.
This question is hard to address as there are many possible reasons as to why PI 3-
kinase is constitutively activated in SCLC cells under quiesced basal conditions
(section 3.3).
Polymerase chain reactions may be performed using primers to both the p85 and
pi 10 subunits of PI 3-kinase. From the sequences obtained you could potentially
sequence the subunits to try to identify any possible mutations. Theoretically a
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mutation in the p85 regulatory subunit may cause the removal of an inhibitory
constraint. A mutation in either subunit may result in a conformational alteration
leading to enzyme activation.
Localisation studies may be performed to address the question is PI 3-kinase
constitutively activated due to the catalytic subunit being targeted to the plasma
membrane in the absence of any exogenous stimulation. This targeting could be due
to mutations within the enzyme itself, or in the receptor at the plasma membrane.
Immunohistochemical methods may be used. Given that the actual percentage of PI
3-kinase in all cells is very low, small changes in localisation maybe hard to
visualise. Thus, using specific lysis techniques, separation of different compartments
of SCLC cells maybe achieved. Activity levels of PI 3-kinase may then be assessed
in each cellular fraction. This may give a more accurate picture of the localisation of
active PI 3-kinase within the SCLC cells.
iii) The role of PI 3-kinase in MAP kinase activation.
To investigate if in SCLC cells, the MAP kinase pathway is regulated upstream by PI
3-kinase, co-incubation assays could be performed. MAP kinase activity assays
maybe undertaken in the presence and absence ofPI 3-kinase inhibitors to investigate
if either wortmannin or LY294002 could inhibit either neuropeptide-stimulated, or
basal MAP kinase activity levels.
The effect of LY294002 and PD 098059 on SCLC cell proliferation rates may be
also investigated by incubating the cells in the presence of each inhibitor both alone
and in combination.
iv) The role of PI 3-kinase in ECM colony formation.
Inhibition of PI 3-kinase was shown to prevent basal and neuropeptide-stimulated
colony formation. To investigate if the increase in colony formation in the presence
of different ECM proteins was mediated by PI 3-kinase, experiments where SCLC
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cells in semi-solid medium were incubated with LY294002 and ECM alone, and in
combination would have to be performed.
v) Further elucidation of the mechanism underlying ECM-mediated resistance
to chemotherapy-induced apoptosis.
Given that resistance to chemotherapy is one of the major causes of SCLC patient
death, any information on how this may occur is invaluable in the search for novel
therapeutic drugs. Using inhibitors to specific proteins further chemotherapy assays
maybe performed. This technique is only of use if the inhibitors are known to be
enzyme specific. Given that PI 3-kinase has been shown to be stimulated on SCLC
cell adhesion to ECM proteins, the possible role of this protein on SCLC cell
resistance to chemotherapy-induced apoptosis should be assessed. In the case of
p70s6k (which was shown by Shi and co-workers (1995) to be important in cis-platin-
induced apoptosis), rapamycin could be utilised to investigate the possible role of
p70s6k as it is still thought to be an enzyme specific inhibitor.
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The Presence of a Constitutively Active Phosphoinositide 3-Kinase in Small Cell-
Lung Cancer Cells Mediates Anchorage-independent Proliferation via a
Protein Kinase B and p70s6k-dependent Pathway1
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ABSTRACT
Small ceil lung cancer (SCLC) is characterized by early and widespread
metastases. Anchorage-independent growth is pivotal to the ability of
tumor ceils to survive and metastasize in vivo and under in vitro conditions
allows transformed cells to form colonies in semisolid medium. Here we
report that of five SCLC cell lines tested, all exhibited high basal consti¬
tutive phosphoinositide 3-kinase (PI 3-kinase) activity, which results in
high basal protein kinase B (PKB) and ribosomal p70 S6 kinase activity
(P70***). Inhibition of PI 3-kinase activity markedly inhibited SCLC cell
proliferation in liquid culture as a result of stimulating apoptosis and
promoting cell cycle delay in Gv Furthermore, PI 3-kinase inhibition
reduced basal SCLC cell colony formation in agarose semisolid medium
that could not be overcome by the addition of neuropeptide growth
factors. Thus, constitutive PI 3-kinase activity in SCLC cells plays an
important role in promoting the growth and anchorage independence of
SCLC. This is not due to activating ras mutations or increased basal src or
focal adhesion kinase activity. These data represent the first description of
constitutively activated PI 3-kinase/PKB in any human cancer. Constitu¬
tive activation of these integrin-dependent signaling events provides a
molecular explanation for the anchorage-independent growth of SCLC
cells and may account for the nonadherent phenotype and highly meta¬
static nature of this aggressive cancer. Up-regulation of the PI 3-kinase/
PKB pathway may therefore represent a novel target for therapeutic
intervention in SCLC.
INTRODUCTION
Lung cancer is the commonest fatal malignancy in the developed
world. SCLC4, constitutes 25% of ail lung neoplasms and is charac¬
terized by early and widespread metastasis with a 5-year survival of
3—8% (1). The aim of our work has been to devise novel and more
rational therapeutic strategies based on a better understanding of the
molecular events that are responsible for metastasis and sustaining the
growth and preventing the death of SCLC ceils.
The molecular mechanisms regulating SCLC cell proliferation and
apoptosis are beginning to be elucidated. We have shown recently that
tyrosine phosphorylation and tyrosine kinase activation is an impor¬
tant mitogenic signal in SCLC cells and that the regulation of the level
of tyrosine phosphorylation may represent a critical determinant of
whether SCLC ceils survive and proliferate or die by apoptosis (2).
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However, little is known about the precise nature of the tyrosine
kinases involved or the downstream signaling pathways that may be
involved in these responses.
The PI 3-kinase family of enzymes phosphoryiate inositol contain¬
ing phospholipids on the 3' position of the nonpoiar inositol head
group. Although PI 3-kinase can phosphoryiate PI. PI (4)P, and PI
(4,5)P3 in vitro, PI (4,5)P, is believed to be the preferred substrate in
vivo generating the second messenger PI (3,4,5)P3 (3-6). PI 3-kinase
is an enzyme thai acts as a direct biochemical link between a phos¬
phoinositide pathway and a number of proteins containing intrinsic or
associated tyrosine kinase activities including the receptors for insuiin
and colony-stimulating factor and the products of the oncogenes v-src
and v-abl (7). Phosphorylation of specific tyrosine residues on acti¬
vated polypeptide growth factor receptors activates the p85-pl 10 PI
3-kinase heterodimeric complex via an SH2 domain of the p85 reg¬
ulatory subunit (8). In addition, adhesion to extracellular matrix
stimulates the integrin-dependent interaction of the p85 PI 3-kinase
complex with FAK. causing increased accumulation of PI (3,4)P, and
PI (3,4,5)P3 (9). Thus, PI 3-kinase is a critical component of signaling
pathways that can be activated by a variety of growth factors, onco¬
genes, chemokines, ceil surface receptors, and integrins. Use of the
selective PI 3-kinase inhibitors wortmannin (10) and LY294002 (11)
and dominant-negative or constituciveiy active mutants of PI 3-kinase
have shown that this enzyme plays a key role in a variety of distinct
cellular functions including the mitogenic response, apoptosis. intra¬
cellular vesicle trafficking/secretion, and regulation of actin and inte-
grin function (reviewed in Ref. 12). Furthermore, recent studies sug¬
gest that integrin-mediated PI 3-kinase activarion-is important for cell
migration and can promote carcinoma invasion (13, 14).
In view of these important physiological functions, much interest
has focused on potential downstream effectors of PI 3-kinase. Evi¬
dence is accumulating to show that PI 3-kinase is a crucial mediator
of ribosomal S6 kinase (p70s6k) activation in response to serum and
growth factors (15). Activation of p70'6k regulates a wide variety of
cellular processes involved in the mitogenic response including pro¬
tein synthesis, translation of specific mRNA species, and progression
from G, to S phase of the cell cycle (16-18). Seufferiein and Rozen-
gurt (19) demonstrated recendy that p70*6k is constitutively phospho-
rylated in SCLC ceils and that the p70s61c inhibitor rapamycin inhibits
SCLC cell proliferation. Rapamycin inhibits p70s6t indirectly, form¬
ing a complex with FK-506-binding protein, which in turn interacts
with RAPT/mTOR, a lipid kinase that is a putative upstream regulator
of p70»6k (17).
The serine/threonine proto-oncogene PKB is the cellular homo-
logue of the transforming oncogene product v-Akt (20). PKB has been
shown to be activated by growth factors, oncogenes, and integrins,
signaling through PI 3-kinase (reviewed in Ref. 21). PKB has been
shown to be overexpressed in 12% of ovarian, 3% of breast, and 10%
of pancreatic cancers, where it has been associated with a poor
prognosis and increased tumorigenicity (22. 23). However, the activ¬
ity state of PKB in tumor ceils has not been examined previously.
The ability of cancer ceils to grow in the absence of cell adhesion
to extracellular matrix has been shown to correlate cioseiy with
1




coNsrmmvB pi wonash activity in sclc ctlls k-Lc cwJw^Tt-
tuinorigenicity in animal models (24). The main cause of death in
padents with cancer arises as a result of either primary tumor invasion
or secondary metastatic deposits. Therefore, the ability of tumor cells
to survive and grow in inappropriate environments is ceniral to
cancer-related death.
The induction of complete oncogenic transformation appears to
require both serum and anchorage-independent growth (25). Consri-
tutive sdmuladon of growth factor pathways by ectopic growth factor
expression is mitogenic rather than oncogenic, resulting in benign
hyperplasia in animal models (26-28). In vivo, autocrine growth
factor expression can also be associated with accelerated or serum-
independent growth of otherwise normal ceils. (29). Our previous
work suggests that the unrestrained proliferation of SCLC cells is
driven by multiple autocrine and paracrine growth loops involving
caicium-mobilizing neuropeptides (30). SCLC cells grow as nonad¬
herent, free-floating aggregates in vitro-, however, the mechanisms
resulting in anchorage-independent growth of SCLC ceils are unclear.
The fact that integrins transmit intracellular signals that protect cells
from apoptosis suggests that constitutive activation of these down¬
stream second messengers may mediate anchorage independence.
Transformation of adherent cells by cytoplasmic oncogenes such as
ras or src is accompanied by the ability to grow in suspension. Cell
detachment-induced apoptosis does not occur in epithelial ceils ex¬
pressing activated src or ras (31). These oncogenes appear to provide
constitutively activated signals, mimicking those initiated by ligand-
bound integrins, thereby overcoming the induction of apoptosis initi¬
ated by ceil detachment from extracellular matrix. A recent study has
shown that the ability of ras and src to protect epithelial cells from
cell detachment-induced apoptosis is mediated through PI 3-kinase
and PKB (32). However, neither high src activity nor activating ras
mutations have been found in SCLC cells (33-35).
These preliminary findings suggest that the PI 3-kinase pathway
may be sensitive to oncogenic conversion and could be important in
the development of human cancers. The role of PI 3-kinase-mediated
signal pathways in regulating the growth, apoptosis, and anchorage
independence ofSCLC cells is unknown. Here we demonstrate that all
five SCLC cell lines tested have high basal constitutive PI 3-kinase
activity. This results in high levels of basal PKB and p70sSk activity.
Furthermore, our results suggest that PI 3-kinase activity piays an
important role in promoting the growth and anchorage independence
of SCLC ceils and may account for the highly metastatic and aggres¬
sive nature of this tumor. We believe that this is the first description
of constitutively active PI 3-kinase/PKB in a human cancer.
MATERIALS AND METHODS
Cell Culture. SCLC cell lines NCI-H345. NCI-H69. and NCI-H510 and
human alveolar type H epithelial cells (A549) were purchased from the
American Type Tissue Culture Collection (Rockville. MD). Swiss 3T3 ceils
were from the European Cell Culture Collection (Porton Down. United King¬
dom). SCLC ceil lines LS274 and DMS79 were kind gifts from Professor J.
Smyth (ICRF, Edinburgh, Scotland). BTSM ceils were established in primary
Ck culture in our laboratory. 16HBE140 ceils were originally from D. Gruenert
(University ofCaiifornia.,CA). All SCLC cell lines were grown in RPMI1640
with 25 raid HEPES supplemented with 10% (v/v) heat-inactivated FBS.
BTSM, A549, and Swiss 3T3 ceils were grown in DMEM containing 10%
(v/v) FBS. 16HBE140 cells were cultured in MEM supplemented with 10%
FBS and 1% nonessential amino acids. All media contained 50 units/ml
penicillin. 50 /xg/ml streptomycin, and 5 /xg/ml L-glutamine, and ceils were
cultured in a humidified atmosphere of 5% CO-/95% air at 37°C.
For experimental purposes, SCLC ceils 5 days after passage were trans¬
ferred into SITA medium consisting of RPMI 1640 with 25 mM HEPES
supplemented with 30 nM selenium. 5 /xg/ml insulin. 10 /xg/ml transferrin.
0.25% (w/v) BSA. 50 units/ml penicillin, 50 /xg/ml streptomycin, and 5 /xg/ml
L-glntnminn and cultured for another 2 days before use. Alternatively, cells,
were taken from growth medium, washed thoroughly with quiescent medium,
and incubated in fresh quiescent medium for 24 h before experimentation.
Quiescent medium comprised RPMI 1640 with 25 mM HEPES supplemented,
with 0125% (w/v) BSA. 50 units/mi penicillin, 50 /xg/mi streptomycin, and 5
/xg/ml u-giuramine. BTSM cells were quiesced for 48 h before use in DMEM
containing 0-5% FBS. 16HBE140 and A549 ceils, were quiesced for 24 h in
serum-free MEM and DMEM, respectively. Cell viability was confirmed by
trypan blue exclusion and was always >95%.
PI 3-Kinase Activity Assay. Adherent cells were washed three with
PBS at 37°C. transferred to ice, and lysed using ice-cold lysis buffer containing
50 mM HEPES (pH 7.4), 150 mM NaCL 1-5 mM MgCL, 1 mM EGTA. 10 mM
sodium PP„ 100 mM sodium fluoride, 10% (v/v) glycerol. 1% (v/v) Triton
X-100, 05 mM DTT, 1 mM sodium orthovanadare, 50 /xm AEBSF. 5 /xg/ml
leupeptin, 20 /xg/ml aprotinln. and 10 /xg/ml soybean trypsin inhibitor. SCLC
cells (1 X 107) that had been washed three times with PBS at 37°C were
transferred to 24-well plates in 1 ml of PBS and allowed to equilibrate at 37°C
for 1 h before the addition of varying concentrations ofwortmannln or DMSO
vehicle (final concentration, 0.1% v/v) for 20 min. Cells were then transferred
to ice. pelleted, and lysed. Lysates were clarified by centrifugarion at
13.000 X g for 10 min. For each assay point. 1 mg of total protein from the
supernatant was incubated with 25 /xg of p85-PI 3-kinase antibody for 90 min
ar 4°C. Thirty /xl of goat anti-mouse IgG agarose beads in lysis buffer were
added for an additional 2 h. The beads were then pelleted and washed
sequentially with: lysis buffer. 100 mM Tris-HCL and 500 mM LiCl (pH 7.6).
once: and twice with 200 mM HEPES, 40 mM MgCL, 600 mM Nad (pH 7.4).
PI 3-kinase assays were performed using phosphatidylinositol as substrate in a
final volume of 200 /xl containing: (final concentrations) 50 mM HEPES (pH
7.4), 10 mM MgCL, 150 mM NaCL [r3JP]ATP (10 /xCi. 3000 Ci/ramoi), 50
/xm ATP, and 05 mg/ml sonicated phosphatidylinositohphosphatidylserine
(3:1, w/w). Reactions were carried out for 20 nun at 37°C and terminated by
the addition of chloroioimtmethanohO.l m HC1 (40:80:1, v/v/v; 750 /xl), and a
phase-partition was achieved by the addition of chloroform (250 /xl) and 0.1 M
HQ (250 /xl). After centrifugation, the lower phase was washed twice with
synthetic upper phase, dried, and the lipids were separated by TLC. Phospho-
rylated lipids were identified by autoradiography and radioactivity quantified
by liquid scintillation counting. For assays involving LY294002 immunopre-
cipitates from untreaied cells were prepared as above, washed, and incubated
with varying concentrations of LY294002 for 20 min ar 37°C before PI
3-kinase activity assays as above.
p70~" Activity Assay. P70"6* activity was assayed essentially as described
by Scott et aL (36) with some minor modifications. Cells cultured in SITA
medium were washed and plated as outlined above before the addition of
varying concentrations of inhibitors at 37°C for 20 min. Ceils were soiubilized
for 30 min at 4°C in a buffer containing 50 mM Tris/HQ (pH 8.0), 120 mM
NaCl. 20 mM NaF, 5 mM EGTA, 1 mM EDTA, 10 mM sodium PP., 10 mM
p-nitrophenyl phosphate. 1 mM benzamidine, 0.1 mM phenylmethyisulfonyl
fluoride and 1% (v/v) NP40. Lysates were clarified at 13,000 X g for 10 nun
and equal quantities of protein equilibrated supernatant incubated with 2 /xg
polyclonal anti-p70l61t antibody. After 90 min. the lysates were further incu¬
bated with 25 /xl of Pansorbin. The immunoprecipitares were washed twice in
lysis buffer and twice in the same buffer without detergent. This was followed
by two washes in a buffer containing 25 mM HEPES (pH 7.4), 20 mM
/3-glycerophosphate, 20 mM MgCL, 3 mM EGTA. 0.2 mM sodium orthovana-
date. and 2 mM dithiotreitol and then incubated in the same buffer containing
100 /xm S40 substrate peptide. 10 /xm adenosine 3',5'-cyclic monophosphare-
dependent protein kinase inhibitor and [y-32P]ATP (10 /xm: 1 /xQ. 3000
Ci/mmol) in a volume of 30 /xi for 20 min at 30°C The reaction was
terminated by the addition of 10 /xi of 300 mm phosphoric acid, and the
mixture was spotted onto P81 chromatography paper. The papers were washed
twice with 05% (v/v) phosphoric acid, allowed to dry, and phosphorylation of
the S40 substrate peptide was quantified by liquid scintillation counting as an
index of enzymatic activity.
PKB Activity Assay. SCLC cells (1 X 106) cultured in quiescent medium
for 24 h before experimentation were washed three times in PBS and aiiquoted
as outlined above before the addition of varying concentrations of inhibitor for
20 min. Ceils were then lysed using 250 /xi of ice-cold buffer containing 50 mM
Tris/HQ (pH 7.5), 0.1% (v/v) Triton X-100, 1 mM EDTA. 1 mM EGTA, 0327
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sodium PPt. I mM sodium oithovanadate, 0.1% (v/v) 2-mercaptoethanoi. 1 /xM
microcystis 5 /xg/mi leupeptin, 20 /xg/ml aprotinin. and 10 /xg/rai soybean
trysin inhibitor. Lysates were clarified by centrifugarion at 13.000 X g for 10
mm, and PKB was immunoprecipicated by incubating the lysates (containing
150 /xg of protein) for 90 min at 4°C with I /xg of anti-PKBa antibody
preconjugated to 15 /xi of protein G-Sepharose in lysis buffer. Immunopre-
cipitates were washed twice with lysis buffer containing 0.5 m Nad and once
with a buffer consisting of 50 mM Tris/HG (pH 7.5), 0.03% (v/v) Brij-35, 0T
mM EGTA. and 0.1% (v/v) 2-mercaptoethanol. PKB activity was assayed by
incubating washed immunoprccipitates at 30°C for 20 min in a thermomixer in
30 /xl of kinase assay buffer (50 /am Crosstide, 50 mM Tris/HG, 0.1 mM
EGTA, 20 /am adenosine 3\5'-cyclic monophosphate-dependent protein ki¬
nase inhibitor, 20 mM MgAc, 0.2 mM ATP, 1 /am microcystis and [y-32P]ATP
(1.0 /xG, 3000 G/mmoi). The assays were terminated by placing 40 /xl of
assay mixture onto P81 chromatography paper and washing four times with
0.5% (v/v) phosphoric acid and once with acetone. Radioactive incorporation
was quantified by liquid scintillation counting.
fmmunoblotting. Cell pellets were lysed at 4°C in PI 3-kinase lysis buffer
(see above) for 30 min. Lysates were clarified by centrifugation at 13,000 X g
for 10 rain at 4°C. Twenty /xg of protein were solubilized in SDS-PAGE
sample buffer and resolved on 10% gels. The proteins were transferred to
nitrocellulose membranes, blocked using 5% (w/v) nonfatmilk in TBS-Tween
[20 mM Tris-HG (pH 7.4), 150 mM NaG, and 0.02% (v/v) Tween 20]
overnight at 4°C and then incubated sequentially with primary and secondary
antibodies diluted in blocking buffer for I h each at room temperature. Primary
antibodies (used at a 1:1000 dilution) were the same as those used in the
activity assays. The secondary antibodies were species appropriate horseradish
peroxidase-conjugated antibodies. Immunoreactive bands were identified us¬
ing ECL according to the manufacturer's instructions.
Liquid Growth Assay. Cultures of SCLC cell lines H345, H69, and H510
at 5 days after passage were grown for 2 days in SITA medium. Before
experimentation, ceils were washed twice and rcsuspended in fresh SITA
medium before being gently disaggregated by two passes through a 21-gauge
needle into an essentially single-ceil suspension as judged by light microscopy.
Viability was determined by trypan blue exclusion on a hemocytometer. Cells
(1 X 103) were seeded into 24-well plates in SITA medium and incubated for
4 h in a humidified atmosphere of 5% C02/95% air at 37°C before the addition
of inhibitors (see figure legends); cells were then further incubated under the
same conditions before being removed at various times and disaggregated into
a single-ceil suspension using a 21-gauge needle, and cell number was deter¬
mined using a Coulter Cell Counter (Coulter Electronics.^JJnited Kingdom).
Clonogenic Assay. SCLC cells, 3-5 days after passage, were washed and
resuspended in SITA medium. Cells were then disaggregated into a single-cell
suspension by two passes through a 21-gauge needle. Viability was judged by
trypan blue exclusion. Ceil number was determined with a Coulter ceil counter
and I X 104 viable ceils mixed with SITA containing 0.3% (w/v) agarose and
agonist/antagonist at the concentrations indicated (see figure legend) and
layered over a solid base of 0.5% (w/v) agarose in SITA with agonist/
antagonist at the same concentration, in 35-ram plastic High»« The cultures
were incubated in humidified 5% CO-v'95% air at 37°C for 21 daye~and then
stained with the vital stain nitroblue tetrazolium. Colonies of >120-/Am
diameter (16 ceils) were counted with a microscope.
Morphological Assessment of SCLC Cell Apoptosis. SCLC cells
(1 X 103) were seeded into 96-well plates in 200 /xl of SITA medium and
incubated in the presence or absence of 10 /am LY294002. 100 nM wortman-
nin. or appropriate diluent for 24 h. One /xl of an ethidium bromide (100
/Ag/ml):acridine orange (100 /xg/ml; 1:1 (v/v)] mixture was added to each well,
and the percentage of ceils undergoing apoptosis was assessed using fluores¬
cent microscopy as described previously (37).
Flow Cytometric Assessment of Cell Cycle Phase. Ceils (1 x 103) were
cultured in SITA medium in the presence or absence of LY294002 (10 /am).
After 24 h, ceils were washed twice in PBS and fixed in 70% ice-cold ethanol.
Cellular DNA content was determined by stainingwith 50 /xg/mi of propidium
iodide and analyzed according to forward and side scarier properties using an
EPICS Profile II (Coulter Electronics, Luton. United Kingdom). The propor¬
tion of ceils in Glt S. and G2-M phases (minimum of 3000 ceils analyzed per
condition) was calculated using standard methods.
Materials. RPMI1640, BSA agarose. IgG protein agarose, rapamycin, and
wortmannin were purchased from Sigma Chemical Co. (Poole. United King¬
dom). Monoclonal p85-SH3 antibody and the S40 peptide substrate were from
TCS (Buckingham. United Kingdom); polyclonal P70** antibody was ob¬
tained from Santa Cruz Biotechnology (Santa Cruz, CA). Adenosine 3',5'-
cyciic monophosphate-dependent protein kinase inhibitor and LY294002 were
from Caibiochem-Novabiochem Corp (Nottingham. United Kingdom).
[y-32P]ATP (3000 /xCl/mmoi) and Hybond C nitrocellulose membranes were
purchased from Amersham International (Amersham. United Kingdom), and
horseradish peroxidase-conjugated antibodies were obtained from DAKO UK.
PKBa antibody and Crosstide substrate peptide were a kind gift from Dr. D.
Alessi and Professor P. Cohen (University of Dundee, Dundee, United King¬
dom). All other reagents were of the purest grade available.
RESULTS
SCLC Ceils Display Constitutive PI3-Kinase Activity, Which Is
Inhibited by Wortmannin and LY294002. PI 3-kinase is known to
be critically involved in ceil proliferation and anchorage-independent
growth (32). We therefore tested whether the highly aggressive phe-
notype of SCLC might, in pan, result from constitutive PI 3-kinase
activity. Western blot analysis of lysates from H69, H345, H510,
LS274, and DMS79 SCLC cell lines showed expression of the p85a
subunit of PI 3-kinase (Fig. 1A). ^
Fig. 1. A PI 3-kinase expression and activity in
SCLC ceil lines. Upper panel. Western blots of
SCLC cell lysates (DMS79, LS274, H69, H345.
and H510) and Swiss 3T3 lysates were probed with
a monoclonal anu-pS5a-SH3 antibody and visual¬
ized using ECL. Lower panel, for activity assays.
PI 3-kinase was immunoprecipitated from ceil ly¬
sates using an anu-p85a-SH3 antibody. PI 3-kinase
activity was assayed (as described in "Materials
and Methods") using phosphatidylinositoi as sub¬
strate. 3-Phosphorylated lipids were resolved using
TLC, identified by autoradiography and quantified
by liquid scintillation counting. Results axe the
means of two independent experiments: bars. SD.
HBE. human bronchial epithelial cells; A549, hu¬
man alveolar type II epithelial ceils: 3T3. Swiss
3T3 fibroblasts. B. basal PI 3-kinase activity in
SCLC cells. SCLC cells grown in serum-free SITA
medium or quiescent medium (Q) were washed
three times in PBS and then equilibrated in fresh
PBS for I h. Ten % FCS indicates cells taken from
quiescent medium and stimulated with 10% FCS
for 10 min before lysis.
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Fig. 2. Effect of PI 3-kinase inhibition on PI 3-ki¬
nase activity in SCLC ceils. Concentration response of
wortmannin (left) and LY294002 (right) on PI 3-kinase
activity in H69 (upper) and H345 (lower) SCLC ceils.
Values shown are tiie means of two to three independ¬
ent experiments performed in duplicate: bars. SE. Ba¬
sal PI 3-kinase activity is taken as 100%. Representa¬
tive autoradiographs showing the 3-phosphorylated-
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To examine basal PI 3-kinase activity, SCLC cells were cultured in
serum-firee SITA medium for 48 h and then maintained for an addi¬
tional 24 h in growth factor-free quiescent medium. The cells were
then washed extensively in PBS and allowed to equilibrate in PBS for
l h to remove exogenous/autocrine growth factors. PI 3-kinase activ¬
ity from p85a immunoprecipitates was measured as described in
"Materials and Methods." The identity of the PI (3)P was confirmed
by monomethyiamine deacylarion and HPLC analysis using a SAX 5
column and (NHJjHPO,; gradient and authentic tritiated standards as
markers (data not shown). Fig. 1A shows a markedly elevated basal PI
3-kinase activity in all of the SCLC ceil lines tested (H69, H345,
H510, DMS79, and LS274) compared with human bronchial epithe¬
lial cells (16HBE140), BTSM cells, human alveolar type n epithelial
cells (A549), and Swiss 3T3 cells. Fig. 1B shows that SCLC cells
grown in either serum-free SITA medium or growth factor-free qui¬
escent medium have equally high basal PI 3-kinase activity. Thus,
under conditions where every effort was made to remove all-exoge¬
nous/autocrine growth factors, high basal PI 3-kinase activity was
seen in SCLC ceils. Furthermore, 10% FCS could induce only a
modest addidonai increase in PI 3-kinase activity (151 £ 19.4%; Fig.
IB). We therefore concluded that SCLC cells possess a consdtuuvely
active PI 3-kinase. This was further supported by data using the PI
(3,4,5)P3 mass assay (38), which showed that SCLC cells in a basal
state have elevated levels of PI (3,4,5)P3 (4.5 £ 2.1 pmot/mg) com¬
pared with a number of other ceil types including Swiss 3T3 and
1321N1 astrocytoma ceils (2.16 £ 1.0 pmol/mg).5
Wortmannin and LY294002 (at concentrations up to 100 nM and
100 pM, respectively) are specific PI 3-kinase inhibitors and have
3 J. van der Kaay, personal communication.
emerged as useful tools to elucidate the cellular function and signal
transduction pathways of PI 3-kinase (10, 11). Treatment of SCLC
cells with wortmannin for 20 min (Fig. 2, left panels) or the addition
of LY294002 directly to immunoprecipitates 20 min before assaying
for PI 3-kinase activity (Fig. 2, right panels) caused a concentration-
dependent inhibition of basal PI 3-kinase activity in three SCLC lines
examined. The IC30 of PI 3-kinase activity by wortmannin in H69 and
H345 ceils was 8.0 £ 2.1 nM and 0.27 £ 1.1 nM, respectively, and for
LY294002, 3.4 £ 1.4 and 0.85 £ 0.41 pM, respectively (mean £ SE;
n = 2-4). Similar results were also seen in H510 cells (IC.0,
11.1 £ 4.1 nM and 1.2 £ 0.4 pM for wortmannin and LY294002.
respectively).
p'O*6" Activity Is PI 3-Kinase Dependent. The molecular targets
of PI 3-kinase are being defined by studies using PI 3-kinase inhibi¬
tors. Evidence is accumulating that PI 3-kinase is a crucial mediator
of p70s6k activation (15). Fig. 3A shows a Western blot analysis of
p70,6k expression in SCLC ceil lines H69, H345, and H510. We
therefore investigated the possibility that the constitutive phosphoryl¬
ation of p70l6k described previously in SCLC cells (19) causes high
basal p70,6k activity that is driven by constitutive PI 3-kinase activity.
Immunoprecipitation of p70s6k from SCLC ceils maintained under
conditions identical to those described by Seufferlein and Rozengurt
(Ref. 19; see "Materials and Methods") showed a high level of basal
p705Ok activity. For H69 cells, basal activity was 4317 £ 346 cpm,
and in H345 cells, basal activity was 4417 £ 897 cpm (mean £ SE;
n = 3-4). Preincubation of intact SCLC ceils with the PI 3-kinase
inhibitors wortmannin (Fig. 3B, left panels) and LY294002 (Fig. 3B,
right panels) for 20 min caused a concentration-dependent inhibition
of p70,6k activity in H69 ceils (IC30, 1.3 £ 0.73 nM and 0.9 £ 0.68
pM, respectively) and H345 cells (IC30, 14.6 £ 5.5 nM and 4.2 £ 1.2
4
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Fig. 3. A. expression of the p70 isoform of nbosomai s6
kinase in SCLC cell lines H69. H345. and H510 and Swiss 3T3.
Cell lysaies were Western blotted and probed using a rabbit
polyclonal anri-p70"6lt antibody. Immunoreactive bands were
visualized by SCL. B. plOT6* activity in SCLC Well-washed
H69 (upper) and H345 (lower) SCLC cells were equilibrated in
fresh PBS for 1 h and treated with wortmannin (left) or
LY294002 (right), at concentrations indicated, for 20 min be¬
fore lysis. P70** was immunopredpitaied from ceil lysaies.
and activity was assayed in an in vitro kinase reaction using S40
peptide as substrate (as described in "Materials and Methods").
Values shown are the means of three to four independent
experiments performed in duplicate: bars. SE. Basal p70*6k
activity is expressed as 100%. For H69 experiments, basal
activity was 4317 — 346 cpm. and nonspecific background
acavity was 698 ± 158 cpm: in H345 experiments, basal
activity was 4417 897 cpm. and background activity was
392 s 90 cpm.
B
H69 H346 H510 3T3
ai 1 10 100 1000 o
Wartmannln (nM)
0.01 0.1 1 10
LY294002 (pM)
jam, respectiveiy; mean ± SEM: n = 3-4). Similar results were seen
in H510 cells with wortmannin and LY294002 (IC50, 4.1 nM and 1.0
jiM, respectively). These results are similar to the IC50s obtained for
wortmannin and LY294002 inhibition of PI 3-kinase. The maximal
inhibition of p70s6k activity achieved using either 100 nM wortmannin
or 10 jiM LY294002 was 75%. The addition of rapamycin, a highly
potent inhibitor of p70s6k, to intact SCLC ceils for 20 min caused a
100% inhibition of p70s6k activity (data not shown). The addition of
either 100 nM wortmannin or 10 jam LY294002 to the in vitro kinase
reaction had no effect on the kinase activity of p70s6k immunopre-
cipitates (data not shown). Thus, wortmannin and LY294002 do not
affect p70sdk activity directly but regulate p70,61c activity via wort-
mannin/LY294002 sensitive PI 3-kinase activity.
Constitutive PKB Activity in SCLC Cells Is PI 3-Kinase De¬
pendent. In integrin and growth factor signal transduction, PKB has
been identified as a key downstream effector of PI 3-kinase (21).
Western blot analysis of SCLC cell lines H510, H69, and H345
revealed expression of the at isoform of PKB (Fig. 44). Hence, we
examined basal PKB activity in SCLC cells. SCLC ceils that had been
maintained in growth factor-free quiescent medium for 24 h before
experimentation were thoroughly washed, and PKB activity was de¬
termined using an in vitro kinase assay as described in "Materials and
Methods." Fig. 4B shows that under basal conditions. SCLC H69 cells
display constitutive PKB activity that could be completely inhibited
by 100 nM wortrnannin. The p70s6k inhibitor rapamycin had no effect
on PKB activity (Fig. 4fl). Similar results were seen in H345 and
H510 ceils (results not shown). Under identical conditions, very low
levels of basal PKB activity was seen in Swiss 3T3 cells despite a
similar level of expression of PKBa as judged by Western blot
analysis (Fig. 4, A and 3). The addition of LY294002 (Fig. 4C, left)
or wortmannin (Fig. 4C, right) to H69 cells for 20 min caused a
concentration-dependent inhibition of basal PKB activity. The IC50
for LY294002 and wortmannin was 2.7 i 0.1 jam and 2.0 ± 0.6 nM.
respectiveiy (mean ri SE; n = 3). These values correlate well with
those seen for PI 3-kinase inhibition. When added directly to PKB
immunoprecipitates. wortmannin and LY294002 had no effect on
PKB activity. These results suggest that the elevated basal PKB
activity in SCLC cells is a direct downstream consequence of consti¬
tutive PI 3-kinase activity in these cells.
SCLC Cell Growth in Liquid Culture Is PI 3-Kinase Depend¬
ent. We went on to examine the biological consequences of blocking
constitutive PI 3-kinase signaling. SCLC ceils were grown in SITA in
the presence of increasing concentrations of LY294002. and the ceil
number was counted at day 9. LY294002 caused a marked concen¬
tration-dependent reduction in SCLC cell number in liquid culture
(IC50s, 10.0 ± 0.8, 2.9 * 0.2. and 13.3 r 0.8 jam for H69, H345. and
H510 cells, respectively; mean ± SE; n — 3-5; Fig. 5). These results
are in good agreement with data obtained for inhibition of PI 3-kinase,
PKB, and p70s6k activity by LY294002. Thus, constitutive PI 3-kinase
activity appears to play an important role in the proliferation of this
aggressive cancer.
To determine the relative contribution of the p70s6k patirway to PI
3-kinase-mediated growth in SCLC, .SCLC cells were grown in the
presence of the specific inhibitors LY294002 and rapamycin both
alone and in combination, as described in "Materials and Methods."
Kg. 6 shows that the addition of a maximally effective concentration
of LY294002 (100 jam) was able to inhibit H69 and H345 SCLC
growth by 92% over a 9-day period, whereas a maximally effective
concentration of rapamycin (20 nM; Ref. 19) caused a 6.5 and 33%
reduction in growth over the same time period in H69 and H345 cells.
f*.
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Fig. 4. A. PKBa expression in SCLC ceil lines
H69. H345. H510. and Swiss 3T3. Western bioa of
ceil lysates were probed with an ann-PKBa anti¬
body and visualized by ECL. 3. PKB activity in
SCLC ceils. SCLC ceils grown in quiescent me¬
dium were well washed and then equilibrated in
fresh PBS for 1 h. PKB was immunoprecipitated
from cell lysates. and activity was assayed in an in
vitro kinase reaction using Crossnde as substrate
(as described in "Materials and Methods")- Basal
PKB activity was measured in H69 SCLC ceils
preincubated with diluent (0), 100 nw wortmannin
(WM), or 20 nM rapamycin (Rap). Basal 3T3 shows
PKB activity in Swiss 3T3 ceils under identical
conditions as described above. Results expressed
as percentage of PKB activity above nonspecific
background are the means of two independent ex¬
periments in duplicate: bars. SD. C concentration-
dependent inhibition of basal PKB activity by PI
3-kinase inhibitors in SCLC ceils. SCLC ceils were
treated with LY294002 (left) orwortmannin (right)
for 20 min before lysis. Each point represents the
mean of three independent experiments performed
in duplicate: bars. SE. Basal PKB activity is ex¬
pressed as 100% (1824 d: 241 cpm: nonspecific
background. 596 — 87 cpm).
(X01 0.1 1 10
LY294Q02 (jiM)
(LQ1 (XOI CL1 1 10
Wortmannln (nM)
100
respectively. Incubation of H69 and H345 cells with a combination of
10 /am LY294002 (a value close to the IC50) and 20 nm rapamycin (a
maximally effective concentration) caused an —61-68% inhibition of
SCLC cell growth over 9 days (Fig. 6). Similar results were seen in
H510 cells. These results suggest that PI 3-kinase exerts its growth
effects by both p70"6k-dependent and independent pathways in SCLC.
However, it appears that the majority of the PI 3-kinase effect is
mediated .via a p70"'k-independent patiiway, potentially signaling
through PKB.
SCLC Cell Survival Is PI 3-Kinase Dependent. Activation of PI
3-kinase and PKB activity has been implicated in the protection of
cells from apoptosis. The effect ofPI 3-kinase inhibitors on the rate of
SCLC cell apoptosis was determined using acridine orange/ethidium
bromide staining under fluorescent microscopy. The background level
of SCLC ceil apoptosis in these experiments was 8%. H345 cells
treated with 10 /am LY294002 or 100 nM wortmannin for 24 h showed
a 41 ± 12 and 31 - 13% increase in the percentage of ceils
undergoing, apoptosis, respectively. The figures for H69 cells were
82 i 30% and 95 i 22%, respectively (mean - SE; n = 3; Fig. 7A).
These data were corroborated using an immunoassay that detected
cytoplasmic histone-associated DNA fragments (data not shown).
During this time course, trypan blue positivity remained consistently
<5%. Thus, although inhibition of PI 3-kinase activity in SCLC cells
caused a marked inhibition of cell growth in liquid culture, this did not
occur as a result of increased cell necrosis but was due, in part, to an
increase in apoptosis. Because the proapoptotic effect due to PI
3-kinase inhibition was relatively modest, we examined the effect of
PI 3-kinase inhibitors on cell cycle kinetics. Fig. IB shows that 10 /am
LY294002 causes a cell cycle delay in Gt and a decrease in the
number of ceils entering mitosis. Therefore, the growth-inhibitory
effects induced by LY294002 are due to a combination of an increase
in apoptosis and a delay in the cell cycle.
LY294002 Inhibits SCLC Cell Tumorigenicity and Neuropep-
tide-stimulated Colony Growth. The ability to form colonies in
agarose semisolid medium is a marker of anchorage-independent
growth that is characteristic of the transformed phenotype. There is a
positive correlation between the cloning efficiency of ceils and the
histological involvement and invasiveness of the tumor in specimens
taken from SCLC (39). We therefore examined the effect of 10 /am
LY294002 on SCLC colony formation in agarose semisolid medium.
LY294002 (pM)
Fig. 5. Concennanon-dependent effect of LY294002on H69, H345. orH510 SCLC growth. SCLC cells (1 X 1031 were washed and incubated in fresh SITA medium in the presence
of increasingconcentranons of LY294002 as shown. Ceil number was determined on day 9. and results were expressed as a percentage of ceil growth in the presence of dilucnl alone.
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CONSTTIUTTVE PI 3-KINASE ACTIVrrY IH SCLC CELLS
J
Fig. 6. Effect of LY294002 and rapamyan on
H69 (left) and H345 (right) SCLC ceil growth.
Ceils (1 X 10*) were washed and incubated in fresh
SITA medium in the presence of LY294002 (LY)
and rapamyan (Rap) alone or in combination, at
the concentrations indicated On day 9, ceil number
was measured. Results expressed as percentage in¬
hibition of growth compared with control cell
growth are means of three to five independent
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Fig. 8 shows that 10 [jlM LY294002 inhibited basal colony formation
of ail three SCLC cell lines by up to 80%. Our previous work has
suggested that SCLC ceil growth is sustained by multiple autocrine
and paracrine growth loops involving calcium mobilizing peptides. As
shown previously, the neuropeptides vasopressin (50 nM), gastrin (100
nM), and bombesin (50 run) caused a marked stimulation of colony
formation in H69, H510, and H345 ceils, respectively (30). However,
the addition of vasopressin, gastrin, or bombesin failed to rescue the
LY294002-induced inhibition of colony formation in these cell lines
(Fig. 8). Thus, PI 3-kinase appears to play a critical role in sustaining
the anchorage-independent growth of SCLC.
DISCUSSION
SCLC has the highest metastatic potential of any of the solid tumors
with >90% of patients having widespread metastases at presentation.
A characteristic feature of cancer cells is their ability to grow in the
absence of ceil adhesion to extracellular matrix. The development of
secondary metastatic deposits at sites remote from the primary tumor
is one of the main causes of death in patients with cancer. Therefore,
the ability of tumor ceils to survive and proliferate in inappropriate
environments is central to cancer-related death. Thus, anchorage-
independent growth is pivotal to the highly proliferative and meta¬
static nature of this cancer.
The novel findings of this study are that in all five SCLC cell lines
examined, constitutive PI 3-kinase activity was found that results in
high levels of basal PKB and p70s6lc activity. Inhibition of PI 3-kinase
activity blocks SCLC ceil growth in liquid culture and colony forma¬
tion in semisolid medium. We show that this occurs due to a combi¬
nation of a stimulation of apoptosis and a delay in the ceil cycle in G;
with a consequent decrease in the number of ceils entering mitosis.
Our results also show that SCLC growth and survival is mediated both
by p70"'k;-dependent and -independent pathways, the latter potentially
acting through PKB. Thus, downstream pathways) driven by a con-
stitutiveiy active PI 3-kinase appear to play an important role in
promoting the growth and anchorage independence of SCLC. Re¬
cently, PI 3-kinase activation has been implicated in anchorage-
independent growth, metastasis, and ceil invasion (13, 14). To our
knowledge, this is the first description of constitutiveiy activated PI
3-kinase/PKB in any human cancer. Constitutive activation of these
integrin-dependent signaling events may provide a molecular expla¬
nation for anchorage-independent growth and account for the highly
metastatic nature of SCLC. We propose that anchorage independence
mediated by constitutive PI 3-kinase activity, in concert with serum
independence mediated by multiple autocrine/paracrine-growth loops
driven by calcium-mobilizing neuropeptides, is responsible for the
very aggressive nature of SCLC
The origin of this constitutive PI 3-kinase activity in SCLC ceils is
unclear. Before analysis ofPI 3-kinase activity, every effort was made
to remove exogenous growth factors by extensive ceil washing.
Hence, we feel that it is unlikely that exogenous growth factor
stimulation is mediating this high PI 3-kinase activity, and further¬
more, under identical conditions PI 3-kinase activity is low in control
cells. PI 3-kinase can be activated by intracellular second messengers
such as ras. FAK. and src. which are also able to promote anchorage-
independent growth (24, 32, 40, 41). However, several studies have
failed to show any evidence of activating ras mutations in SCLC (33,
34). In addition, we have shown previously that under the basal
conditions described above, FAK phosphorylation is low (2). Further-
100 -
LY WM i_Y WM
Fig. 7. A. effect of the PI-3 kinase inhibitors LY294002 and
wortmannin on H69 (left) and H345 (right) SCLC cell apop¬
tosis. Cells (1 X 10*) were washed and ipenbated in fresh SITA
for 24 h in the presence of either diluent or 10 pM LY294002
(LY) or 100 nM wonmanmn (WM). Apoptobc ceils were iden¬
tified using acridine orange/ethidium bromide under fluores¬
cence microscopy. The results that are expressed as a percent¬
age of stimulation of apoptosis over control cells axe the mrans
of six independent experiments performed in triplicate; bars.
SE. 3. effect of LY294002 on SCLC ceil cycle. H69 ceils that
had for 24 h in the prr^eivy* or absence of 10 /am
LY294002 (LY) were washed in PBS and fixed with 70%
ice-cold ethanoL fibular DNA was determined by
training with propidium iodide, and cell cycle phase was ana¬
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Fig. 8. Effect ofLY294002 on SCLC clonal growth in semisolid medium. H69. H345.
and H510 SCLC ceils, 3-5 days after passage, were washed, and 1 X 10* viable cells/ml
were plated in SITA medium containing 0.3% agarose on top of a base of 0.5% agarose
in culture medium as described in "Materials and Methods." Both layers contained either
no neuropeptide additions (■) or 50 dm vasopressin (VP), 50 nw bombesin (Bom), or 100
nw gastrin (G; 3) in the presence (+) or absence (—) of 10 (jja LY294002 (LY). After 21
days, colonies of >120 hm (16 cells) were counted. Results are expressed as colonies/
dish, means of triplicates of two independent experiments; bars. SD.
more, pp60 sre activity is low in SCLC cells (35). This suggests the
possibility of a novel mechanism of PI 3-kinase activation or a
mutationaily activated PI 3-kinase in SCLC cells.
The molecular targets of PI 3-kinase are being defined by studies
using PI 3-kinase inhibitors. In this study, we used the PI 3-kinase
inhibitors woranannin and LY294002 To ensure the specificity of
effects seen with pharmacological agents, it is important that inhibi¬
tors with differing mechanisms of action produce similar effects
within the concentration range described for other cell systems. Wort-
mannin (IC30, 3 nM) is noncompeddve with respect to ATP, binding
irreversibly to the pUO catalytic subunit of PI 3-kinase (10), whereas
LY294002 (IC30, 1.4 fiM) behaves as a competitive inhibitor for the
ATP binding site of PI 3-kinase (11).
PKB and p70Ifik have been identified as downstream effectors of PI
3-kinase (15, 21). Our results may underlie the constitutive basal
phosphorylation of p70*6k noted previously in SCLC ceil lines H510,
H69, and H345 (19). This constitutive basal phosphorylation is re¬
flected in the high basal activity of p7056k. Wortmannin and
LY294002 inhibit p70i6k activity by 70-80% with IC30s similar to
those seen for both PI 3-kinase and p70sok inhibition. Thus, the
constitutive phosphorylation and kinase activity of p70s6k is, in part,
driven by constitutive PI 3-kinase activity. However, even when high
concentrations ofwortmannin (100 nw) and LY294002 (100 jtM) were
used, residual p70sok activity was noted. This may be due to activation
of p70,6k by other pathways, e.g., the PKC pathway as described in
other ceil systems (17). This may also explain why H345 cell p70"k
was more resistant to the effects of PI 3-kinase inhibitors than-in H69
ceils with an IC30 shifted to the right and higher residual p70s6k
activity, despite maximal PI 3-kinase inhibition. Constitutive activa¬
tion of the e isoform of PKC has been described in a SCLC cell line
(42).
PKB ove:expression in human ovarian, breast, and pancreatic can¬
cers has been shown to be associated with a poor prognosis and
increased tumorigenicity (22, 23). However, these studies did not
examine PKB activity. All three.SCLC lines that we examined ex¬
pressed the a isoform of PKB and had elevated basal PKB activity
that could be completely inhibited by wortmannin and LY294002 In
a concentranon-depencient manner similar to PI. 3-kinase. Therefore,
the high basal PKB activity in SCLC cells occurs as a consequence of
constitutive PI 3-icinase activity. The doublet band for PKBa was only
activity m sclc cells
seen in H510 cells and was a constant finding (n = 3). The reason is
obscure- but may be due to a posttranslationai modification or an
alternatively spliced form of the protein. '
To examine the functional importance of this up-regulated pathway;
we used the PI 3-kinase inhibitor LY294002. The addition of
LY294002 to SCLC ceils in liquid culture resulted in a marked
concentration-dependent reduction in cell numbers. The IC30s are
very similar to the ICjqS for inhibition ofPI 3-kinase, PKB, and p70"lk
activity by LY294O02. PI 3-kinase inhibition can almost totally block
SCLC cell proliferation. Thus, constitutive PI 3-kinase-dependent
signaling is playing a critical role in SCLC growth.
The addition of PI 3-kinase inhibitors, wortmannin, and LY294O02
to SCLC cells showed a modest but consistent increase in the per¬
centage of cells undergoing apoptosis. In addition, PI 3-kinase inhi¬
bition causes a cell cycle delay, and the combination of cell cycle
delay and stimulation of apoptosis appear to be responsible for the
growth inhibition seen. Studies using trypan blue and acridine orange
excluded a toxic effect being responsible. PI 3-kinase inhibition may
arrest growth by preventing normal growth factor signaling. Recent
evidence suggests that growth factors do not induce DNA synthesis in
3T3 cells in the absence of integrin activation (43). This appears to
result from the inability of growth factors to activate the MAP kinase
pathway in the absence of integrin-mediated second messenger sig¬
nals. We propose that constitutive activation of PI 3-kinase in SCLC
cells may mimic integrin-dependent signal transduction and facilitate
growth factor-mediated activation of the MAP kinase pathway. When
this second messenger pathway is blocked, growth factors can no
longer activate MAP kinase, leading to SCLC cell growth arrest.
PI 3-kinase acting through PKB has been shown to promote an-'
chorage-independent growth (32). This may be central to the survival
and growth of tumor cells in inappropriate environments. The ability
of cells to grow in soft agar is a feature of anchorage independence
and pathognomonic of the transformed phenotype, correlating with
tumorigenicity and invasiveness of the tumor (39). SCLC basai colony
growth can be stimulated by neuropeptide growth factors (30, 44).
These observations, along with the finding that SCLC ceils produce a
variety of neuropeptides and hormones (45), gave rise to the auto¬
crine/paracrine theory of SCLC growth. LY294002 markedly inhib¬
ited basal colony formation of SCLC cells in agarose semisolid
medium. This block could not be overcome by the addition of vaso¬
pressin, gastrin, or bombesin in H69, H510, and H345 cells, respec¬
tively. This shows that PI 3-kinase activity is crucial for anchorage-
independent growth in SCLC ceils. Furthermore, these results suggest
that PI 3-kinase activity is required for neuropeptide autogenic sig¬
naling. In SCLC cells, neuropeptides have been.shown to activate
MAP kinase through G-protein-coupied receptors (46). PI 3-kinase
activity may be necessary for neuropeptide activation ofMAP kinase
in SCLC. It remains to be established whether MAP kinase activation
can be potentiated by growth factor/integrin-dependent PI 3-kinase
activation and whether this underlies our observations of the effects of
PI 3-kinase inhibition on SCLC growth.
Although both PKB and p70lok are known to be physiological
targets of PI 3-kinase. it is unclear whether these enzymes lie on the
same signaling pathway or on parallel pathways. Observations that
constitutively activated forms of PKB led to the activation of p70s6k
implied that PKB may mediate mitogenic signaling through p70"°k
activation (47). Recently, PDK1, the enzyme that phosphorylates
Thr308 of PKB, has been shown to. directly phosphorylate and acti¬
vate p70"'k, resulting in a PI 3-kinase-dependent mechanism of acti¬
vation that may circumvent PKB in the proliferative pathway (48).
Differential activation of PKB and P7056" can be achieved under
distinct cellular calcium levels; this may be important for integrating
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latter findings. PI 3-kinase regulation of SCLCceil growth is medi¬
ated both by pTO^-dependeni and -independent pathways. It appears
that pTO1®" activation makes approximately a 20-30% contribution to
the PI 3-kinase effect, with a 70-8095 contribution from another
pathway, potentially signaling through PKB. H69 cells were noted to
be less sensitive to rapamycin than H345 cells, and this may be due to
different cell line growth rates. Similar effects were seen by Seuffer-
lein and Rozengurt (19). Because the principle mechanism of action of
rapamycin is G, cell cycle delay rather than apoptosis or necrosis, we
propose that the faster growth rate and cell cycling of H69 cells
diminishes the growth-inhibitory effect of rapamycin at longer time
points compared with H345 cells. This is supported by'the observation
that at shorter time points the effect of rapamycin on H69 and H345
cell growth is similar (38 ± 1.395 versus 29 ri 2.795 growth inhibi¬
tion, respectively).
We have shown that constitutive PI 3-kinase activity in SCLC
regulates proliferation, anchorage-independent growth; and apoptosis.
Recent studies have suggested that PI 3-kinase activation induces
integrin-mediated cell motility and invasiveness (13, 14). In addition.
PI 3-kinase/PKB activation can promote adhesion-independent
growth, protecting cells in suspension from undergoing apoptosis
(32). The pathways driven by constitutive PI 3-kinase in SCLC cells
may therefore be responsible for the Highly metastatic and nonadher¬
ent phenotype of SCLC cells. We predict that constitutive PI 3-kinase
activation may be a late event in the development of SCLC, allowing
transformed cells to become locally invasive and metastatic. Given the
likely importance of growth and survival in suspension for mainte¬
nance of the transformed phenotype, and particularly for metastatic
spread of cancer cells within the body, an understanding of the
mechanisms that result in constitutive activation of PI 3-kinase and of
its downstream effectors could be of benefit in designing novel
therapies for SCLC.
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ABSTRACT
Proliferation of airway smooth muscle results from persistent
inflammatory cytokine and growth factor stimulation and is a
critical component of airway luminal narrowing in chronic
asthma. Using primary cultures of bovine tracheal smooth mus¬
cle (BTSM) cells to examine the signaling basis of cell prolifer¬
ation, platelet-derived growth factor (PDGF)-BB and thrombin
(which act through distinct receptor types) were found to in¬
duce DNA synthesis in BTSM cells. Mitogen-induced DNA syn¬
thesis could be completely inhibited by LY294002, a selective
phosphoinositide 3-kinase (Ptdlns 3-kinase) inhibitor. Exposure
of BTSM cells to PDGF-BB or thrombin resulted in rapid acti¬
vation of Ptdlns 3-kinase and accumulation of phosphoinosi-
tide-3,4,5-trisphosphate. Protein kinase B, a novel signaling
protein kinase, was identified in BTSM cells and was activated
by PDGF-BB and thrombin in a Ptdlns 3-kinase-dependent
manner; this may underlie mitogen-stimulated activation of
p70s6k. PD98059, a mitogen-activated protein kinase kinase 1
inhibitor, also partially inhibited PDGF-BB- and thrombin-stim-
ulated DNA synthesis, indicating a modulatory role for mitogen-
activated protein kinase in proliferation. GF109203X, Ro 31-
8220, calphostin C, and chelerythrine (selective protein kinase
C inhibitors) had no effect on PDGF-BB- or thrombin-stimu-
lated DNA synthesis, suggesting that, despite abolishment of
mitogen-stimulated protein kinase C activity, cell proliferation
stimulated by PDGF-BB and thrombin is protein kinase C-
independent. These data demonstrate that the Ptdlns 3-kinase/
protein kinase B pathway represents a key signaling route in
airway smooth muscle proliferation, with the mitogen-activated
protein kinase kinase 1 /mitogen-activated protein kinase cas¬
cade providing a complementary signal required for the full
mitogenic response.
Hypertrophy and hyperplasia of airway smooth muscle are
major components of the structural changes that result in
airway luminal narrowing in chronic asthma. This response
is thought to occur as a consequence of inflammation and the
subsequent release of cytokines and mitogens. Because air¬
way resistance relates to the fourth power of the luminal
radius, minor increases in the cell size and the number of
airway smooth muscle cells in the bronchial walls of asth¬
matic patients have pronounced effects on airway resistance.
In addition, mathematical modeling has demonstrated that
This work was supported by the National Asthma Campaign (UK). E.R.C. is
a Wellcome Senior Research Fellow in Clinical Science.
an increase in smooth muscle mass is the most important
component in reducing airflow in patients with chronic
asthma (James et al., 1989). Although a number of candidate
pathways have been proposed, the signaling events that me¬
diate airway smooth muscle proliferation have not been fully
elucidated. Activation of the serine/threonine protein kinase
p70 ribosomal S6 kinase family (p70sSk) has been shown to be
involved in protein and DNA synthesis in these cells (Scott et
al., 1996) and may explain in part the mitogenic effects of
certain growth factors. In addition, growth factor-induced
activation of Ptdlns 3-kinase, which results in phosphoryla¬
tion of phosphoinositide-4,5-bisphosphate to PtdIns(3,4,5)P3,
has been proposed to play an important role in DNA synthe-
ABBREVIATIONS: Ptdlns 3-kinase, phosphoinositide 3-kinase; BTSM, bovine tracheal smooth muscle; HEPES, A/-(2-hydroxyethyl)piperazine-
A/'-(2-ethanesulfonic acid); EGTA, ethylene glycol-bis(/3-aminoethyl ether)-A/,A/,A/',A/'-tetraacetic acid; MAP kinase, mitogen-activated protein
kinase; MEK1 or -2, mitogen-activated protein kinase kinase 1 or 2; PDK-1, 3-phosphoinositide-dependent protein kinase-1; Ptdlns(3,4,5)P3,
phosphoinositide-3,4,5-trisphosphate; ERK, extracellular signal-regulated kinase; PCR, polymerase chain reaction; DMEM, Dulbecco's modified
Eagle medium; PDGF, platelet-derived growth factor; EGF, epidermal growth factor.
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sis. Furthermore, because wortmannin, a Ptdlns 3-kinase
inhibitor, inhibits p70s6k activation by growth factors, Ptdlns
3-kinase has been proposed to lie upstream of p70s6k in the
proliferative pathway (Scott et ol., 1996).
More recently, protein kinase B has been identified as a
novel signaling protein kinase that is activated in response to
insulin and growth factors (Marte and Downward, 1997).
Overexpression of a constitutively active form of protein ki¬
nase B was found to activate p70s6k, and this response was
sensitive to inhibition by rapamycin (Burgering and Coffer,
1995). Because protein kinase B activity can be inhibited by
wortmannin, this again suggests that protein kinase B oper¬
ates upstream of p70s6k and downstream of Ptdlns 3-kinase.
Another pathway shown to be associated with growth in a
variety of cell types is the MAP kinase cascade; activation of
this pathway through Ras/Raf-1 stimulates phosphorylation
of substrates such as p90s6k and c-jun and initiates protein
synthesis (Malarkey et al., 1995b). The MAP kinases, also
termed ERKs, are 42- and 44-kDa serine/threonine kinases
that are activated after phosphorylation by the dual-specific-
ity protein kinase MEK1 (MAP or ERK kinase). Activation of
MEK1, and a second isoform termed MEK2, occurs after
phosphorylation on Ser218 and Ser222 by Raf-1 (Zheng and
Guan, 1994).
A role for protein kinase C in airway smooth muscle pro¬
liferation has also been proposed, on the basis that selective
inhibitors of this enzyme family could attenuate mitogen-
induced proliferation of rabbit tracheal smooth muscle cells
(Hirst et al., 1995). Recently, a number of protein kinase C
isoforms, namely protein kinase C S, e, 17, and f, have been
demonstrated to be activated by 3-phosphorylated phosphoi-
nositides generated by the action ofPtdlns 3-kinase (Nakan-
ishi et al., 1993; Toker et al., 1994). A study in canine airway
smooth muscle has identified the presence of protein kinase
C 01, 011, 5, e, 6, and £ isoforms (Donnelly et al., 1995). Most
protein kinase C inhibitors do not, however, show substantial
selectivity among protein kinase C isoforms; therefore, the
possibility that these novel isoforms represent downstream
targets of Ptdlns 3-kinase remains to be addressed.
In this study, we have investigated the role of Ptdlns
3-kinase in mitogen-induced BTSM cell proliferation and
demonstrated that PDGF-BB and thrombin activate Ptdlns
3-kinase, stimulate PtdIns(3,4,5)P3 accumulation, and acti¬
vate protein kinase B. We have also shown that the degree of
activation of Ptdlns 3-kinase achieved by PDGF-BB and
thrombin correlates closely with their mitogenic efficacy and
that 10-min exposure to these stimuli is sufficient to commit
cells to DNA synthesis. Finally, inhibitors of Ptdlns 3-kinase,
in contrast to inhibitors of protein kinase C or MEK1, cause
complete inhibition of proliferation. These data suggest that
agonist-stimulated activation of the Ptdlns 3-kinase/
PtdIns(3,4,5)P3/protein kinase B pathway represents a key
route for initiating cell division in airway smooth muscle
cells.
Materials and Methods
Cell culture. Bovine trachealis was obtained from the local ab¬
attoir. Small strips of trachealis muscle, dissected free of epithelium
and connective tissue, were washed in DMEM containing penicillin/
streptomycin (5 units/ml and 5 pg/ml, respectively) and amphoteri¬
cin B (2.5 pg/ml) and were incubated in this medium with collage-
nase type IV (1 mg/ml) for 1 hr at 37°, with intermittent shaking.
After addition of fetal calf serum, the muscle digest was filtered
through gauze, and isolated tracheal smooth muscle cells were col¬
lected by centrifugation at 250 x g for 4 min. Cells were plated and
cultured in supplemented DMEM containing fetal calf serum (10%,
v/v). Cells from passages 3-9 were used for all experiments. Cells
were made quiescent in DMEM containing fetal calf serum (0.5%,
v/v) for 48 hr before experiments. The identity of the tracheal smooth
muscle cells was confirmed by immunocytochemistry using a smooth
muscle-specific, anti-a-actin, mouse monoclonal antibody (data not
shown).
PCR amplification of PDGF-a and -fi receptor mENA. Total
RNA was isolated by lysis of adherent cells with Trizol reagent and
extraction, according to the instructions provided by the manufacturer
(Life Technologies, Paisley, UK). A total of 2 pg of RNA was reverse-
transcribed in 50 mu Tris-HCl, pH 8.3, 75 mM KC1, 3 mM MgCl2,10 mM
dithiothreitol, 10 units of RNase inhibitor, 0.1 mM deoxynucleotide
mixture, 50 pg/ml oligo(dT)11_18, with 200 units of murine leukemia
virus reverse transcriptase, at 35° for 60 min. After first-strand cDNA
synthesis, PCR amplifications were carried out in 25-pl volumes con¬
taining 10 mM Tris-HCl, pH 8.3, 50 mM KC1, 2.5 mM MgCl2, 1 pM
primers, 200 pM deoxynucleotide mixture, and 1 unit of Thermus
aquaticus DNA polymerase and were performed as follows: 94° for 30
sec, 55° for 60 sec, and 72° for 30 sec for 35 cycles and then 72° for 5 min.
The PDGF-a primers were 5'-AATAAGATCAAGAGTGGGTACAGG-3'
and 5 '-TATGCCGATGTCGTCCATCATGTC-3', PDGF-0 primers were
5 '-TGACCACCCAGCCATCCTTTC-3' and 5'-GAGGAGGTGTTGACT-
TCATTC-3', and glyceraldehyde-3-phosphate dehydrogenase primers
were 5'-CCACCCATGGCAAATTCCATGGCA-3' and 5'-TCTAGACG-
GCAGGTCAGGTCCACC-3'. The amplified products were subjected to
electrophoresis on 1.5% agarose gels in 45 mM Tris-borate, 1 mM EDTA,
were identified with a UV transilluminator after staining with
ethidium bromide (0.5 pg/ml), and were photographed using a Polaroid
DS-5 system.
[3H]Thymidine incorporation. Confluent and quiescent cells
were washed twice in serum-free DMEM, inhibitors and mitogens
were added as indicated, and cells were incubated for an additional
24 hr. [3H]Thymidine (0.1 pCi/ml) was added for the final 4 hr of the
incubation. Cells were washed twice with phosphate-buffered saline,
twice with trichloroacetic acid (5%, w/v), and twice with ethanol and
were finally solubilized with NaOH (0.3 M). [3H]Thymidine incorpo¬
ration was determined by liquid scintillation counting.
Cell stimulation, immunoprecipitation, and Ptdlns 3-ki-
nase activity assay. Cells were incubated in serum-free DMEM
before the addition of inhibitors and agonists, as detailed in the
figure legends. Reactions were terminated by rapid aspiration of the
medium, followed by two washes with phosphate-buffered saline and
the addition of ice-cold lysis buffer (50 mM HEPES, pH 7.5, 150 mM
NaCl, 10%, v/v, glycerol, 1%, v/v, Triton X-100, 1.5 mM MgCl2, 1 mM
EGTA, 10 pg/ml leupeptin, 10 pg/ml aprotinin, 1 mM phenylmethyl-
sulfonyl fluoride, 200 pM Na3V04, 10 mM sodium pyrophosphate, 100
mM NaF). Insoluble material was removed from cell lysates by cen¬
trifugation, and Ptdlns 3-kinase was immunoprecipitated using an-
ti-p85 or anti-phosphotyrosine antibody complexed to Pansorbin
(Calbiochem, Nottingham, UK) (Scott et al., 1996). Ptdlns 3-kinase
activity in immunoprecipitates was assayed as previously described
(Carter and Downes, 1993). Immunoprecipitates were suspended in
50 pi of assay buffer (100 mM HEPES, pH 7.4, 200 mM NaCl, 1 mM
EGTA) and mixed with 20 pi of sonicated phosphatidylinositol and
phosphatidylserine (3:1, 0.2 mg/ml). Reactions were initiated by the
addition of [-y-32P]ATP (10 p.Ci) and were incubated for 30 min at 30°.
Reactions were terminated by the addition of 750 pi of chloroform/
methanol/HCl (40:80:1, v/v/v) and phase partitioning achieved with
the subsequent addition of 250 pi of chloroform and 250 pi of HC1
(0.1 M). Phospholipids were washed with chloroform/methanol/HCl
(47:48:3, v/v/v). 32P-labeled phosphoinositide 3-phosphate was then
quantified by thin layer chromatography using a solvent system
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containing chloroform/methanol/ammonia/water (20:15:3:5, v/v/v/v);
32P incorporation was determined by liquid scintillation counting.
PtdIns(3,4,5)P3 accumulation. Cells grown to confluence in
100-mm cell culture dishes were made quiescent, washed twice with
phosphate-free HEPES-buffered saline (20 mM HEPES, pH 7.4, 140
mM NaCl, 2.5 mM MgS04, 1 mM CaCl2, 5 mM KC1), and labeled in the
same buffer containing 2 mCi/ml [32P]orthophosphate, for 3 hr at
37°. Cells were then washed twice with HEPES-buffered saline be¬
fore addition of agonists, as detailed in the figure legends. Reactions
were terminated by the addition of trichloroacetic acid (0.5 M), and
lipids were extracted with chloroform/methanol/0.1 M HC1 (4:8:3,
v/v/v) in the presence of Folch fraction I phosphoinositides (0.5 mg/
extraction). Dried lipids were deacylated with monomethylamine at
53° for 30 min, with intermittent shaking, and the resulting deacy¬
lated lipids were analyzed by strong anion exchange high perfor¬
mance liquid chromatography using a two-step (NH4)H2P04 (0.5
M)/water gradient, essentially as described by Carter and Downes
(1993). Deacylated lipids were identified by comparison of retention
times with those of 3H-labeled phosphoinositide standards and rel¬
evant nucleotides; 32P incorporation was determined by liquid scin¬
tillation counting.
Assay of protein kinase Bo activity. BTSM cells were lysed in
buffer containing 50 mM Tris-HCl, pH 7.5, 0.1% (w/v) Triton X-100, 1
mM EDTA, 1 mM EGTA, 50 mM NaF, 10 mM sodium glycerophos¬
phate, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate,
0.1% (v/v) 2-mercaptoethanol, 0.27 M sucrose, 1 pM microcystin-LR,
and protease inhibitors (protease inhibitor cocktail; Boehringer
Mannheim, Lewes, UK). Insoluble material was removed from cell
lysates by centrifugation, and protein kinase Ba was immunopre-
cipitated by incubation at 4° with 2 pg of anti-protein kinase Ba
antibody conjugated to 5 pi of Protein G-Sepharose. Immunoprecipi-
tates were washed three times with 1 ml of 50 mM Tris-HCl buffer,
pH 7.5, containing 0.1 mM EGTA, 0.1 mM EDTA, 0.1% (v/v) 2-mer-
captoethanol, and 0.5 M NaCl and twice in the same buffer without
NaCl. Kinase activity was assayed by incubation with peptide sub¬
strate (GRPRTSSFAEG, termed 'Crosstide') and [y-32P]ATP (0.5
pCi) for 10 min at 30° in a shaking water bath; the reaction was
terminated by transferring 40 pi of the assay mixture to phospho-
cellulose P81 paper. The phosphocellulose paper, which binds the
peptide substrate but not ATP, was washed five times with or-
thophosphoric acid (0.5%, v/v) and once with acetone and dried; 32P
incorporation was determined by liquid scintillation counting.
Assay of MAP kinase activity. After pretreatment with inhib¬
itors and addition of mitogens as described in the figure legends,
BTSM cells were lysed under conditions identical to those used for
protein kinase B activity measurements; insoluble material was
removed by centrifugation, and activity was immunoprecipitated
using anti-p42 MAP kinase antibodies. After conjugation with Pro¬
tein G-Sepharose, enzymatic activity was assayed using a specific
MAP kinase substrate peptide derived from the EGF receptor (5
pg/incubation) and [y-32P]ATP (1 pCi), in a buffer containing 75 mM
HEPES, pH 7.4, and 1.2 mM MgCl2, for 30 min at 37°. Reactions were
terminated and phosphorylated peptide was isolated as detailed for
assays of protein kinase B activity.
Assay of cytosolic protein kinase C activity. BTSM cells were
lysed in buffer containing 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 0.5
mM EGTA, 0.1% (v/v) 2-mercaptoethanol, 0.02% (v/v) Triton X-100,
and protease inhibitors (protease inhibitor cocktail; Boehringer
Mannheim), after pretreatment with inhibitors and mitogens. After
centrifugation at 30,000 x g for 30 min at 4°, supernatants were
removed, Nonidet P-40 (1%, v/v, final concentration) was added, and
the mixture was shaken for 30 min at 4° to form the cytosolic
fraction. Protein kinase C activity in the cytosolic fraction was par¬
tially purified on DE52 diethylaminoethyl cellulose matrix, with
activity being eluted with lysis buffer containing 120 mM NaCl.
Enzymatic activity was assayed in a buffer containing 10 mM MgCl2,
1.2 mM CaCl2, phospholipids (96 pg/ml phosphatidylserine and 6.4
pg/ml diolein), 1 pCi of [y-32P]ATP, and 1 mg/ml histone Ills as
substrate. Reactions were carried out at 30° for 30 min and were
terminated by addition of buffer containing 10% (w/v) trichloroacetic
acid, 10 mM sodium pyrophosphate, and 1 mM ATP plus bovine
serum albumin (500 pg/reaction, added before vortex-mixing). Sam¬
ples were filtered through phosphocellulose P81 paper and washed
four times with buffer containing 5% (w/v) trichloroacetic acid and 10
mM sodium pyrophosphate; 32P incorporation was determined by
liquid scintillation counting.
Materials. Antibody to the p85 regulatory subunit of Ptdlns 3-ki-
nase (monoclonal anti-amino-terminal SRC homology 3 domain of
p85) was purchased from TCS (Botolph Claydon, UK), and antibod¬
ies to phosphotyrosine (PY20) and p42 MAP kinase (ERK2) were
purchased from Insight Biotechnology (Wembley, UK). [y-32P]ATP.
[32P]orthophosphate, [3H]thymidine, and enhanced chemilumines-
cence reagents were purchased from Amersham International (Am-
ersham, UK), secondary antibodies were obtained from SAPU (Car¬
luke, UK), and antibody to smooth muscle a-actin was purchased
from DAKO (Ely, UK). Trizol reagent, murine leukemia virus re¬
verse transcriptase, and T. aquaticus DNA polymerase were pur¬
chased from Life Technologies (Paisley, UK), and the deoxynucle-
otide mixture was purchased from Pharmacia (St. Albans, UK).
Protein kinase Ba peptide substrate (Crosstide) and antibodies to
protein kinase Ba were generous gifts from Dr. D. Alessi and Prof. P.
Cohen (University of Dundee, UK). Folch fraction I phosphoinosi¬
tides were obtained from Sigma (Poole, UK). Protease inhibitor cock¬
tail tablets were purchased from Boehringer Mannheim. All other
reagents were of the highest purity commercially available.
Results
PDGF receptor expression in primary cultures of
BTSM cells. PDGF is a dimer composed of A chains and B
chains connected by disulfide bonds, and it exists in three
isoforms, namely PDGF-AA. PDGF-AB, and PDGF-BB.
PDGF receptors are composed of two subunits, namely a and
13, that form dimeric receptors as act, a(3, or (3f3 forms; ligand
binding studies have demonstrated that aa receptors bind all
three PDGF isoforms, a(3 receptors bind PDGF-AB and -BB.
and (3f3 receptors bind only PDGF-BB (Seifert et al., 1989).
Using reverse transcription-PCR of RNA derived from pri¬
mary cultures of BTSM cells, we demonstrated the presence
of both a and {3 chains of the PDGF receptor (Fig. 1). In
subsequent experiments, PDGF-BB was used as an agonist
with activity at all three PDGF receptor subtypes.
Induction of BTSM cell proliferation by PDGF-BB
and thrombin. Confluent primary cultures of BTSM cells
that had been made quiescent for 48 hr in DMEM containing
0.5% fetal calf serum were used to assess cell proliferation by
measurement of [3H] thymidine incorporation after agonist
treatment. PDGF-BB and thrombin were used as mitogens,
to allow comparison of the effects of growth factor receptor
stimulation (which involves autophosphorylation of specific
tyrosine residues) and G protein-coupled receptor stimula¬
tion (where activation occurs through a 'tethered-ligand'
mechanism of action) (Vu et al., 1991). As demonstrated in
Fig. 2a, PDGF-BB (20 ng/ml) induced a 51.3 ± 1.0-fold in¬
crease and thrombin (1 unit/ml) induced a 13.3 ± 0.3-fold
increase in [3H] thymidine incorporation, compared with con¬
trol values, after a 24-hr exposure. The potential role of
Ptdlns 3-kinase in mediating this response was studied ini¬
tially by using the selective inhibitor LY294002 (Vlahos et
al., 1994). PDGF-BB- and thrombin-induced [3H]thymidine
incorporation was inhibited to control levels, in a concentra¬
tion-dependent manner, by LY294002 (IC50, 2.4 and 2.2 p.M,
respectively) (Fig. 2b).
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Time course of mitogen-induced proliferation. A
'washout' protocol was used to assess the minimal period of
agonist stimulation required to induce [3H] thymidine incor¬
poration; at each time point, PDGF-BB or thrombin was
added to quiescent BTSM cells for varying times, the mito-
gen-containing medium was removed, and the cells were
washed extensively with DMEM containing 0.5% fetal calf
serum (quiescent medium) and then incubated for an addi¬
tional 20 hr in fresh quiescent medium before assessment of
[3H]thymidine incorporation. The data presented in Fig. 3
demonstrate a rapid time-dependent increase in [3H] thymi¬
dine incorporation and indicate that a 10-min exposure to
PDGF-BB or thrombin is sufficient to induce proliferation
equivalent to that observed after a 24-hr exposure to agonist.
These data suggest that these cells are fully committed to
undergo cell division after only a brief period of agonist
exposure; hence, a rapid signaling mechanism underlies the
proliferative response induced by these mitogens.
Time course of Ptdlns 3-kinase activation. Because
mitogen-induced BTSM cell proliferation was sensitive to
inhibition by Ptdlns 3-kinase inhibitors and BTSM cells
could be committed to transition into the S-phase of the cell
cycle by a rapid signaling mechanism, we examined the time
course ofPtdlns 3-kinase activation. In anti-p85 immunopre-
cipitates, PDGF-BB (20 ng/ml) and thrombin (1 unit/ml) in¬
duced time-dependent activation of Ptdlns 3-kinase, which
was maximal by 5 min for thrombin and by 10 min for
PDGF-BB, with increases of 9 ± 1.2- and 3.5 ± 0.7-fold over
control values, respectively (Fig. 4a). PDGF-BB- and throm-
bin-induced activation of Ptdlns 3-kinase was sensitive to
inhibition by LY294002 over a concentration range similar to
that used for inhibition of [3H]thymidine incorporation (IC50,
1.7 and 1.9 p.M, respectively) (Fig. 4b).
Time course of PtdIns(3,4,5)P3 generation. Using
[32P]orthophosphate-labeled BTSM cells, we examined the
generation of PtdIns(3,4,5)P3, the lipid product of Ptdlns
3-kinase activation, after cell stimulation with PDGF-BB or
thrombin. Phosphoinositides were extracted from control and
agonist-stimulated cells, deacylated to generate glycero-de-
rivatives of phosphoinositide lipids, and analyzed by high
performance liquid chromatography using a SAX 5 column
(Whatman, Maidstone, UK) and an (NH4)H2P04/water two-
step gradient. As shown in Fig. 4c, PDGF-BB (20 ng/ml)
induced rapid generation of glycero-PtdIns(3,4,5)P3 over 10
min, achieving an 8.8 ± 1.5-fold increase over control levels.
Thrombin (1 unit/ml) induced a 4.1 ± 1.7-fold increase in
glycero-PtdIns(3,4,5)P3 levels, with maximal stimulation be¬
ing observed at 5 min (Fig. 5).
Activation of protein kinase Ba in BTSM cells. Mito¬
gen-induced BTSM cell proliferation was previously shown to
occur through activation of p70s6k in a Ptdlns 3-kinase-de-
pendent manner (Scott et al., 1996). Recently, protein kinase
Ba has been proposed to act as a signaling intermediate
between Ptdlns 3-kinase and the activation of p70s6k after
stimulation of cells with growth factors (Marte and Down¬
ward, 1997). Protein kinase Ba was identified by Western
blotting in BTSM cells (data not shown) and was found to be
4.5 ± 0.7- and 3.7 ± 0.2-fold activated by PDGF-BB and
thrombin, respectively, by 10 min (Fig. 5a). In addition, pro¬
tein kinase Ba activity was found to be inhibited after pre-
treatment of BTSM cells with the Ptdlns 3-kinase inhibitor
LY294002, confirming that protein kinase Ba lies down¬
stream from Ptdlns 3-kinase in the proliferative pathway
(Fig. 5b).
Role of MAP kinase in BTSM cell proliferation. To
investigate a potential role for the MAP kinase pathway in
mitogen-induced proliferation, we used the specific MEK1
inhibitor PD98059. The mechanism of action of PD98059
involves interaction with and inhibition of the inactive form
of MEK1, the upstream activator of MAP kinase (Dudley et
al., 1995). Pretreatment of BTSM cells with 100 p.M PD98059
inhibited PDGF-BB- and thrombin-induced [3H]thymidine
incorporation by 79.4 ± 4.5 and 82.9 ± 4.5%, respectively
(Fig. 6a); however, PD98059-mediated inhibition of PDGF-
BB-stimulated MAP kinase activity in these cells was maxi¬
mal at a concentration of 10 pM (Fig. 6b), suggesting that
PD98059 may have nonspecific effects on DNA synthesis and
cell integrity at concentrations above 10 pM. Of note, pre¬
treatment of BTSM cells with a maximally effective concen¬
tration of LY294002 (10 pM) had no significant effect on MAP
kinase activation induced by PDGF-BB or thrombin (97.9 ±
1.2 and 98.3 ± 1.8% of control values, respectively) (Fig. 6b,
inset), suggesting that the MAP kinase pathway is not a
downstream target ofPtdlns 3-kinase. In addition, PD98059
(10 pM) had no significant effect on Ptdlns 3-kinase activa¬
tion induced by PDGF-BB or thrombin (95.0 ± 6.8 and 98.2 ±
4.4% of control values, respectively) (Fig. 4b). Taken to¬
gether, these data suggest that the Ptdlns 3-kinase pathway







Fig. 1. Expression of PDGF-a and -0 receptor subunits in BTSM cells. After reverse transcription-PCR with appropriate primers, amplified products
were separated by electrophoresis on 1.5% (w/v) agarose gels, stained with ethidium bromide, and visualized using a UV transilluminator. Primers
specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (610-base pair product) were used to amplify this 'housekeeping' gene product; the
PDGF-a receptor (520-base pair product) and PDGF-0 receptor (252-base pair product) were identified as indicated. Amplification was performed
using cDNA originally derived from normal human articular chondrocytes (lane 2), LL24 fetal lung fibroblasts (lane 3), and primary cultures of BTSM
cells (lane 4)\ negative controls containing no cDNA were included in each PCR amplification (lane 1).
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Role of protein kinase C in BTSM cell proliferation.
In a number of cell types, including airway smooth muscle
cells, protein kinase C has been proposed to play a role in cell
proliferation. Despite the identification of a number of iso-
forms of protein kinase C, with differing requirements for
Ca2+ and phosphatidylserine, no inhibitors exist that are
entirely selective for distinct protein kinase C isoforms, to
enable the precise cellular roles for these isoforms to be
established. Using purified baculovirus-expressed kinases,
activation of certain protein kinase C isoforms has been
demonstrated to occur in the presence of 3-phosphorylated
phosphoinositides generated as a result of Ptdlns 3-kinase
activation. GF109203X, a bisindolylmaleimide that is re¬
ported to be a potent, selective, broad-spectrum, protein ki¬
nase C inhibitor whose action is mediated by competitive
inhibition for ATP (Toullec et al., 1991), was found to have no
effect on either PDGF-BB- or thrombin-induced [3H] thymi¬




















Fig. 2. DNA synthesis induced by PDGF-BB and thrombin in BTSM
cells, a, [3H]Thymidine incorporation was assessed in quiescent BTSM
cells after exposure to PDGF-BB (20 ng/ml) (PDGF) or thrombin (1
unit/ml) (Thr) for 24 hr, as detailed in Materials and Methods, b, BTSM
cells were treated with LY294002 for 20 min before addition of PDGF-BB
(20 ng/ml) (□) or thrombin (1 unit/ml) (■). [3H]Thymidine incorporation
was assessed after 24 hr, as detailed in Materials and Methods; results
are expressed as mean ± standard error of incorporation from an exper¬
iment that was performed in triplicate and was representative of three
other experiments with similar results.
tion of 1 p.M (Fig. 7). Use of GF109203X at concentrations
above 3 pM was found to induce cell detachment and necrosis
(data not shown). Similar results were obtained with the
protein kinase C inhibitor Ro 31-8220, which acts hy a sim¬
ilar mechanism (data not shown). In addition, calphostin C
(100 nM), an inhibitor of protein kinase C that acts at the
regulatory domain, and chelerythrine (1 pM), which inhibits
protein kinase C in a noncompetitive manner with respect to
ATP, were both found to have no significant effect on PDGF-
BB- and thrombin-induced [3H] thymidine incorporation
(97.3 ± 2.7 and 99.3 ± 1.4% of PDGF-BB control values and
98.1 ± 2.5 and 97.6 ± 3.4% of thrombin control values,
respectively). Both PDGF-BB and thrombin were found to
activate protein kinase C, as assessed in cytosolic extracts of
BTSM cells using histone Ills as substrate, and this activity
was completely inhibited by GF109203X (1 pM) (Fig. 7b).
These data suggest that protein kinase C does not play a
major role in mediating or modulating mitogen-induced cell
proliferation in primary cultures of BTSM cells.
Discussion
In this study, we have demonstrated that PDGF-BB and
thrombin are potent mitogens for primary cultures of BTSM
cells and that a relatively short exposure to these agonists
(<10 min) is sufficient to initiate a full mitogenic response.
PDGF-BB and thrombin were used as agonists because both
are known to act through a distinct receptor type; this would
possibly allow us to determine whether a common key sig¬
naling pathway operates to mediate cell proliferation.
The ability of LY294002 to completely abolish PDGF-BB-
and thrombin-induced [3H] thymidine incorporation by
BTSM cells suggested that Ptdlns 3-kinase is a key regulator
of this response. This finding was supported by the demon¬
stration that these agonists caused rapid activation ofPtdlns
3-kinase and generation of the second messenger
PtdIns(3,4,5)P:j, the extent of which correlated closely with
the magnitude of [3H] thymidine incorporation. Importantly,
this is one of the first direct observations that stimulation of
a G protein-coupled receptor can activate a p85/pll0 Ptdlns
3-kinase in a nonhematopoietic cell type. Other studies ex¬
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Fig. 3. Time course of mitogen-induced DNA synthesis in BTSM cells.
BTSM cells were exposed to PDGF-BB (20 ng/ml) (□) or thrombin (1
unit/ml) (M) for the times indicated and were then removed by washing
the cells with quiescent DMEM containing 0.5% (v/v) fetal calf serum;
[3H]thymidine incorporation was assessed after an additional 24 hr.
Results are expressed as mean ± standard error of incorporation from an
experiment that was performed in triplicate and was representative of
four other experiments with similar results.
1012 Walker ef al.
tion of a novel /3-y-sensitive form of Ptdlns 3-kinase; in par¬
ticular, thrombin was shown to activate this form of Ptdlns
3-kinase in platelets, as was formyl-methionvl-leucyl-phenyl-
alanine in neutrophils (Zhang et al., 1995; Stephens et al.,
1997). A recent study by Belham et al. (1997) showed that
thrombin-induced activation of p70s6k in pulmonary artery
fibroblasts was inhibited by wortmannin but Ptdlns 3-kinase
activity was undetectable in antiphosphotyrosine immuno-
precipitates. These observations suggested the involvement
of a Ptdlns 3-kinase isoform that was distinct from the ac¬
tivity found in antiphosphotyrosine immunoprecipitates
from PDGF-treated cells. Wilson et al. (1996) demonstrated
that lysophosphatidic acid activated p70s6k via a G protein-
coupled receptor in Rat-1 fibroblasts and this activation
could be abrogated by pretreatment with wortmannin; there¬
fore, it was speculated that a /37-sensitive form of Ptdlns
3-kinase might mediate this activity.
A previous study with BTSM cells demonstrated that cell
growth was mediated through activation of p70sSk in a Pt¬
dlns 3-kinase-dependent manner (Scott et al., 1996). In ad¬
dition, that study showed that rapamycin, a selective inhib¬
itor of p70s6k activation, could completely inhibit BTSM cell
proliferation, thus supporting the proposal that activation of
p70s6k is a key step in the growth pathway.
Protein kinase B was originally identified as a product of
the v-akt oncogene, from the acutely transforming retrovirus
AKT-8 found in rodent T cell lymphoma cells (Bellacosa et al.,
1991). Reports that protein kinase B lies downstream from
Ptdlns 3-kinase and can associate with 3-phosphorylated
phosphoinositides (James et al., 1996) led to the character¬
ization of two phosphorylation sites on protein kinase B,
namely Thr308 and Ser473, which must both be phosphory-
lated for full activation (Alessi et al., 1997a).
Burgering and Coffer (1995) reported that a constitutively
active form of protein kinase B induced p70s6k activation but
had no effect on MAP kinase. In addition, because both
protein kinase B and p70s6k are known to lie downstream
from Ptdlns 3-kinase, this suggests that p70s6k activation
may be mediated by protein kinase B. We demonstrated in
this study that protein kinase B is activated in BTSM cells
after stimulation with PDGF-BB and thrombin, both of
which were shown to be potent mitogens and were able to
induce rapid activation of Ptdlns 3-kinase. More recently,
PDK-1 was demonstrated to directly phosphorylate and ac¬
tivate p70s6k both in vivo and in vitro (Alessi et al., 1997b).
Phosphorylation of p70s6k in vitro was found to be indepen¬
dent of PtdIns(3,4,5)P3, which contrasts with the phosphoi-
nositide-dependent phosphorylation of protein kinase B by
PDK-1. These observations suggest that PDK-1 is involved in
a cooperative role to phosphorylate and mediate p70s6k acti¬
vation.
Activation of the MAP kinase cascade is known to be in¬
volved in mitogenesis. Using PD98059, a specific MEK1 in¬
hibitor, a role for the MAP kinase pathway in BTSM cell
proliferation was investigated. At concentrations of PD98059
that completely inhibit MAP kinase activity, DNA synthesis
was only partially inhibited. This suggests that MAP kinase
is necessary, but not sufficient, for a full mitogenic response
in these cells. These data are in accord with those reported by
Malarkey et al. (1995a), who showed marked differences in
the mitogenic potency of PDGF-BB and endothelin-1 in
BTSM cells despite identical degrees of MAP kinase activa-
[LY294002] (|]M)







Fig. 4. Ptdlns 3-kinase activation and PtdIns(3,4,5)P3generation in mitogen-stimulated BTSM cells, a, BTSM cells were stimulated with PDGF-BB
(20 ng/ml) (□) or thrombin (1 unit/ml) (■) for the times indicated. Cells were lysed and Ptdlns 3-kinase was immunoprecipitated using an anti-p85
antibody; Ptdlns 3-kinase activity was assayed using phosphoinositide as substrate. Results are expressed as mean ± standard error of the fold
increase from three independent experiments performed in duplicate, b, BTSM cells were pretreated with LY294002 at varying concentrations, as
indicated, for 20 min before addition of PDGF-BB (20 ng/ml) (□) or thrombin (1 unit/ml) (■) for 10 min. Alternatively, BTSM cells were pretreated
with PD98059 (10 p.M, 30 min) before addition of PDGF-BB (20 ng/ml) (A) or thrombin (1 unit/ml) (A) for 10 min; these experiments were carried out
in the absence of LY294002. Cells were assayed for Ptdlns 3-kinase activity as described above; results are expressed as mean percentage of control
values (PDGF-BB- or thrombin-treated cells, as appropriate) from a single experiment that was performed in triplicate and was representative of two
others with similar results. An autoradiograph of phosphoinositide-3-phosphate (PtdIns3P), separated by thin layer chromatography, from a
representative experiment is also shown (top), c, BTSM cells were labeled with [32P]orthophosphate as detailed in Materials and Methods and were
stimulated with PDGF-BB (20 ng/ml) (□) or thrombin (1 unit/ml) (■) for varying times, as indicated. Phosphoinositide lipids were extracted,
deacylated, and analyzed by strong anion exchange high performance liquid chromatography. Results are expressed as mean ± standard error of the
percentage of deacylated PtdIns(3,4,5)P3/deacylated phosphoinositide-4,5-bisphosphate \gPI(3,4,5)P3 /gPI(4,5)P2] from three individual experiments;
mean deacylated phosphoinositide-4,5-bisphosphate values were 386,809 cpm.
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tion. In contrast, a report by Karpova et al. (1997) concluded
that activation of MEK1 and the MAP kinase pathway was
essential for PDGF-induced DNA synthesis. However, in this
study even supramaximal concentrations of PD98059 did not
attenuate PDGF-induced [3H] thymidine synthesis to control
levels; the pathway mediating this resistant component has
not yet been elucidated. Mitogen-induced MAP kinase acti¬
vation was unaffected by pretreatment with a Ptdlns 3-ki-
nase inhibitor, and PD98059 did not inhibit Ptdlns 3-kinase
activity; this suggests that in BTSM cells the MAP kinase
and Ptdlns 3-kinase pathways act in a parallel manner to
induce proliferation. However, it is evident from our study
that Ptdlns 3-kinase is the principal regulatory pathway,
with MAP kinase activation being required for a full mito-
genic response. Interactions with Ptdlns 3-kinase seem to
vary among cell types and within cell lines, depending on the








(1997) demonstrated that PDGF-induced MAP kinase activ¬
ity was inhibited by wortmannin at low PDGF concentrations
but wortmannin had no effect at maximal concentrations of
PDGF, suggesting that Ptdlns 3-kinase activates MAP ki¬
nase when small numbers of PDGF receptors are activated
but a parallel pathway activates MAP kinase when most
PDGF receptors are activated. Our study has focused on cell
proliferation and its underlying signaling events induced by
maximally effective concentrations of mitogens; the possibil¬


































b PDGF +LY Thr +LY
Fig. 5. Time course of protein kinase B activation in mitogen-stimulated
BTSM cells, a, BTSM cells were stimulated with PDGF-BB (20 ng/ml) (□)
or thrombin (1 unit/ml) (■) for varying times, as indicated. Cells were
lysed, protein kinase B was immunoprecipitated, and activity was as¬
sayed using Crosstide as the substrate, as detailed in Materials and
Methods. Results are expressed as the mean ± standard error of the fold
increase above control values (untreated cells) from four experiments,
each performed in duplicate, b, BTSM cells were pretreated with
LY294002 (10 /xM) (+LY) for 20 min before addition of PDGF-BB (20
ng/ml) (PDGF) or thrombin (1 unit/ml) (Thr) as indicated. Protein kinase
B activity was assessed in immunoprecipitates as detailed above; results
are expressed as mean ± standard error of activity from a single exper¬
iment that was performed in triplicate and was representative of two
others with similar results.
basal PDGF 3liM 10uM 30^M 100uM
[PD98059]
Fig. 6. Role of MAP kinase in mediating DNA synthesis in BTSM cells,
a, BTSM cells were incubated with varying concentrations ofPD98059 for
30 min before the addition of PDGF-BB (20 ng/ml) (□) or thrombin (1
unit/ml) (■), as indicated. [3H]Thymidine incorporation was assessed
after 24 hr, as detailed in Materials and Methods; results are expressed
as mean ± standard error of the incorporation from five independent
experiments, each performed in triplicate, b, BTSM cells were stimulated
with PDGF-BB (20 ng/ml, 10 min) (PDGF) after preincubation with
PD98059 at varying concentrations, as indicated. Cells were lysed, MAP
kinase was immunoprecipitated using an anti-p42 MAP kinase antibody,
and enzyme activity was assayed using an EGF receptor fragment as the
substrate, as detailed in Materials and Methods. Results are expressed as
mean ± standard error of the activity from a single experiment that was
performed in triplicate and was representative of two others with similar
results. Inset, BTSM cells were incubated with LY294002 (10 /xM) (+LY)
for 20 min before addition of PDGF-BB (20 ng/ml) (PDGF) or thrombin (1
unit/ml) (Thr), as indicated, and assessment of MAP kinase activity;
results are expressed as mean ± standard error from three experiments
performed in triplicate, b, basal.
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tween signaling pathways may occur at submaximal mitogen
concentrations.
We have demonstrated that DNA synthesis is unaffected
by a maximally effective concentration of GF109203X, sug¬
gesting that mitogen-induced proliferation of BTSM cells is
independent of protein kinase C. Similar results were also
obtained with calphostin C and chelerythrine, which have
different mechanisms of action, either targeting the regula¬
tory domain of protein kinase C or acting as a noncompetitive
inhibitor for ATP. Furthermore, it has been shown that pre-
treatment of BTSM cells with phorbol-12-myristate-13-ace-
tate to down-regulate protein kinase C does not inhibit
PDGF-induced [3H]thymidine incorporation (Scott et al.,
1996), and it remains unlikely that protein kinase C is sig¬
nificantly involved in DNA synthesis in this tissue. Recently,
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Fig. 7. Role of protein kinase C in mediating DNA synthesis in BTSM
cells, a, BTSM cells were incubated with GF109203X (1 pM), as indicated,
for 5 min before the addition of PDGF-BB (20 ng/ml) (□) or thrombin (1
unit/ml) ffl) as indicated. [3H]Thymidine incorporation was assessed af¬
ter 24 hr, as detailed in Materials and Methods; results are expressed as
mean ± standard error of the incorporation from four independent ex¬
periments, each performed in triplicate, b, BTSM cells were stimulated
with PDGF-BB (20 ng/ml) (□) or thrombin (1 unit/ml) (® after preincu¬
bation with GF109203X at the concentrations indicated. Cells were lysed
and cytosolic protein kinase C activity was assayed as detailed in Mate¬
rials and Methods. Results are expressed as mean activity from a single
experiment that was performed in triplicate and was representative of
two others with similar results.
of human airway smooth muscle cells with a dominant neg¬
ative protein kinase C £ inhibited PDGF-induced prolifera¬
tion by approximately 80% (Black et al., 1998). Hirst et al.
(1995) also reported inhibition of serum-stimulated prolifer¬
ation of rabbit tracheal smooth muscle cells by protein kinase
C inhibitors. Donnelly et al. (1995) demonstrated the pres¬
ence of conventional protein kinase C isoforms /3I and J3II,
novel isoforms S, e, and 0, and the atypical isoform £ in canine
airway smooth muscle but did not address whether selective
activation occurs after spasmogenic or mitogenic stimulation.
The differences in results in these studies may reflect differ¬
ential expression of protein kinase C isoforms or may indi¬
cate that there is differential regulation of these isoforms
among species.
The ability of thrombin, acting through a G protein-cou¬
pled receptor, to activate Ptdlns 3-kinase has been observed
in only a limited number of cell types. In neutrophils, a novel
form ofPtdlns 3-kinase that is composed of a plOl regulatory
subunit and a pl20 catalytic subunit and is sensitive to
activation by fiy subunits derived from heterotrimeric G pro¬
teins has been identified (Stephens et al., 1997). However,
the finding that thrombin induced activation of Ptdlns 3-ki¬
nase in anti-p85 immunoprecipitates suggests an alternative
mechanism of activation. Such an effect could be explained
by trans-activation of a growth factor receptor, as has been
described by Daub et al. (1996) for Rat-1 fibroblasts trans-
fected with EGF receptors. Agonists such as endothelin-1,
lysophosphatidic acid, and thrombin induced tyrosine phos¬
phorylation of EGF receptors in these cells in a manner
similar to that observed after stimulation with EGF. There¬
fore, thrombin may act through tyrosine kinases to induce
phosphorylation ofgrowth factor receptors in BTSM cells and
thus induce activation of a p85/pll0 form of Ptdlns 3-kinase.
Chen et al. (1994) showed that thrombin, acting through its G
protein-coupled receptor, induces activation of src and fyn in
a lung fibroblast cell line, suggesting a possible mechanism of
activation to initiate proliferation.
In conclusion, this study has demonstrated that BTSM cell
DNA synthesis induced by two distinct mitogens is initiated
by the rapid activation of Ptdlns 3-kinase. The MAP kinase
pathway contributes significantly to the proliferative re¬
sponse and is necessary for a full mitogenic response. This
pathway, however, does not seem to be the key regulatory
pathway that drives growth but seems to act in a parallel
manner. Because proliferation in BTSM cells is known to be
dependent on Ptdlns 3-kinase-mediated p70sSk activation
(Scott et al., 1996), the precise role of mitogen-induced pro¬
tein kinase B activation in this response remains to be de¬
termined. The predominant involvement of receptor-medi¬
ated Ptdlns 3-kinase activation in airway smooth muscle
proliferation and the major consequences of this cellular re¬
sponse in vivo make this pathway an attractive therapeutic
goal that could be targeted by the inhalation route.
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